

Supplementary Information

Sequence variants at *CHRNA3-CHRNA6* and *CYP2A6* affect smoking behavior

Thorgeir E. Thorgeirsson^{1,2}, Daniel F. Gudbjartsson¹, Ida Surakka^{3,4}, Jacqueline M. Vink⁵, Najaf Amin⁶, Frank Geller¹, Patrick Sulem¹, Thorunn Rafnar¹, Tõnu Esko^{7,8}, Stefan Walter⁶, Christian Gieger⁹, Rajesh Rawal⁹, Massimo Mangino¹⁰, Inga Prokopenko^{11,12}, Reedik Mägi^{11,12}, Kaisu Keskitalo¹³, Iris H. Gudjonsdottir¹, Solveig Gretarsdottir¹, Hreinn Stefansson¹, John R. Thompson¹⁴, Yurii S. Aulchenko⁶, Mari Nelis^{7,8}, Katja K. Aben^{15,16}, Martin den Heijer^{15,17}, Asger Dirksen¹⁸, Haseem Ashraf¹⁸, Nicole Soranzo^{10,19}, Ana M Valdes¹⁰, Claire Steves¹⁰, André G Uitterlinden^{6,20}, Albert Hofman⁶, Anke Tönjes^{21,22}, Peter Kovacs²³, Jouke Jan Hottenga⁵, Gonneke Willemssen⁵, Nicole Vogelzangs²⁴, Angela Döring⁹, Norbert Dahmen²⁵, Barbara Nitz⁹, Michele L. Pergadia²⁶, Berta Saez²⁷, Veronica De Diego²⁸, Victoria Lezcano²⁸, Maria D. Garcia-Prats²⁹, Samuli Ripatti^{3,4}, Markus Perola⁴, Johannes Kettunen¹⁹, Anna-Liisa Hartikainen³⁰, Anneli Pouta³¹, Jaana Laitinen³², Matti Isohanni³⁰, Shen Huei-Yi^{3,4}, Maxine Allen¹¹, Maria Krestyaninova³³, Alistair S Hall³⁴, Gregory T. Jones³⁵, Andre M. van Rij³⁵, Thomas Mueller³⁶, Benjamin Dieplinger³⁶, Meinhard Haltmayer³⁶, Steinn Jonsson³⁷, Stefan E. Matthiasson³⁸, Hogni Oskarsson³⁹, Thorarinn Tyrfinngsson⁴⁰, Lambertus A. Kiemeny^{15,16,41}, Jose I. Mayordomo⁴², Jes S Lindholt⁴³, Jesper Holst Pedersen⁴⁴, Wilbur A. Franklin⁴⁵, Holly Wolf⁴⁶, Grant W. Montgomery⁴⁷, Andrew C. Heath²⁶, Nicholas G. Martin⁴⁷, Pamela A.F. Madden²⁶, Ina Giegling⁴⁸, Dan Rujescu⁴⁸, Marjo-Riitta Järvelin^{31,49,50,51}, Veikko Salomaa⁴, Michael Stumvoll²¹, Tim D Spector¹⁰, H-Erich Wichmann^{9,52,53}, Andres Metspalu^{7,8}, Nilesh J. Samani⁵⁴, Brenda W. Penninx²⁴, Ben A. Oostra⁵⁵, Dorret I. Boomsma⁵, Henning Tiemeier⁶, Cornelia M. van Duijn⁶, Jaakko Kaprio^{3,13,56}, Jeffrey R. Gulcher¹, The ENGAGE Consortium⁵⁷, Mark I. McCarthy^{11,12}, Leena Peltonen^{3,19}, Unnur Thorsteinsdottir^{1,38,*}, Kari Stefansson^{1,38,*}

*Corresponding authors:

Kari Stefansson, deCODE genetics, Sturlugata 8, 101 Reykjavík, Iceland.
kstefans@decode.is, Phone:354-5701900, fax 354-5701901.

Unnur Thorsteinsdottir, deCODE genetics, Sturlugata 8, 101 Reykjavik, Iceland.
unnur.thorsteinsdottir@decode.is, Phone: 354-5701992, fax 354-5701901


¹Decode genetics, Sturlugata 8, Reykjavik, Iceland. ²Center for Biomolecular Science and Engineering, Baskin School of Engineering, University of California, Santa Cruz, CA95064, USA. ³Institute for Molecular Genetics Finland, FIMM, University of Helsinki, Finland. ⁴National Institute for Health and Welfare, Helsinki, Finland. ⁵Department of Biological Psychology, VU University Amsterdam, Amsterdam, The Netherlands. ⁶Department of Epidemiology, Erasmus University Medical Center, Rotterdam, The Netherlands. ⁷Estonian Genome Project of University of Tartu, Tiigi str 61b, Tartu 50410, Estonia. ⁸IMCB of University of Tartu and Estonian Biocentre, Riia str 23, Tartu 51010, Estonia. ⁹Institute of Epidemiology, Helmholtz Zentrum München, Ingolstaedter Landstr. 1, 85764 Munich/Neuherberg, Germany. ¹⁰Department of Twin Research and Genetic Epidemiology, King's College London, St. Thomas' Hospital Campus, London SE1 7EH, UK. ¹¹Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Old Road, OX3 7LJ, Oxford, UK6. ¹²Wellcome Trust Centre for Human Genetics, University of Oxford, Roosevelt drive, OX3 7BN, Oxford, UK. ¹³Department of Public Health, University of Helsinki, Helsinki, Finland. ¹⁴Department of Health Sciences and Genetics, University of Leicester,

LE1 7RH Leicester, UK. ¹⁵Radboud University Nijmegen Medical Centre, Dept. of Epidemiology, Biostatistics and HTA, Nijmegen, The Netherlands. ¹⁶Comprehensive Cancer Centre East, Nijmegen, The Netherlands. ¹⁷Radboud University Nijmegen Medical Centre, Dept. of Endocrinology, Nijmegen, The Netherlands. ¹⁸Department of pulmonary Medicine Y, Gentofte University Hospital, DK-2900 Hellerup, Denmark. ¹⁹Wellcome Trust Sanger Institute, Hinxton, UK. ²⁰Department of Internal Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands. ²¹Department of Medicine, University of Leipzig, Liebigstr. 18, 04103, Leipzig, Germany. ²²Coordination Centre for Clinical Trials, University of Leipzig, Härtelstr. 16-18, 04103, Leipzig, Germany. ²³Interdisciplinary Centre for Clinical Research, University of Leipzig, Inselstr. 22, 04103, Leipzig, Germany. ²⁴EMGO Institute/Department of Psychiatry, VU University Medical Center, Amsterdam, The Netherlands. ²⁵Department of Psychiatry, University of Mainz, Mainz, Germany. ²⁶Washington University School of Medicine, Department of Psychiatry, St Louis, Missouri, USA. ²⁷Instituto de Nanotecnología de Aragón, 50009 Zaragoza, Spain. ²⁸Division of Dermatology, Hospital San Pedro, 26006 Logroño, Spain. ²⁹Division of Pathology, San Jorge Hospital, 22004 Huesca, Spain. ³⁰Institute of Clinical Medicine, University of Oulu, Oulu, Finland. ³¹Lifecourse and service Department, National Institute of Health and Welfare, Oulu, Finland. ³²Finnish Institute of Occupational Health, Oulu, Finland. ³³European Bioinformatics Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, CB10 1SD, UK. ³⁴Multidisciplinary Cardiovascular Research Centre (MCRC), Leeds Institute of Genetics, Health and Therapeutics (LIGHT), University of Leeds, Leeds, LS2 9JT, UK. ³⁵Vascular Research Group, Otago Medical School, PO Box 913, Dunedin 9054, New Zealand. ³⁶Department of Laboratory Medicine, Konventhospital Barmherzige Brüder Linz, Seilerstaette 2-4, A-4020 Linz, Austria. ³⁷Landspítali University Hospital, Department of Medicine, Reykjavik, Iceland. ³⁸University of Iceland, School of Medicine, Reykjavik, Iceland. ³⁹Therapeia, 101 Reykjavik, Iceland. ⁴⁰Vogur SAA Addiction Treatment Center, Reykjavik, Iceland. ⁴¹Radboud University Nijmegen Medical Centre, Dept. of Urology, Nijmegen, The Netherlands. ⁴²University of Zaragoza, 50009 Zaragoza, Spain. ⁴³Vascular Research Unit, Viborg Hospital, DK-8800 Viborg, Denmark. ⁴⁴Department of Cardiothoracic Surgery RT, Rigshospitalet/ University of Copenhagen, DK-2100 Copenhagen, Denmark. ⁴⁵Department of Pathology, University of Colorado Denver, Aurora, CO 80045, USA. ⁴⁶Community & Behavioral Health, Colorado School of Public Health, University of Colorado Denver, Aurora, CO 80045, USA. ⁴⁷Queensland Institute of Medical Research, Queensland, Australia. ⁴⁸Department of Psychiatry, University of Munich (LMU), Munich, Germany. ⁴⁹Department of Epidemiology and Public Health, Imperial College, Faculty of Medicine, London, UK. ⁵⁰Institute of Health Sciences, University of Oulu, Oulu, Finland. ⁵¹Biocenter Oulu, University of Oulu, Oulu, Finland. ⁵²Institute of Medical Informatics, Biometry and Epidemiology, Ludwig-Maximilians-Universität, Munich, Germany. ⁵³Klinikum Grosshadern, Munich, Germany. ⁵⁴Department of Cardiovascular Sciences, University of Leicester, Clinical Sciences Wing, Glenfield Hospital, Groby Road, Leicester, LE3 9QP, UK. ⁵⁵Department of Clinical Genetics, Erasmus University Medical Center, Rotterdam, The Netherlands. ⁵⁶Department of Mental Health and Alcohol Abuse Services, National Institute for Health and Welfare, Helsinki, Finland. ⁵⁷A list of ENGAGE members appears in the **Supplementary Note**.

Table of Contents

	Page
Supplementary Figure 1	4
QQ Plot	
Supplementary Figure 2	5-11
Forest Plots	
Supplementary Figure 3	12
Conditional Analysis Chrs 15q25	
Supplementary Table 1	13
Meta-analyses (CPD and SI): Sample sizes and inflation factors	
Supplementary Table 2	14-43
Results – SNPs in selected regions (CPD)	14-34
Results – SNPs in selected regions (Initiation)	35-43
Supplementary Table 3	44-55
SNPs from Table 1 – Results from Individual Studies	
Supplementary Table 4	56-57
(A) Association with Nicotine Dependence	
(B) Association with Peripheral Arterial Disease	
Supplementary Note	58-74
Sample Descriptions	58-69
Acknowledgements/Funding	69-72
Engage Members	72-73
References	73-74


Supplementary Figure 1. A: Q-Q plots of the GWA meta-analysis for CPD Quantile-Quantile plot of the 2,500,000 SNPs in the GWA meta analysis for CPD measurements, including (black dots) and excluding (blue dots) the markers at the 15q25 locus. The diagonal red line represents where the dots are expected to fall under the null hypothesis of no association. The horizontal green line represents the threshold for genome-wide significance. **B: Q-Q plot of the GWA meta-analysis for smoking initiation** Quantile-Quantile plot of the 2,500,000 SNPs in the GWA meta analysis for smoking initiation. The diagonal red line represents where the dots are expected to fall under the null hypothesis of no association. The horizontal green line represents the threshold for genome-wide significance.



Supplementary Figure 2 - A

Forest plot of the results for each sample in the CPD meta analysis for the SNP


Rs1051730-A on chromosome 15



Supplementary Figure 2 – B

Forest plot of the results for each sample in the CPD meta analysis for the SNP


Rs215614-G on chromosome 7



Supplementary Figure 2 - C

Forest plot of the results for each sample in the CPD meta analysis for the SNP


Rs6474412-T on chromosome 8



Supplementary Figure 2 - D

Forest plot of the results for each sample in the CPD meta analysis for the SNP


Rs7937-T on chromosome 19



Supplementary Figure 2 - E

Forest plot of the results for each sample in the CPD meta analysis for the SNP


Rs1801272-A on chromosome 19



Supplementary Figure 2 - F

Forest plot of the results for each sample in the CPD meta analysis for the SNP


Rs4105144-C on chromosome 19




Supplementary Figure 2 - G

Forest plot of the results for each sample in the CPD meta analysis for the SNP

7260329-G on chromosome 19




Supplementary Figure 3. Conditional analysis on chromosome 15q25. Shown are the $-\log_{10}$ association P values of SNPs in the region with CPD from the ENGAGE meta analysis, conditional on the effect of rs1051730 (black circles), the SNP build 36 coordinates, the genes in the region and their exons (in blue) and recombination rates in centimorgans (cM) per megabase (Mb) (pink histogram). The green line indicates the significance level ($P < 5 \cdot 10^{-8}$).



Supplementary Figure 2 - G

Forest plot of the results for each sample in the CPD meta analysis for the SNP

7260329-G on chromosome 19



Supplementary Table 2. CPD and Smoking Initiation association of markers within the regions selected by ENGAGE. Results are given for the ENGAGE discovery sample, the *in-silico* replication studies using data from the TAG and OX/GSK consortia (see accompanying papers). Shown are the number of smokers (N, for CPD only), the effect allele (A1) and the other allele (A2), the allele frequencies (Freq), the chromosome number and position, the estimated allelic effect sizes and their standard errors (Effect and SE), the P value for the test of association (P), the P value for the test for heterogeneity in effect size (P_{het}), and an estimate of the proportion of total variation in study estimates that is due to heterogeneity (I^2).

SNP	A1	A2	chr	Position	ENGAGE		In silico		Combined			P_{het}	I^2
					Effect±SE	P	Effect±SE	P	N	Effect±SE	P		
CPD													
rs12130751	G	A	1	51,937,813	0.33±0.08	1.1e-05	0.05±0.07	0.46	76,592	0.17±0.05	0.00074	0.40	4
rs10888734	A	G	1	52,038,830	0.31±0.06	1.1e-06	0.08±0.06	0.15	77,009	0.18±0.04	2e-05	0.32	9
rs7541944	A	C	1	52,042,644	0.24±0.07	0.00054	0.11±0.06	0.084	76,961	0.16±0.05	0.00037	0.45	1
rs7551758	G	T	1	52,046,666	0.31±0.06	1.6e-06	0.09±0.06	0.11	77,007	0.18±0.04	1.3e-05	0.27	12
rs2982846	G	T	1	52,052,238	0.30±0.07	1.7e-05	0.08±0.06	0.22	76,971	0.17±0.05	0.00019	0.49	0
rs2747525	C	A	1	52,056,606	0.32±0.07	2.3e-06	0.12±0.06	0.047	76,976	0.20±0.04	4.8e-06	0.60	0
rs11205896	G	T	1	52,063,572	0.31±0.06	9.8e-07	0.08±0.06	0.16	76,980	0.18±0.04	1.7e-05	0.70	0
rs2077725	A	G	1	52,066,158	0.28±0.07	1.9e-05	0.12±0.06	0.045	76,981	0.19±0.04	1.6e-05	0.62	0
rs11205897	T	C	1	52,070,739	0.31±0.06	7.7e-07	0.07±0.06	0.2	77,001	0.18±0.04	2.5e-05	0.59	0
rs6702037	G	A	1	52,083,344	0.31±0.06	1e-06	0.10±0.06	0.082	77,022	0.19±0.04	6.3e-06	0.59	0
rs4422953	T	C	1	52,083,470	0.29±0.07	8.7e-06	0.13±0.07	0.083	57,620	0.22±0.05	8.7e-06	0.48	0
rs6676789	C	T	1	52,089,373	0.31±0.06	1.2e-06	0.10±0.06	0.079	77,008	0.19±0.04	6.4e-06	0.61	0
rs883058	T	A	1	52,089,819	0.34±0.07	1.1e-06	0.10±0.06	0.11	76,792	0.20±0.05	1.1e-05	0.47	0
rs7526552	C	T	1	52,093,147	0.32±0.06	4.4e-07	0.07±0.06	0.2	77,014	0.18±0.04	1.9e-05	0.63	0
rs11205899	C	T	1	52,095,249	0.29±0.07	2.3e-05	0.08±0.06	0.21	76,973	0.17±0.05	0.00021	0.54	0
rs6691091	C	G	1	52,096,360	0.31±0.06	1.1e-06	0.07±0.06	0.22	77,011	0.17±0.04	4.6e-05	0.41	3
rs6588415	A	G	1	52,106,635	0.31±0.07	3.4e-06	0.11±0.06	0.071	76,983	0.19±0.04	1.1e-05	0.60	0
rs1538881	C	T	1	52,109,627	0.31±0.06	8.3e-07	0.10±0.06	0.089	77,005	0.19±0.04	6.3e-06	0.54	0
rs1890946	C	T	1	52,115,015	0.31±0.06	1.4e-06	0.11±0.06	0.07	76,993	0.19±0.04	6e-06	0.58	0
rs6663305	A	G	1	52,115,885	0.30±0.07	8.8e-06	0.12±0.06	0.04	76,959	0.20±0.04	8.4e-06	0.76	0
rs736756	C	A	1	52,117,002	0.30±0.06	4.4e-06	0.09±0.06	0.12	76,892	0.18±0.04	2.9e-05	0.72	0
rs10888738	C	T	1	52,119,626	0.26±0.06	4.5e-05	0.09±0.06	0.11	76,987	0.17±0.04	0.00011	0.96	0
rs11205902	T	G	1	52,121,357	0.29±0.07	1.3e-05	0.09±0.06	0.11	76,995	0.18±0.04	5e-05	0.97	0

rs1954260	T	C	1	52,163,620	0.29±0.06	5e-06	0.12±0.06	0.035	77,004	0.20±0.04	4.7e-06	0.98	0
rs11205911	G	A	1	52,168,900	0.32±0.07	1.8e-06	0.15±0.06	0.014	76,995	0.22±0.04	6.3e-07	0.93	0
rs12566236	T	G	1	52,169,531	0.32±0.07	1.6e-06	0.14±0.06	0.016	77,003	0.22±0.04	7.1e-07	0.94	0
rs10888740	G	A	1	52,172,685	0.31±0.06	1.9e-06	0.12±0.06	0.036	77,008	0.20±0.04	2.6e-06	0.97	0
rs2795002	T	C	1	52,174,617	0.25±0.07	0.00039	0.10±0.06	0.1	76,819	0.17±0.05	0.00039	0.89	0
rs6698110	C	T	1	52,176,729	0.33±0.07	5.1e-07	0.15±0.06	0.011	77,008	0.23±0.04	2.1e-07	0.95	0
rs1935288	T	C	1	52,178,276	0.25±0.07	0.00037	0.10±0.06	0.1	76,819	0.17±0.05	0.00039	0.88	0
rs1935289	C	T	1	52,179,460	0.41±0.07	4.1e-08	0.09±0.07	0.16	74,287	0.22±0.05	4.6e-06	0.30	10
rs2809943	C	T	1	52,188,728	0.25±0.07	0.00042	0.11±0.06	0.092	76,827	0.17±0.05	0.00036	0.92	0
rs2809944	T	C	1	52,190,126	0.25±0.07	0.00035	0.10±0.06	0.12	76,821	0.16±0.05	0.00045	0.87	0
rs7541308	T	G	1	52,190,709	0.32±0.06	8.4e-07	0.12±0.06	0.039	77,009	0.21±0.04	1.7e-06	0.97	0
rs6686975	A	G	1	52,195,722	0.32±0.07	2.8e-06	0.12±0.06	0.06	76,852	0.20±0.05	6.7e-06	0.96	0
rs10888743	T	C	1	52,195,755	0.39±0.08	3.5e-07	0.12±0.07	0.081	76,321	0.23±0.05	4.2e-06	0.33	9
rs2809948	G	A	1	52,196,682	0.26±0.07	0.00037	0.12±0.07	0.082	76,677	0.18±0.05	0.00025	0.76	0
rs10888744	G	T	1	52,204,400	0.34±0.09	0.00013	0.10±0.08	0.22	76,230	0.20±0.06	0.00073	0.24	14
rs17107020	A	G	1	52,299,174	0.58±0.18	0.0016	0.04±0.14	0.77	76,470	0.23±0.11	0.036	0.40	4
rs4394585	G	A	1	52,485,622	0.28±0.07	4.9e-05	0.08±0.06	0.19	76,659	0.16±0.05	0.00028	0.60	0
rs7513934	G	A	1	52,590,776	0.21±0.06	0.00082	0.12±0.06	0.035	76,646	0.16±0.04	0.00015	0.22	15
rs12044739	C	T	1	52,601,327	0.47±0.15	0.0017	0.07±0.11	0.52	76,711	0.21±0.09	0.018	0.18	18
rs9633423	A	G	1	52,608,727	0.33±0.07	1.5e-06	0.10±0.06	0.12	76,702	0.19±0.05	1.7e-05	0.30	10
rs835036	C	T	1	52,769,828	0.30±0.07	4.5e-06	0.11±0.06	0.078	76,518	0.19±0.04	1.4e-05	0.29	11
rs6671552	A	G	1	52,854,173	0.58±0.18	0.001	0.11±0.12	0.33	76,969	0.25±0.10	0.0091	0.25	13
rs17012387	A	G	2	33,032,150	1.11±0.26	2.8e-05	-0.29±0.20	0.14	72,857	0.17±0.14	0.23	0.065	29
rs17012390	C	T	2	33,032,718	1.10±0.27	6.4e-05	-0.39±0.20	0.048	72,421	0.08±0.13	0.54	0.050	32
rs17012393	G	A	2	33,032,785	1.10±0.27	4.7e-05	-0.37±0.20	0.063	72,619	0.11±0.14	0.43	0.045	32
rs4952325	A	G	2	33,038,890	0.96±0.25	0.00012	-0.33±0.19	0.085	75,055	0.12±0.13	0.37	0.098	25
rs4952326	C	T	2	33,041,196	0.91±0.23	6.4e-05	-0.31±0.19	0.11	75,055	0.17±0.14	0.2	0.093	25
rs17012409	A	G	2	33,042,874	0.78±0.23	0.00063	-0.27±0.19	0.15	75,341	0.12±0.13	0.35	0.28	12
rs11124300	G	T	2	33,061,280	0.85±0.24	0.00047	-0.19±0.20	0.33	73,131	0.19±0.14	0.18	0.12	23
rs12468402	G	A	2	33,065,980	1.11±0.27	3.5e-05	-0.19±0.21	0.38	72,577	0.27±0.16	0.078	0.082	27
rs17012426	C	T	2	33,070,188	0.93±0.24	8.4e-05	-0.17±0.21	0.41	74,746	0.28±0.15	0.06	0.12	23

rs1542343	T	C	2	33,076,523	1.10±0.26	3e-05	-0.08±0.20	0.69	74,472	0.31±0.15	0.037	0.042	32
rs17569615	T	G	2	33,091,430	0.91±0.23	0.00011	-0.16±0.20	0.43	76,686	0.27±0.15	0.064	0.062	29
rs3769554	A	G	2	33,108,941	1.06±0.26	6.6e-05	-0.15±0.20	0.46	74,284	0.27±0.15	0.08	0.056	30
rs11124301	T	A	2	33,109,675	0.71±0.22	0.0011	-0.16±0.20	0.44	76,716	0.22±0.14	0.12	0.073	27
rs6727912	T	C	2	33,142,223	1.07±0.25	1.3e-05	-0.26±0.20	0.18	74,764	0.22±0.14	0.12	0.074	28
rs2123915	A	C	2	33,150,083	1.09±0.27	3.8e-05	-0.29±0.21	0.17	72,649	0.20±0.15	0.18	0.11	24
rs10490451	A	G	2	33,165,965	1.09±0.25	1.1e-05	-0.26±0.18	0.16	72,571	0.19±0.14	0.17	0.031	35
rs11124303	A	G	2	33,170,204	0.94±0.26	0.00039	-0.27±0.20	0.17	72,866	0.13±0.14	0.35	0.21	16
rs1902030	G	A	2	33,174,095	0.91±0.24	0.00017	-0.17±0.18	0.33	74,485	0.17±0.13	0.19	0.10	25
rs11687781	A	G	2	236,118,985	0.47±0.13	0.00026	-0.07±0.09	0.46	74,272	0.11±0.07	0.13	0.31	10
rs6718421	C	T	2	236,119,282	0.47±0.13	0.00025	-0.07±0.09	0.48	74,536	0.11±0.07	0.12	0.35	7
rs13421279	C	G	2	236,120,581	0.47±0.13	0.00025	-0.11±0.09	0.24	74,268	0.08±0.07	0.24	0.29	11
rs13021173	T	C	2	236,121,417	0.43±0.10	1.7e-05	-0.04±0.08	0.62	76,965	0.13±0.06	0.029	0.11	23
rs7586914	A	G	2	236,122,252	0.43±0.10	1.5e-05	-0.03±0.08	0.7	76,959	0.14±0.06	0.02	0.043	31
rs12475206	C	T	2	236,122,627	0.45±0.10	9.4e-06	-0.01±0.08	0.89	76,937	0.16±0.06	0.0092	0.034	32
rs12470301	G	C	2	236,122,942	0.49±0.10	1.1e-06	-0.05±0.08	0.51	74,682	0.15±0.06	0.015	0.020	36
rs7581943	T	G	2	236,126,122	0.47±0.13	0.00024	-0.06±0.10	0.51	74,528	0.12±0.07	0.11	0.39	5
rs13018365	T	G	2	236,126,752	0.46±0.13	0.00055	-0.07±0.10	0.49	76,383	0.11±0.08	0.14	0.40	4
rs13431390	A	G	2	236,128,971	0.60±0.14	1.4e-05	-0.03±0.10	0.76	74,430	0.18±0.08	0.022	0.36	6
rs1865947	G	A	2	236,130,793	0.47±0.13	0.00027	-0.05±0.10	0.63	74,524	0.13±0.08	0.082	0.44	2
rs6414040	A	C	2	236,135,306	0.33±0.09	0.00019	0.01±0.08	0.92	76,797	0.14±0.06	0.014	0.63	0
rs12692173	A	C	2	236,135,601	0.47±0.13	0.00033	-0.05±0.10	0.58	74,236	0.13±0.08	0.097	0.37	6
rs12634857	A	G	3	128,566,720	0.30±0.09	0.00063	-0.05±0.07	0.46	76,984	0.08±0.05	0.13	0.22	15
rs2121851	T	C	3	128,641,324	0.35±0.07	1.6e-06	-0.07±0.06	0.29	76,808	0.10±0.05	0.028	0.045	31
rs13065243	T	C	3	128,642,649	0.37±0.08	1e-06	-0.08±0.06	0.18	76,517	0.09±0.05	0.046	0.014	38
rs12486396	G	A	3	128,643,205	0.36±0.07	1.1e-06	-0.09±0.06	0.18	76,811	0.09±0.05	0.047	0.020	36
rs732548	A	G	3	128,644,442	0.37±0.07	9.9e-07	-0.09±0.06	0.18	76,819	0.09±0.04	0.047	0.016	37
rs732549	T	G	3	128,644,479	0.36±0.07	1.4e-06	-0.09±0.06	0.16	76,788	0.09±0.04	0.057	0.017	37
rs737646	C	A	3	128,645,161	0.36±0.08	2.8e-06	-0.09±0.07	0.18	76,762	0.09±0.05	0.066	0.023	35
rs2594220	T	G	3	128,676,117	0.36±0.10	0.00021	-0.04±0.08	0.66	76,702	0.12±0.06	0.048	0.34	8
rs6859788	A	T	5	161,262,342	0.28±0.07	0.00017	-0.02±0.07	0.82	76,717	0.10±0.05	0.027	0.44	2

rs1870230	C	T	5	161,270,378	0.29±0.08	0.00012	-0.02±0.07	0.81	76,717	0.11±0.05	0.027	0.45	1
rs10068984	A	G	5	161,274,708	0.28±0.08	0.00023	-0.02±0.07	0.81	76,717	0.10±0.05	0.034	0.43	3
rs7723554	T	C	5	161,276,527	0.28±0.07	0.00014	-0.02±0.07	0.8	76,717	0.10±0.05	0.026	0.43	2
rs13186615	T	C	5	161,278,335	0.28±0.07	0.00024	-0.02±0.07	0.8	76,717	0.10±0.05	0.033	0.42	3
rs1457703	A	G	5	161,280,570	0.28±0.08	0.0002	-0.02±0.07	0.79	76,717	0.10±0.05	0.033	0.43	3
rs7730737	G	A	5	161,282,399	0.28±0.07	0.00016	-0.01±0.07	0.83	76,717	0.10±0.05	0.027	0.43	2
rs6893787	C	T	5	161,282,903	0.29±0.08	0.00016	-0.02±0.07	0.78	76,717	0.10±0.05	0.032	0.44	2
rs1902795	T	C	5	161,286,763	0.31±0.08	0.00019	-0.02±0.07	0.76	76,579	0.11±0.05	0.031	0.20	16
rs6556564	G	A	5	161,290,316	0.30±0.08	0.00024	-0.02±0.07	0.75	76,580	0.11±0.05	0.033	0.19	17
rs1350374	C	T	5	161,291,288	0.30±0.08	8.7e-05	-0.03±0.07	0.69	76,697	0.10±0.05	0.032	0.41	4
rs1350375	C	G	5	161,291,466	0.30±0.08	7.7e-05	-0.05±0.07	0.44	76,697	0.09±0.05	0.055	0.35	7
rs9313903	C	T	5	161,291,777	0.31±0.08	0.00012	-0.03±0.07	0.72	76,579	0.12±0.05	0.024	0.19	17
rs1585196	G	A	5	161,293,077	0.32±0.08	4.9e-05	-0.02±0.07	0.76	76,655	0.12±0.05	0.019	0.51	0
rs1585198	G	A	5	161,294,336	0.30±0.08	7.1e-05	-0.02±0.07	0.75	76,689	0.11±0.05	0.023	0.42	3
rs1902796	A	G	5	161,301,520	0.30±0.07	5.4e-05	-0.02±0.07	0.8	76,689	0.11±0.05	0.019	0.36	7
rs1457705	A	G	5	161,307,052	0.33±0.07	1.4e-05	-0.02±0.07	0.8	76,689	0.12±0.05	0.011	0.36	7
rs10050729	T	C	5	161,309,251	0.32±0.07	2e-05	-0.02±0.07	0.79	76,689	0.12±0.05	0.012	0.37	6
rs6866875	C	T	5	161,330,637	0.31±0.07	4.3e-05	-0.02±0.07	0.71	76,686	0.11±0.05	0.022	0.37	6
rs2112596	A	G	5	161,348,056	0.33±0.08	9.9e-06	-0.03±0.07	0.65	76,653	0.11±0.05	0.016	0.23	15
rs6887149	A	G	5	161,353,253	0.34±0.08	5.7e-06	-0.04±0.07	0.59	76,637	0.11±0.05	0.015	0.23	15
rs3886595	C	G	5	161,353,951	0.31±0.08	2.8e-05	-0.07±0.07	0.29	76,610	0.08±0.05	0.068	0.22	15
rs1862328	A	G	5	161,354,432	0.32±0.07	2.1e-05	-0.05±0.07	0.49	76,610	0.10±0.05	0.031	0.29	11
rs1475365	A	C	6	41,658,150	0.30±0.09	0.00052	0.10±0.07	0.17	76,573	0.17±0.05	0.0013	0.30	10
rs12207736	G	T	6	41,681,966	0.41±0.09	4.2e-06	0.09±0.08	0.27	76,863	0.22±0.06	0.00015	0.045	30
rs2495229	T	C	6	41,713,808	0.33±0.09	0.00013	0.08±0.08	0.29	76,909	0.19±0.06	0.0011	0.28	11
rs16875791	G	C	7	32,222,133	0.25±0.07	0.00038	0.02±0.06	0.75	77,003	0.12±0.05	0.012	0.0056	42
rs1860224	A	G	7	32,222,167	0.26±0.07	0.00022	0.01±0.06	0.89	77,004	0.11±0.05	0.013	0.0075	40
rs12672267	G	A	7	32,225,259	0.29±0.08	0.00015	0.02±0.07	0.81	76,799	0.13±0.05	0.0091	0.15	20
rs719585	C	G	7	32,225,610	0.35±0.08	2e-05	0.05±0.07	0.52	76,713	0.17±0.05	0.0013	0.16	19
rs6945244	T	C	7	32,225,798	0.27±0.06	2.2e-05	0.11±0.06	0.059	76,918	0.18±0.04	2.4e-05	0.079	26
rs12669911	A	C	7	32,228,902	0.35±0.07	1.4e-06	0.13±0.06	0.032	74,808	0.22±0.05	2.7e-06	0.090	25

rs10233045	A	G	7	32,231,017	0.33±0.07	4.1e-06	0.15±0.06	0.016	76,978	0.22±0.05	1.6e-06	0.063	28
rs10233473	T	C	7	32,231,532	0.34±0.08	1.8e-05	0.05±0.07	0.51	74,826	0.16±0.05	0.0013	0.0048	43
rs10237329	C	T	7	32,232,250	0.33±0.07	3.6e-06	0.15±0.06	0.015	76,978	0.22±0.05	1.3e-06	0.070	27
rs4141108	T	C	7	32,233,484	0.35±0.08	1.4e-05	0.05±0.07	0.5	76,994	0.17±0.05	0.001	0.0067	41
rs10269368	G	A	7	32,238,039	0.34±0.08	1.2e-05	0.04±0.07	0.58	76,984	0.16±0.05	0.0014	0.012	38
rs1014242	C	T	7	32,238,830	0.36±0.08	3.6e-06	0.19±0.07	0.0039	76,808	0.26±0.05	2.4e-07	0.21	16
rs7786576	C	A	7	32,239,239	0.38±0.08	1.1e-06	0.17±0.07	0.0097	74,630	0.25±0.05	4.2e-07	0.29	11
rs7806224	C	T	7	32,239,632	0.36±0.08	3.4e-06	0.19±0.07	0.0039	76,808	0.26±0.05	2.3e-07	0.22	15
rs9639646	G	A	7	32,246,768	0.40±0.09	8.2e-06	0.06±0.08	0.43	76,819	0.20±0.06	0.00057	0.19	17
rs10259431	C	T	7	32,247,922	0.38±0.08	1.8e-06	0.19±0.07	0.0038	74,640	0.27±0.05	1.5e-07	0.17	19
rs9639648	A	G	7	32,248,667	0.39±0.09	9.4e-06	0.07±0.08	0.37	76,815	0.20±0.06	0.00045	0.096	24
rs10263673	T	C	7	32,249,044	0.41±0.09	5.1e-06	0.07±0.08	0.38	74,648	0.20±0.06	0.00037	0.082	26
rs9638875	A	T	7	32,249,439	0.33±0.07	3e-06	0.16±0.06	0.012	76,977	0.23±0.05	7.8e-07	0.080	26
rs10241729	G	A	7	32,256,404	0.32±0.10	0.00075	0.14±0.09	0.12	76,839	0.21±0.06	0.00075	0.16	19
rs10236197	C	T	7	32,258,286	0.35±0.07	1.5e-06	0.17±0.06	0.0085	74,809	0.24±0.05	3.4e-07	0.070	27
rs11773343	T	C	7	32,258,841	0.29±0.08	0.00062	0.18±0.07	0.01	74,814	0.22±0.05	3.5e-05	0.15	20
rs7798739	A	T	7	32,259,486	0.35±0.07	1.4e-06	0.16±0.06	0.0098	74,809	0.24±0.05	4.1e-07	0.068	28
rs13221985	A	C	7	32,259,510	0.29±0.08	0.00062	0.18±0.07	0.0095	74,809	0.22±0.05	3.2e-05	0.15	20
rs929456	G	T	7	32,260,169	0.34±0.07	1.3e-06	0.15±0.06	0.017	76,962	0.23±0.05	7.4e-07	0.084	26
rs13224417	A	G	7	32,265,118	0.29±0.08	0.00062	0.18±0.07	0.0081	74,813	0.22±0.05	2.6e-05	0.16	19
rs11762194	A	G	7	32,266,694	0.29±0.08	0.00056	0.19±0.07	0.0073	74,818	0.23±0.05	2.2e-05	0.13	22
rs6948856	A	G	7	32,268,872	0.29±0.08	0.00071	0.19±0.07	0.007	74,773	0.23±0.05	2.4e-05	0.16	19
rs975122	A	T	7	32,269,319	0.29±0.08	0.00056	0.19±0.07	0.0054	74,817	0.23±0.05	1.5e-05	0.17	19
rs7806397	T	C	7	32,269,864	0.35±0.07	7.5e-07	0.16±0.06	0.011	76,979	0.24±0.05	2.6e-07	0.084	26
rs7796692	G	A	7	32,271,390	0.29±0.08	0.00052	0.19±0.07	0.0076	76,983	0.23±0.05	2.1e-05	0.21	15
rs7780515	T	C	7	32,271,799	0.35±0.07	9.2e-07	0.16±0.06	0.011	76,970	0.24±0.05	3.6e-07	0.092	25
rs4368879	C	T	7	32,274,450	0.36±0.07	3.2e-07	0.16±0.06	0.012	76,972	0.24±0.05	1.7e-07	0.054	29
rs4370439	C	T	7	32,274,626	0.29±0.08	0.00039	0.18±0.07	0.0091	76,975	0.22±0.05	2.1e-05	0.15	20
rs1450869	G	T	7	32,278,197	0.36±0.07	4.7e-07	0.16±0.06	0.0096	76,968	0.24±0.05	1.7e-07	0.063	28
rs1450870	T	C	7	32,278,251	0.37±0.07	2.2e-07	0.13±0.06	0.032	76,960	0.23±0.05	7.1e-07	0.10	24
rs7778162	C	T	7	32,281,009	0.30±0.08	0.00025	0.18±0.07	0.0084	76,975	0.23±0.05	1.4e-05	0.11	23

rs7778443	T	C	7	32,281,215	0.38±0.07	1.3e-07	0.14±0.06	0.027	76,964	0.23±0.05	3.9e-07	0.11	24
rs10226228	G	A	7	32,282,138	0.36±0.07	5e-07	0.16±0.06	0.011	76,971	0.24±0.05	2.4e-07	0.059	28
rs1476765	G	T	7	32,286,983	0.37±0.07	1.8e-07	0.16±0.06	0.011	76,972	0.25±0.05	1.3e-07	0.050	30
rs9771228	C	T	7	32,289,021	0.38±0.07	1.8e-07	0.18±0.06	0.0046	76,967	0.26±0.05	3.5e-08	0.043	31
rs12540232	C	T	7	32,289,486	0.36±0.07	4.2e-07	0.16±0.06	0.011	76,972	0.24±0.05	2.2e-07	0.064	28
rs215596	A	G	7	32,292,898	0.41±0.07	6.3e-09	0.13±0.06	0.027	76,973	0.25±0.05	7.9e-08	0.052	30
rs11768207	C	G	7	32,293,832	0.32±0.08	0.00011	0.14±0.07	0.033	76,996	0.21±0.05	5e-05	0.053	29
rs215599	C	T	7	32,296,654	0.40±0.07	2.3e-08	0.13±0.06	0.032	76,953	0.24±0.05	2.2e-07	0.077	26
rs10271037	T	G	7	32,296,861	0.33±0.08	9.2e-05	0.16±0.07	0.014	77,011	0.22±0.05	1.5e-05	0.074	27
rs215600	G	A	7	32,300,167	0.41±0.07	1.6e-08	0.15±0.06	0.017	76,987	0.25±0.05	7e-08	0.069	27
rs215601	A	C	7	32,300,446	0.40±0.07	1.9e-08	0.13±0.06	0.04	76,976	0.23±0.05	3.1e-07	0.11	23
rs215605	G	T	7	32,303,490	0.39±0.07	1.7e-08	0.17±0.06	0.0035	77,012	0.26±0.04	5.4e-09	0.12	22
rs215607	G	A	7	32,304,862	0.39±0.09	8.6e-06	0.24±0.09	0.0082	57,610	0.31±0.06	5.6e-07	0.62	0
rs215610	G	A	7	32,306,119	0.36±0.08	1.8e-05	0.24±0.07	0.00074	77,021	0.28±0.05	1.1e-07	0.72	0
rs12531858	A	C	7	32,306,624	0.34±0.08	2e-05	0.23±0.07	0.00081	77,020	0.28±0.05	1.2e-07	0.77	0
rs215611	C	G	7	32,307,963	0.40±0.07	6.4e-09	0.05±0.06	0.42	76,998	0.19±0.04	1.9e-05	0.0084	40
rs7780009	A	G	7	32,308,068	0.37±0.08	1e-05	0.24±0.07	0.00068	77,022	0.29±0.05	6.3e-08	0.72	0
rs11771526	G	A	7	32,309,143	0.37±0.10	0.00033	0.12±0.10	0.2	76,933	0.23±0.07	0.00089	0.32	9
rs6952609	G	A	7	32,309,860	0.32±0.08	9.2e-05	0.25±0.07	0.00063	76,948	0.28±0.05	2.9e-07	0.65	0
rs7779181	C	T	7	32,311,808	0.35±0.08	2.8e-05	0.24±0.07	0.00048	77,025	0.28±0.05	9.5e-08	0.71	0
rs7779130	T	G	7	32,313,483	0.35±0.08	2.5e-05	0.24±0.07	0.00051	77,028	0.28±0.05	9.1e-08	0.71	0
rs7778788	C	A	7	32,313,499	0.35±0.08	3.1e-05	0.24±0.07	0.00059	77,025	0.28±0.05	1.3e-07	0.65	0
rs7779180	G	A	7	32,313,727	0.36±0.08	1.2e-05	0.24±0.07	0.00045	77,026	0.29±0.05	4.6e-08	0.66	0
rs215614	G	A	7	32,313,860	0.38±0.07	2.4e-08	0.17±0.06	0.0036	77,008	0.26±0.04	7.1e-09	0.10	24
rs10951331	G	A	7	32,320,899	0.35±0.08	2.9e-05	0.24±0.07	0.00064	77,018	0.28±0.05	1.4e-07	0.70	0
rs215622	C	T	7	32,324,184	0.38±0.07	9.5e-08	0.15±0.06	0.013	77,015	0.24±0.05	1.2e-07	0.11	23
rs215625	G	A	7	32,324,838	0.38±0.07	1.3e-07	0.16±0.06	0.0097	76,997	0.25±0.05	1e-07	0.077	26
rs215629	G	C	7	32,326,989	0.38±0.07	1.6e-07	0.18±0.06	0.0031	76,998	0.26±0.05	2.4e-08	0.14	21
rs1653876	T	C	7	32,327,144	0.33±0.08	8.1e-05	0.15±0.07	0.025	77,021	0.22±0.05	3e-05	0.13	21
rs6462354	G	A	7	32,333,008	0.33±0.09	0.0001	0.19±0.07	0.0063	77,000	0.24±0.05	5.8e-06	0.26	12
rs1115318	A	G	7	32,334,175	0.34±0.09	6.3e-05	0.18±0.07	0.0094	77,002	0.24±0.05	6.6e-06	0.29	10

rs215632	A	G	7	32,335,049	0.37±0.07	2e-07	0.18±0.06	0.0025	76,972	0.26±0.05	1.9e-08	0.13	21
rs215634	A	G	7	32,335,673	0.37±0.07	7.8e-08	0.16±0.06	0.0075	76,966	0.25±0.05	4.6e-08	0.16	19
rs6955346	C	T	7	32,336,078	0.37±0.07	5e-07	0.17±0.06	0.0062	74,823	0.25±0.05	1.4e-07	0.13	21
rs215635	C	T	7	32,336,745	0.36±0.07	1.8e-07	0.18±0.06	0.003	76,972	0.25±0.05	2e-08	0.11	23
rs10264177	G	A	7	32,337,387	0.42±0.08	3.2e-08	0.18±0.07	0.0076	76,780	0.27±0.05	2.4e-08	0.070	27
rs215636	C	G	7	32,338,444	0.31±0.08	0.00026	0.16±0.07	0.019	76,975	0.21±0.05	4.3e-05	0.21	15
rs215639	C	T	7	32,340,164	0.36±0.07	8.9e-07	0.17±0.06	0.0075	74,795	0.24±0.05	2.6e-07	0.13	22
rs6977196	C	T	7	32,340,403	0.31±0.08	0.0002	0.17±0.07	0.013	76,976	0.23±0.05	2e-05	0.44	2
rs10238006	A	C	7	32,343,478	0.32±0.09	0.00021	0.17±0.07	0.017	76,905	0.22±0.05	3.1e-05	0.36	6
rs10447642	T	C	7	32,344,090	0.34±0.09	0.00015	0.17±0.07	0.022	76,785	0.23±0.06	3.7e-05	0.21	16
rs215669	G	A	7	32,345,504	0.34±0.07	8.5e-07	0.15±0.06	0.017	76,949	0.23±0.05	6.5e-07	0.18	18
rs215670	G	A	7	32,345,743	0.36±0.07	7.5e-07	0.16±0.06	0.011	76,884	0.24±0.05	3.7e-07	0.13	22
rs186229	C	A	7	32,348,082	0.34±0.07	8.3e-07	0.13±0.06	0.038	76,968	0.21±0.05	2.2e-06	0.23	14
rs1653889	G	A	7	32,353,178	0.27±0.08	0.00039	0.11±0.06	0.093	76,943	0.17±0.05	0.00042	0.45	1
rs1668389	G	T	7	32,353,440	0.28±0.08	0.00015	0.11±0.06	0.097	76,943	0.18±0.05	0.00023	0.42	3
rs1668393	C	T	7	32,360,136	0.26±0.07	0.00054	0.10±0.06	0.11	76,943	0.16±0.05	0.00066	0.35	7
rs215692	T	C	7	32,361,383	0.32±0.07	3.5e-06	0.12±0.06	0.043	76,982	0.20±0.04	6.5e-06	0.12	22
rs412876	G	T	7	32,362,185	0.34±0.07	1.3e-06	0.13±0.06	0.034	76,982	0.21±0.04	3e-06	0.15	20
rs215694	T	G	7	32,363,551	0.33±0.07	2.3e-06	0.12±0.06	0.053	76,964	0.20±0.05	8.2e-06	0.13	21
rs215695	C	T	7	32,364,433	0.32±0.07	1.6e-05	0.09±0.06	0.14	76,700	0.18±0.05	0.00014	0.13	22
rs215696	G	A	7	32,364,553	0.29±0.08	0.00018	0.11±0.07	0.1	76,690	0.18±0.05	0.00032	0.18	18
rs215697	C	T	7	32,364,566	0.28±0.08	0.00018	0.12±0.07	0.077	76,704	0.18±0.05	0.00019	0.20	16
rs215698	C	T	7	32,364,619	0.30±0.07	5.3e-05	0.09±0.06	0.15	76,702	0.17±0.05	0.00031	0.16	19
rs4723147	A	G	7	32,364,681	0.33±0.08	4.7e-05	0.13±0.07	0.062	76,988	0.20±0.05	6.9e-05	0.17	18
rs1668394	A	C	7	32,365,210	0.32±0.08	2.4e-05	0.10±0.06	0.13	76,692	0.18±0.05	0.00016	0.15	20
rs215699	C	G	7	32,365,499	0.32±0.07	1.6e-05	0.01±0.06	0.85	76,697	0.13±0.05	0.0048	0.035	33
rs215700	C	T	7	32,365,691	0.27±0.07	0.00015	0.01±0.07	0.84	76,819	0.12±0.05	0.0086	0.067	28
rs215702	G	A	7	32,366,183	0.37±0.07	3.6e-07	0.14±0.06	0.021	76,691	0.23±0.05	6.4e-07	0.091	25
rs10486507	T	G	7	32,366,358	0.43±0.09	3.8e-06	0.11±0.08	0.16	76,690	0.23±0.06	8.6e-05	0.20	16
rs215717	A	G	7	32,382,301	0.56±0.12	5.1e-06	0.06±0.11	0.6	73,978	0.25±0.08	0.0011	0.22	16
rs170016	G	A	7	32,412,842	0.34±0.08	1.5e-05	0.15±0.07	0.019	73,946	0.23±0.05	6.4e-06	0.30	11

rs10236370	C	G	7	32,412,984	0.32±0.08	3.7e-05	0.02±0.06	0.75	76,379	0.14±0.05	0.0048	0.067	28
rs1123893	T	C	7	32,413,455	0.37±0.09	7.1e-05	0.06±0.07	0.39	73,867	0.17±0.06	0.0021	0.21	16
rs896165	C	A	7	32,439,685	0.23±0.07	0.00075	-0.00±0.05	0.95	77,012	0.09±0.04	0.036	0.073	27
rs716500	A	G	7	32,443,454	0.24±0.07	0.0006	0.02±0.06	0.68	77,013	0.11±0.04	0.013	0.15	20
rs10958725	G	T	8	42,643,741	0.28±0.08	0.00063	0.29±0.07	3.7e-05	76,670	0.29±0.05	8.5e-08	0.22	15
rs7837296	C	A	8	42,646,051	0.31±0.09	0.00054	0.29±0.08	0.00019	76,629	0.30±0.06	3.8e-07	0.23	15
rs5005909	A	G	8	42,647,824	0.30±0.09	0.00065	0.29±0.08	0.00019	76,629	0.29±0.06	4.4e-07	0.25	13
rs1979140	C	T	8	42,649,993	0.31±0.08	0.00017	0.30±0.07	3.4e-05	76,668	0.30±0.05	2.3e-08	0.26	12
rs10958726	T	G	8	42,655,066	0.31±0.08	0.00013	0.30±0.07	3.3e-05	76,668	0.30±0.05	1.7e-08	0.25	13
rs7842601	T	C	8	42,656,212	0.30±0.08	0.00018	0.29±0.07	3.8e-05	76,668	0.30±0.05	2.7e-08	0.24	14
rs13273442	G	A	8	42,663,174	0.29±0.08	0.00032	0.29±0.07	3.6e-05	76,669	0.29±0.05	4.3e-08	0.26	13
rs1451239	A	G	8	42,665,699	0.30±0.08	0.00021	0.30±0.07	4e-05	76,643	0.30±0.05	3.2e-08	0.26	13
rs1451240	G	A	8	42,665,868	0.29±0.08	0.00032	0.30±0.07	2.6e-05	76,669	0.30±0.05	3.2e-08	0.27	12
rs1955185	T	C	8	42,668,804	0.31±0.08	0.00024	0.12±0.09	0.19	57,327	0.22±0.06	0.00036	0.43	2
rs6474412	T	C	8	42,669,655	0.31±0.08	0.00017	0.30±0.07	2.6e-05	76,670	0.30±0.05	1.7e-08	0.25	13
rs7004381	G	A	8	42,670,318	0.29±0.08	0.00031	0.30±0.07	2.6e-05	76,670	0.30±0.05	3e-08	0.21	16
rs4950	A	G	8	42,671,790	0.31±0.08	0.00017	0.10±0.09	0.31	57,327	0.21±0.06	0.0006	0.43	3
rs1530848	T	G	8	42,672,065	0.28±0.08	0.00049	0.30±0.07	2.6e-05	76,670	0.29±0.05	4.8e-08	0.23	15
rs13280604	A	G	8	42,678,743	0.31±0.08	0.00012	0.30±0.07	2.7e-05	76,670	0.31±0.05	1.3e-08	0.24	14
rs6997909	G	A	8	42,679,406	0.30±0.08	0.00022	0.30±0.07	2.7e-05	76,670	0.30±0.05	2.3e-08	0.25	13
rs6474414	C	A	8	42,679,493	0.29±0.08	0.00037	0.30±0.07	2.8e-05	76,666	0.29±0.05	3.9e-08	0.23	14
rs6474415	A	G	8	42,682,095	0.30±0.08	0.00024	0.30±0.07	3.2e-05	76,670	0.30±0.05	2.9e-08	0.25	13
rs16891561	C	T	8	42,698,896	0.30±0.09	0.00062	0.31±0.08	4.8e-05	76,610	0.30±0.06	1.1e-07	0.27	12
rs7017612	A	C	8	42,718,402	0.34±0.09	0.00018	0.27±0.08	0.00041	74,551	0.29±0.06	3.8e-07	0.0051	44
rs2304297	G	C	8	42,727,356	0.28±0.08	0.00075	0.15±0.07	0.024	76,681	0.20±0.05	0.00011	0.13	22
rs12376406	G	T	9	27,830,794	0.28±0.07	0.00017	0.08±0.06	0.2	76,940	0.16±0.05	0.00075	0.36	6
rs12376417	C	T	9	27,830,808	0.28±0.07	0.00015	0.08±0.06	0.19	76,940	0.16±0.05	0.00067	0.38	5
rs7853855	G	A	9	27,836,594	0.28±0.07	0.0001	0.08±0.06	0.18	76,945	0.16±0.05	0.00049	0.36	6
rs947521	C	T	9	27,846,707	0.28±0.07	0.00014	0.06±0.06	0.31	76,819	0.15±0.05	0.0015	0.24	14
rs10511818	T	C	9	27,847,771	0.29±0.07	4.6e-05	0.06±0.06	0.32	76,819	0.15±0.05	0.00083	0.25	13
rs10968151	T	C	9	27,847,857	0.28±0.07	8e-05	0.06±0.06	0.32	76,819	0.15±0.05	0.0011	0.25	13

rs4581139	T	C	9	27,850,390	0.29±0.07	6.7e-05	0.06±0.06	0.32	76,818	0.15±0.05	0.001	0.25	13
rs10812677	T	C	9	27,852,281	0.28±0.07	0.00012	0.06±0.06	0.32	76,819	0.15±0.05	0.0015	0.24	14
rs10812678	G	A	9	27,852,655	0.29±0.07	6e-05	0.07±0.06	0.28	76,823	0.15±0.05	0.00079	0.29	11
rs1004158	G	A	9	27,855,600	0.23±0.07	0.00054	0.09±0.06	0.12	76,826	0.15±0.04	0.0006	0.61	0
rs10968157	A	C	9	27,856,582	0.28±0.07	0.00013	0.09±0.06	0.17	76,584	0.16±0.05	0.00049	0.37	6
rs10812680	C	T	9	27,864,522	0.28±0.07	0.00019	0.08±0.06	0.18	76,816	0.16±0.05	0.00076	0.19	17
rs2039997	G	A	9	27,865,763	0.28±0.07	0.00013	0.09±0.06	0.16	76,862	0.16±0.05	0.00049	0.26	12
rs2778429	C	A	9	27,868,045	0.28±0.07	9.3e-05	0.09±0.06	0.16	76,884	0.16±0.05	0.00039	0.25	13
rs10812681	C	G	9	27,869,095	0.24±0.07	0.00022	0.04±0.06	0.48	76,891	0.12±0.04	0.0061	0.14	20
rs7469938	C	T	9	27,884,033	0.29±0.07	6.8e-05	0.09±0.06	0.16	76,910	0.17±0.05	0.00033	0.24	14
rs1930021	T	C	9	27,885,371	0.30±0.07	5.1e-05	0.08±0.06	0.18	76,924	0.16±0.05	0.00036	0.26	13
rs10968177	T	C	9	27,887,124	0.23±0.07	0.00059	-0.03±0.06	0.6	76,912	0.08±0.04	0.07	0.010	39
rs12378440	G	A	9	27,892,874	0.31±0.07	2.2e-05	0.09±0.06	0.16	76,861	0.18±0.05	0.00017	0.17	19
rs2383743	A	G	9	27,894,341	0.30±0.07	3.5e-05	0.08±0.06	0.18	76,900	0.17±0.05	0.00027	0.28	11
rs1930025	G	A	9	27,896,255	0.24±0.07	0.00027	-0.03±0.06	0.61	76,902	0.08±0.04	0.05	0.012	38
rs10812686	A	C	9	27,899,600	0.31±0.07	2.9e-05	0.08±0.06	0.18	76,986	0.17±0.05	0.00025	0.26	13
rs10812687	A	G	9	27,902,332	0.29±0.07	6.2e-05	0.08±0.06	0.2	76,981	0.16±0.05	0.00044	0.23	14
rs10491823	T	A	9	27,904,937	0.31±0.07	1.9e-05	0.08±0.06	0.21	76,980	0.17±0.05	0.00027	0.23	14
rs10491824	G	A	9	27,905,195	0.32±0.07	1.2e-05	0.08±0.06	0.21	76,979	0.17±0.05	0.00021	0.24	14
rs10757695	T	C	9	27,905,464	0.25±0.07	0.00013	-0.03±0.06	0.55	76,974	0.09±0.04	0.045	0.011	39
rs10812690	A	G	9	27,905,481	0.32±0.07	1.6e-05	0.08±0.06	0.22	76,986	0.17±0.05	0.00024	0.24	14
rs13286150	G	A	9	27,911,436	0.28±0.07	4.7e-05	-0.04±0.06	0.54	76,978	0.09±0.04	0.035	0.011	39
rs10757697	A	G	9	27,915,198	0.24±0.07	0.00028	-0.02±0.06	0.73	77,016	0.09±0.04	0.04	0.013	38
rs1930037	G	A	9	27,916,612	0.24±0.07	0.00028	-0.02±0.06	0.71	77,016	0.09±0.04	0.042	0.012	38
rs1930038	C	T	9	27,916,755	0.25±0.07	0.00021	-0.02±0.06	0.67	77,011	0.09±0.04	0.041	0.011	39
rs10812695	G	T	9	27,917,133	0.35±0.07	9.4e-07	0.03±0.06	0.62	77,015	0.15±0.04	0.00054	0.12	22
rs1953037	G	C	9	27,917,768	0.35±0.07	9.5e-07	0.02±0.06	0.7	76,961	0.15±0.04	0.00073	0.14	21
rs1953038	G	A	9	27,918,087	0.35±0.07	1e-06	0.03±0.06	0.67	76,985	0.15±0.04	0.00065	0.16	19
rs1953039	C	A	9	27,918,101	0.35±0.07	8.9e-07	0.02±0.06	0.68	76,985	0.15±0.04	0.00067	0.17	18
rs10812697	A	C	9	27,918,282	0.26±0.07	0.00012	-0.03±0.06	0.66	76,990	0.09±0.04	0.033	0.011	38
rs10968200	A	G	9	27,918,472	0.25±0.07	0.00021	-0.03±0.06	0.66	76,990	0.09±0.04	0.041	0.017	36

rs10491825	T	C	9	27,920,953	0.33±0.07	3.6e-06	0.03±0.06	0.64	76,781	0.15±0.04	0.0011	0.25	13
rs10968202	G	A	9	27,921,179	0.36±0.07	4.6e-07	0.02±0.06	0.71	76,981	0.16±0.05	0.00058	0.17	18
rs10812698	A	G	9	27,922,763	0.25±0.07	0.00028	-0.03±0.06	0.64	76,988	0.08±0.04	0.049	0.020	36
rs10968206	G	A	9	27,924,303	0.34±0.07	1.8e-06	0.03±0.06	0.68	76,985	0.15±0.05	0.00088	0.17	18
rs10968210	A	G	9	27,924,992	0.24±0.07	0.00042	-0.04±0.06	0.55	76,951	0.08±0.04	0.074	0.029	33
rs10812699	G	C	9	27,925,096	0.25±0.07	0.0002	-0.01±0.06	0.8	76,947	0.09±0.04	0.047	0.028	34
rs10968212	G	A	9	27,925,252	0.27±0.07	0.00013	-0.04±0.06	0.53	74,778	0.08±0.04	0.057	0.021	36
rs2383748	C	T	9	27,926,360	0.32±0.07	1.6e-05	0.06±0.06	0.33	76,962	0.16±0.05	0.00056	0.26	13
rs10968213	A	C	9	27,926,769	0.31±0.07	3.3e-05	0.06±0.06	0.33	76,966	0.16±0.05	0.00083	0.24	14
rs10812700	G	C	9	27,926,991	0.32±0.07	1.7e-05	0.08±0.06	0.21	76,958	0.17±0.05	0.00024	0.32	9
rs2804	A	T	9	27,927,750	0.32±0.07	2e-05	0.06±0.06	0.34	76,970	0.16±0.05	0.00065	0.25	13
rs12375721	T	C	9	27,927,803	0.31±0.07	3.4e-05	0.06±0.06	0.34	76,970	0.16±0.05	0.00087	0.23	14
rs12375740	A	G	9	27,927,887	0.32±0.08	2.6e-05	0.06±0.06	0.36	76,917	0.16±0.05	0.00082	0.25	13
rs2383749	C	T	9	27,927,912	0.31±0.07	3.2e-05	0.06±0.06	0.34	76,970	0.16±0.05	0.00086	0.24	14
rs1930041	A	G	9	27,928,615	0.31±0.07	2.9e-05	0.06±0.06	0.36	76,970	0.16±0.05	0.00089	0.22	15
rs10812702	C	T	9	27,929,856	0.30±0.07	4.7e-05	0.05±0.06	0.4	76,955	0.15±0.05	0.0014	0.24	14
rs10968215	T	C	9	27,930,160	0.33±0.08	1.7e-05	0.05±0.06	0.42	74,779	0.16±0.05	0.001	0.15	20
rs1930047	C	T	9	27,933,323	0.31±0.08	3.2e-05	0.05±0.06	0.4	76,892	0.15±0.05	0.0012	0.30	10
rs11037491	T	G	11	43,574,122	0.30±0.09	0.00062	-0.04±0.08	0.58	77,016	0.09±0.05	0.088	0.81	0
rs12800492	A	G	11	43,575,637	0.30±0.09	0.00071	-0.04±0.08	0.58	77,013	0.09±0.05	0.087	0.75	0
rs11037498	G	T	11	43,584,409	0.32±0.09	0.00046	-0.04±0.08	0.55	77,007	0.09±0.06	0.091	0.75	0
rs7936371	G	A	11	43,589,915	0.31±0.08	7.3e-05	-0.06±0.07	0.36	77,000	0.09±0.05	0.07	0.56	0
rs2902373	T	C	11	43,594,139	0.31±0.08	7.6e-05	-0.06±0.07	0.36	77,000	0.09±0.05	0.076	0.53	0
rs11037530	C	G	11	43,613,252	0.29±0.08	0.00017	-0.03±0.07	0.67	77,016	0.10±0.05	0.041	0.71	0
rs11037532	C	T	11	43,614,142	0.28±0.08	0.00027	-0.05±0.07	0.46	77,015	0.08±0.05	0.084	0.49	0
rs9783372	G	A	11	43,616,872	0.30±0.08	0.00013	-0.06±0.07	0.38	77,019	0.08±0.05	0.084	0.63	0
rs11037536	G	A	11	43,621,394	0.27±0.08	0.00038	-0.05±0.07	0.44	77,017	0.08±0.05	0.1	0.58	0
rs11037539	C	A	11	43,630,795	0.29±0.08	0.00026	-0.06±0.07	0.35	77,020	0.08±0.05	0.12	0.77	0
rs7129385	A	G	11	43,641,361	0.29±0.08	0.00018	-0.06±0.07	0.4	77,000	0.08±0.05	0.086	0.52	0
rs11037545	A	G	11	43,644,987	0.30±0.08	0.0002	-0.06±0.07	0.35	77,022	0.08±0.05	0.11	0.77	0
rs7105746	G	A	11	43,648,160	0.29±0.08	0.00025	-0.07±0.07	0.31	77,024	0.07±0.05	0.12	0.70	0

rs9804429	A	T	11	43,706,164	0.34±0.08	4.1e-05	0.01±0.07	0.94	76,543	0.14±0.05	0.0081	0.48	0
rs9971430	T	C	11	43,712,356	0.33±0.08	4.5e-05	-0.00±0.06	0.99	76,892	0.13±0.05	0.01	0.44	2
rs10838159	G	A	11	43,718,786	0.33±0.08	4.7e-05	-0.00±0.06	0.99	76,918	0.13±0.05	0.01	0.41	3
rs10742688	G	A	11	43,724,830	0.26±0.07	0.00034	-0.04±0.06	0.49	76,974	0.08±0.05	0.075	0.41	3
rs7115970	T	C	11	43,725,871	0.26±0.07	0.00036	-0.04±0.06	0.5	76,974	0.08±0.05	0.077	0.42	3
rs10768976	G	T	11	43,730,389	0.27±0.07	0.00033	-0.04±0.06	0.5	76,672	0.08±0.05	0.077	0.38	5
rs4643069	G	A	11	43,732,310	0.26±0.07	0.00035	-0.04±0.06	0.51	76,672	0.08±0.05	0.077	0.40	4
rs7110115	A	G	11	43,736,769	0.30±0.08	0.00019	0.00±0.06	0.99	74,920	0.12±0.05	0.019	0.43	3
rs7110437	A	C	11	43,737,129	0.26±0.07	0.00044	-0.04±0.06	0.53	76,672	0.08±0.05	0.078	0.38	6
rs12273608	A	G	11	43,741,212	0.35±0.08	1.8e-05	-0.00±0.07	0.96	77,014	0.14±0.05	0.0079	0.21	16
rs11037609	T	C	11	43,743,055	0.34±0.08	2.8e-05	-0.00±0.07	0.98	77,014	0.13±0.05	0.0088	0.24	14
rs6485460	T	G	11	43,757,265	0.34±0.08	3.3e-05	-0.01±0.07	0.92	76,715	0.13±0.05	0.012	0.23	14
rs10400325	A	G	11	43,763,578	0.32±0.08	7.8e-05	-0.02±0.07	0.75	76,688	0.11±0.05	0.025	0.35	7
rs10400390	G	T	11	43,763,968	0.33±0.08	4.7e-05	-0.01±0.07	0.89	76,715	0.12±0.05	0.015	0.25	13
rs4755744	A	C	11	43,774,306	0.30±0.08	7.7e-05	-0.01±0.07	0.94	57,326	0.15±0.05	0.0057	0.52	0
rs10838172	A	C	11	43,776,784	0.32±0.08	4.9e-05	-0.01±0.07	0.89	76,701	0.12±0.05	0.015	0.26	12
rs11037654	A	G	11	43,785,335	0.33±0.08	3e-05	-0.01±0.07	0.89	77,025	0.12±0.05	0.013	0.25	13
rs10400343	A	G	11	43,789,081	0.30±0.08	8.8e-05	-0.01±0.07	0.94	57,326	0.15±0.05	0.0061	0.55	0
rs2037296	A	G	11	43,792,647	0.33±0.08	4.4e-05	-0.01±0.07	0.85	76,714	0.12±0.05	0.017	0.23	15
rs7114842	C	A	11	43,796,007	0.34±0.07	4e-06	-0.03±0.06	0.7	76,986	0.12±0.05	0.0086	0.18	17
rs2869030	T	G	15	76,498,858	0.57±0.09	1.3e-10	0.59±0.08	5.6e-15	76,775	0.59±0.06	4.6e-24	0.29	10
rs4887053	C	A	15	76,499,754	0.59±0.08	1.7e-13	0.66±0.07	1.2e-20	77,005	0.63±0.05	1.5e-32	0.052	29
rs2869032	T	C	15	76,501,616	0.61±0.08	2.9e-13	0.66±0.07	1.2e-20	77,004	0.64±0.05	2.6e-32	0.055	29
rs2869045	C	T	15	76,505,954	0.62±0.08	1.1e-13	0.66±0.07	1.3e-20	77,005	0.65±0.05	1.1e-32	0.066	28
rs2568498	A	T	15	76,508,987	0.20±0.06	0.0015	0.17±0.06	0.0046	76,824	0.18±0.04	2.5e-05	0.30	10
rs1394371	T	C	15	76,511,524	0.61±0.07	2.3e-16	0.60±0.06	3.6e-21	76,969	0.61±0.05	6.9e-36	0.0096	39
rs2568500	C	T	15	76,513,983	0.18±0.07	0.0053	0.29±0.08	0.00014	57,609	0.23±0.05	3.6e-06	0.60	0
rs17483548	A	G	15	76,517,368	0.71±0.07	2e-24	0.66±0.06	2.2e-27	77,016	0.68±0.05	6.3e-50	0.061	28
rs17405217	T	C	15	76,518,204	0.71±0.07	8.1e-25	0.66±0.06	1.9e-27	77,017	0.68±0.05	2.5e-50	0.056	29
rs924840	A	T	15	76,518,863	0.58±0.08	1.1e-13	0.62±0.07	4.9e-19	76,995	0.60±0.05	4e-31	0.092	25
rs2938671	G	A	15	76,519,809	0.59±0.08	8.3e-14	0.62±0.07	3.1e-19	76,996	0.61±0.05	1.9e-31	0.095	25

rs17483721	C	T	15	76,520,786	0.71±0.07	7.4e-25	0.67±0.06	8.2e-28	77,022	0.69±0.05	9.1e-51	0.063	28
rs1847529	A	C	15	76,522,125	0.21±0.06	0.0012	0.18±0.06	0.0017	76,829	0.19±0.04	7e-06	0.27	12
rs8041628	C	G	15	76,522,410	0.21±0.06	0.0013	0.15±0.06	0.011	76,824	0.17±0.04	6e-05	0.15	20
rs2568488	A	T	15	76,523,648	0.61±0.08	1.6e-13	0.62±0.07	3.1e-19	77,024	0.62±0.05	3.7e-31	0.093	25
rs2656052	C	A	15	76,527,987	0.72±0.07	6.6e-25	0.67±0.06	2.8e-28	77,023	0.69±0.05	2.7e-51	0.067	28
rs2568494	A	G	15	76,528,019	0.71±0.07	5.7e-25	0.67±0.06	2.4e-28	77,023	0.69±0.05	2e-51	0.053	29
rs7181486	C	T	15	76,528,673	0.72±0.07	5.3e-25	0.67±0.06	2.2e-28	77,019	0.69±0.05	1.7e-51	0.059	28
rs2656073	G	T	15	76,529,331	0.61±0.08	6.4e-14	0.62±0.07	4.7e-19	77,020	0.62±0.05	2.3e-31	0.089	25
rs17483929	A	G	15	76,529,431	0.72±0.07	4.2e-25	0.66±0.06	8.9e-28	77,016	0.69±0.05	6e-51	0.086	25
rs10519198	C	A	15	76,529,809	0.21±0.06	0.0012	0.19±0.06	0.00083	76,825	0.20±0.04	3.4e-06	0.29	10
rs2958719	A	G	15	76,530,084	0.62±0.09	7.7e-13	0.60±0.07	4.2e-16	76,937	0.61±0.06	2.5e-27	0.20	17
rs12909921	A	G	15	76,530,315	0.21±0.06	0.0012	0.19±0.06	0.00099	76,829	0.20±0.04	4.2e-06	0.31	9
rs12910090	A	C	15	76,530,355	0.21±0.06	0.0014	0.19±0.06	0.00094	76,829	0.20±0.04	4.3e-06	0.32	9
rs2656071	A	T	15	76,532,398	0.59±0.08	9.6e-14	0.62±0.07	5e-19	77,023	0.61±0.05	3.5e-31	0.090	25
rs2656069	T	C	15	76,532,762	0.59±0.08	7.4e-14	0.61±0.07	2.1e-18	77,024	0.60±0.05	1.1e-30	0.047	30
rs2656065	A	G	15	76,537,604	0.72±0.07	3.2e-25	0.68±0.06	2.7e-29	77,023	0.70±0.05	1.2e-52	0.090	25
rs2568483	A	G	15	76,539,398	0.58±0.08	1.8e-13	0.62±0.07	2.8e-19	77,024	0.61±0.05	3.7e-31	0.076	26
rs11639224	A	G	15	76,540,426	0.21±0.06	0.001	0.20±0.06	0.00066	76,829	0.20±0.04	2.4e-06	0.34	8
rs1964678	G	A	15	76,541,055	0.48±0.07	5.6e-13	0.56±0.06	5e-21	77,027	0.52±0.04	2.5e-32	0.29	11
rs2009746	G	A	15	76,541,157	0.72±0.07	3.4e-25	0.70±0.06	6.1e-30	77,010	0.71±0.05	2.7e-53	0.096	24
rs2938674	C	A	15	76,544,968	0.59±0.08	1.1e-13	0.62±0.07	4.2e-19	77,025	0.61±0.05	3.3e-31	0.091	25
rs17484235	G	C	15	76,548,469	0.72±0.07	6.3e-25	0.54±0.06	7.1e-19	77,009	0.61±0.05	5.2e-41	3.0e-08	65
rs4299116	A	T	15	76,553,249	0.49±0.07	3.2e-13	0.56±0.06	5.5e-21	77,027	0.53±0.04	1.4e-32	0.29	10
rs1504550	G	A	15	76,553,305	0.73±0.07	2e-25	0.70±0.06	2.1e-30	77,008	0.71±0.05	5.1e-54	0.11	23
rs12910910	T	C	15	76,554,905	0.48±0.07	4e-13	0.56±0.06	5.8e-21	77,027	0.53±0.04	2e-32	0.32	9
rs8043227	G	C	15	76,555,926	0.48±0.07	5.5e-13	0.21±0.06	0.00039	77,011	0.32±0.04	1.6e-13	1.6e-11	71
rs11072766	C	T	15	76,558,601	0.61±0.08	3e-14	0.62±0.07	3.3e-19	77,025	0.62±0.05	7.4e-32	0.11	23
rs17484524	G	A	15	76,559,731	0.73±0.07	1.9e-25	0.71±0.06	8.6e-31	77,008	0.72±0.05	2e-54	0.12	22
rs8042238	T	C	15	76,561,326	0.49±0.07	2.4e-13	0.56±0.06	5.8e-21	77,027	0.53±0.04	1.1e-32	0.28	11
rs8042260	G	A	15	76,561,429	0.48±0.07	3.2e-13	0.56±0.06	5.8e-21	77,027	0.53±0.04	1.6e-32	0.31	10
rs12903295	G	A	15	76,566,027	0.49±0.07	1e-12	0.56±0.06	6.3e-21	77,027	0.53±0.04	5e-32	0.29	10

rs12904234	T	C	15	76,566,439	0.48±0.07	8.7e-13	0.56±0.06	6.5e-21	77,027	0.52±0.04	4.7e-32	0.33	8
rs965604	A	G	15	76,576,278	0.48±0.07	3.8e-13	0.55±0.06	7.1e-21	77,027	0.52±0.04	2.3e-32	0.30	10
rs13180	T	C	15	76,576,543	0.48±0.07	4.4e-13	0.55±0.06	1.1e-20	77,025	0.52±0.04	4.2e-32	0.18	18
rs1062980	T	C	15	76,579,582	0.49±0.07	2e-13	0.56±0.06	5.3e-21	77,027	0.53±0.04	8.7e-33	0.24	14
rs4362358	T	C	15	76,583,159	0.49±0.07	3.6e-13	0.58±0.06	4.5e-22	77,027	0.54±0.04	1.5e-33	0.31	9
rs5019044	T	A	15	76,583,337	0.61±0.08	1.4e-13	0.65±0.07	9.4e-21	77,025	0.64±0.05	9.4e-33	0.076	27
rs9788682	G	A	15	76,589,641	0.69±0.08	1e-17	0.75±0.07	1.3e-25	76,959	0.73±0.05	1.2e-41	0.036	32
rs9788721	C	T	15	76,589,924	0.82±0.07	8.4e-33	0.77±0.06	3.1e-37	77,022	0.79±0.05	5e-68	0.18	18
rs7164594	C	T	15	76,590,112	0.68±0.08	2.7e-16	0.76±0.07	7.6e-27	76,978	0.73±0.05	1.8e-41	0.012	38
rs8034191	C	T	15	76,593,078	0.82±0.07	7.9e-33	0.77±0.06	4.3e-37	76,967	0.79±0.05	6.8e-68	0.18	17
rs12591557	A	G	15	76,598,787	0.22±0.07	0.001	0.30±0.08	8.6e-05	57,614	0.25±0.05	3.9e-07	0.45	1
rs10519203	G	A	15	76,601,101	0.82±0.07	8.7e-33	0.76±0.06	1.6e-36	77,010	0.78±0.05	3.1e-67	0.15	20
rs7163730	A	G	15	76,601,736	0.69±0.08	6.1e-18	0.75±0.07	1.1e-26	77,010	0.73±0.05	6.1e-43	0.033	33
rs8031948	T	G	15	76,603,112	0.82±0.07	9.5e-33	0.77±0.06	2.4e-37	77,000	0.79±0.05	4.6e-68	0.17	18
rs4461039	A	T	15	76,604,502	0.70±0.08	1.5e-18	0.76±0.07	4.4e-27	77,018	0.73±0.05	5.8e-44	0.026	34
rs3885951	G	A	15	76,612,972	0.54±0.12	1.3e-05	0.71±0.10	4.5e-12	76,684	0.64±0.08	4.2e-16	0.00026	52
rs931794	G	A	15	76,613,235	0.83±0.07	5.2e-33	0.78±0.06	7.5e-38	76,993	0.80±0.05	7.3e-69	0.17	18
rs2036534	T	C	15	76,614,003	0.69±0.08	2.6e-18	0.74±0.07	3.3e-26	77,007	0.72±0.05	7.2e-43	0.0040	43
rs3813570	T	C	15	76,619,887	0.66±0.08	1.6e-16	0.75±0.07	1.1e-26	76,955	0.71±0.05	1.7e-41	0.0068	41
rs4243083	G	C	15	76,620,885	0.23±0.07	0.00062	-0.05±0.08	0.51	57,614	0.10±0.05	0.04	0.0027	48
rs4887063	T	C	15	76,626,770	0.24±0.06	0.00018	0.22±0.06	0.00019	76,791	0.23±0.04	1.3e-07	0.32	9
rs1979907	C	T	15	76,629,294	0.29±0.07	8.7e-06	0.23±0.06	8.8e-05	76,970	0.26±0.04	4.4e-09	0.45	1
rs1979905	C	A	15	76,629,429	0.29±0.07	9.7e-06	0.24±0.06	8.5e-05	76,932	0.26±0.04	4.4e-09	0.38	5
rs4887064	C	G	15	76,629,902	0.29±0.07	1.2e-05	0.16±0.06	0.0062	76,970	0.22±0.04	8.2e-07	0.13	21
rs12907966	C	T	15	76,630,106	0.29±0.07	1.2e-05	0.23±0.06	8.6e-05	76,971	0.26±0.04	5.4e-09	0.49	0
rs880395	G	A	15	76,631,411	0.28±0.07	1.4e-05	0.23±0.06	9e-05	76,970	0.26±0.04	6.5e-09	0.49	0
rs905740	C	T	15	76,631,441	0.28±0.07	1.4e-05	0.23±0.06	8.7e-05	76,970	0.26±0.04	6.4e-09	0.49	0
rs7164030	A	G	15	76,631,716	0.28±0.07	1.6e-05	0.23±0.06	8.9e-05	76,970	0.25±0.04	7.2e-09	0.48	0
rs4275821	T	C	15	76,636,596	0.27±0.07	4.7e-05	0.32±0.06	2.8e-07	76,929	0.30±0.05	5.9e-11	0.85	0
rs7173512	T	C	15	76,636,969	0.28±0.07	4e-05	0.32±0.06	2.7e-07	76,929	0.30±0.05	4.8e-11	0.85	0
rs2036527	A	G	15	76,638,670	0.83±0.07	2.3e-31	0.80±0.06	4.6e-38	76,912	0.81±0.05	1.6e-67	0.091	25

rs684513	C	G	15	76,645,455	0.67±0.08	2.9e-15	0.63±0.07	9.6e-19	76,896	0.65±0.05	2.6e-32	4.6e-08	65
rs667282	T	C	15	76,650,527	0.70±0.08	5.4e-18	0.74±0.07	3.4e-26	76,763	0.72±0.05	1.6e-42	0.015	37
rs17486278	C	A	15	76,654,537	0.83±0.07	4.6e-31	0.79±0.06	1.4e-37	76,939	0.80±0.05	1e-66	0.062	28
rs569207	C	T	15	76,660,174	0.72±0.08	4.1e-18	0.61±0.09	6.9e-12	57,573	0.67±0.06	3.7e-28	0.026	37
rs637137	T	A	15	76,661,031	0.71±0.08	2e-18	0.73±0.07	5.8e-26	76,764	0.72±0.05	1e-42	0.018	36
rs7180002	T	A	15	76,661,048	0.83±0.07	6.9e-31	0.79±0.06	1.2e-37	76,943	0.80±0.05	1.4e-66	0.066	28
rs951266	A	G	15	76,665,596	0.83±0.07	1.9e-30	0.78±0.06	3.7e-36	74,879	0.80±0.05	1.4e-64	0.064	29
rs16969968	A	G	15	76,669,980	0.82±0.07	5.4e-32	0.77±0.06	7.6e-38	76,996	0.79±0.05	7e-68	0.089	25
rs518425	A	G	15	76,670,868	0.65±0.07	4.4e-18	0.59±0.06	3e-20	76,790	0.62±0.05	1.5e-36	0.49	0
rs578776	G	A	15	76,675,455	0.64±0.08	2e-17	0.62±0.06	6.7e-22	76,791	0.63±0.05	1.3e-37	0.49	0
rs12910984	A	G	15	76,678,682	0.71±0.08	1.7e-18	0.72±0.07	6.4e-26	76,995	0.72±0.05	9.6e-43	0.0052	42
rs1051730	A	G	15	76,681,394	0.84±0.07	2.1e-33	0.78±0.06	5.6e-38	76,972	0.80±0.05	2.4e-69	0.035	32
rs3743078	G	C	15	76,681,814	0.72±0.08	2.8e-19	0.33±0.07	1.7e-06	76,995	0.48±0.05	6.8e-21	3.7e-18	78
rs1317286	G	A	15	76,683,184	0.81±0.07	4.8e-32	0.77±0.06	7.5e-38	77,002	0.79±0.05	6.2e-68	0.091	25
rs938682	A	G	15	76,683,602	0.72±0.08	1.9e-19	0.72±0.07	6.4e-26	77,006	0.72±0.05	1.1e-43	0.0081	40
rs12914385	T	C	15	76,685,778	0.78±0.07	2.4e-31	0.77±0.06	2.1e-39	76,697	0.78±0.04	6.7e-69	0.061	29
rs11637630	A	G	15	76,686,774	0.72±0.08	2.9e-19	0.74±0.07	6.2e-27	76,993	0.73±0.05	1.6e-44	0.016	37
rs7177514	C	G	15	76,694,461	0.70±0.08	1.4e-17	0.63±0.07	3.7e-20	77,005	0.66±0.05	6.6e-36	2.4e-06	60
rs6495308	T	C	15	76,694,711	0.71±0.08	1.2e-18	0.74±0.07	6.1e-27	77,005	0.73±0.05	6.3e-44	0.016	37
rs12443170	G	A	15	76,694,791	0.63±0.11	6.2e-09	0.78±0.10	3.4e-16	76,566	0.72±0.07	1.7e-23	0.064	28
rs8042059	A	C	15	76,694,914	0.72±0.08	1.7e-19	0.73±0.07	1.7e-26	77,004	0.73±0.05	2.6e-44	0.014	37
rs8042374	A	G	15	76,695,087	0.71±0.08	8.5e-19	0.72±0.07	1.3e-25	77,005	0.71±0.05	9.5e-43	0.0072	40
rs4887069	A	G	15	76,696,125	0.72±0.09	3.8e-17	0.71±0.07	4.6e-24	76,962	0.72±0.05	1.6e-39	0.020	36
rs3743075	C	T	15	76,696,507	0.25±0.07	0.00028	0.27±0.06	6.1e-06	76,657	0.26±0.05	6.7e-09	0.83	0
rs8040868	C	T	15	76,698,236	0.77±0.07	1.9e-29	0.74±0.08	2.5e-22	57,303	0.76±0.05	5.8e-50	0.085	29
rs6495309	C	T	15	76,702,300	0.71±0.08	1.6e-18	0.71±0.07	5.2e-24	76,977	0.71±0.05	7.4e-41	0.014	38
rs17487223	T	C	15	76,711,042	0.78±0.07	9.2e-29	0.75±0.06	3.1e-34	76,928	0.76±0.05	3.9e-61	0.27	12
rs12440014	C	G	15	76,713,781	0.72±0.08	8.4e-19	0.64±0.07	8.8e-20	76,583	0.67±0.05	1.1e-36	3.3e-06	60
rs12441088	T	G	15	76,715,319	0.62±0.09	1e-12	0.77±0.07	2.1e-26	74,467	0.71±0.06	2.6e-37	0.0066	41
rs11636605	G	A	15	76,715,933	0.59±0.09	2.7e-10	0.67±0.07	1.6e-19	74,454	0.64±0.06	3.1e-28	0.032	33
rs12441998	A	G	15	76,716,427	0.59±0.09	2.4e-10	0.66±0.07	1e-19	74,704	0.64±0.06	1.8e-28	0.020	36

rs11072768	G	T	15	76,716,533	0.59±0.09	2.7e-10	0.66±0.07	1.9e-19	74,730	0.64±0.06	3.5e-28	0.038	32
rs1316971	G	A	15	76,717,565	0.59±0.09	1.8e-10	0.65±0.07	4.3e-19	76,883	0.63±0.06	5.5e-28	0.046	30
rs9920506	G	A	15	76,718,112	0.58±0.11	1.4e-07	0.63±0.09	3e-13	74,393	0.61±0.07	2.4e-19	0.079	27
rs11634351	A	G	15	76,731,773	0.64±0.07	1.2e-20	0.65±0.06	5e-27	76,728	0.64±0.05	5.5e-46	0.19	17
rs8023822	G	C	15	76,732,095	0.29±0.09	0.00078	0.19±0.07	0.0073	76,917	0.23±0.06	2.8e-05	5.4e-06	59
rs12594247	C	T	15	76,733,688	0.43±0.09	6e-06	0.61±0.08	2.8e-14	76,519	0.54±0.06	1.9e-18	0.061	29
rs1021070	C	G	15	76,733,918	0.41±0.07	2e-09	0.20±0.06	0.0013	76,626	0.29±0.05	2.6e-10	0.046	31
rs7181405	A	G	15	76,735,207	0.41±0.07	2.9e-09	0.32±0.06	1.9e-07	76,633	0.36±0.05	6e-15	0.78	0
rs11638830	C	G	15	76,735,374	0.61±0.07	2e-19	0.26±0.06	1e-05	76,806	0.40±0.04	5e-20	1.9e-15	76
rs4887074	C	G	15	76,739,165	0.32±0.08	5.7e-05	0.43±0.07	5.4e-10	76,971	0.38±0.05	1.9e-13	0.025	34
rs11072774	C	T	15	76,739,752	0.50±0.10	1.4e-07	0.59±0.08	3.3e-14	74,816	0.56±0.06	3e-20	0.034	33
rs17487514	T	C	15	76,740,840	0.59±0.08	7.6e-13	0.65±0.07	1.5e-19	76,505	0.63±0.05	8.4e-31	0.13	21
rs12899135	G	A	15	76,741,434	0.60±0.07	1.7e-19	0.59±0.06	2.9e-24	76,807	0.60±0.04	4.7e-42	0.21	16
rs12148319	A	G	15	76,743,247	0.43±0.10	2.8e-05	0.56±0.09	1.5e-10	76,675	0.51±0.07	2.6e-14	0.060	29
rs12910237	C	T	15	76,743,393	0.40±0.07	8.4e-09	0.30±0.06	1.1e-06	76,656	0.34±0.05	1e-13	0.71	0
rs1996371	C	T	15	76,743,861	0.61±0.07	4.6e-20	0.59±0.06	2.9e-24	76,808	0.60±0.04	1.4e-42	0.22	15
rs12594550	C	G	15	76,746,092	0.44±0.10	4.2e-06	0.46±0.09	8.8e-08	76,985	0.45±0.06	1.7e-12	0.0067	41
rs6495314	C	A	15	76,747,584	0.59±0.07	1.1e-18	0.59±0.06	2.1e-24	76,809	0.59±0.04	2.1e-41	0.20	16
rs922691	A	G	15	76,751,049	0.37±0.07	7.5e-08	0.28±0.06	7.2e-06	76,630	0.32±0.05	5.2e-12	0.56	0
rs12905641	C	T	15	76,751,417	0.36±0.07	2.6e-07	0.31±0.06	6e-07	76,680	0.33±0.05	9.8e-13	0.88	0
rs11072784	C	T	15	76,753,113	0.25±0.09	0.0065	0.30±0.08	9.3e-05	76,946	0.28±0.06	2e-06	0.24	13
rs11639372	T	C	15	76,753,710	0.61±0.07	1.8e-19	0.59±0.06	8.1e-24	76,808	0.59±0.04	1.4e-41	0.26	12
rs12902602	G	A	15	76,754,456	0.61±0.07	1.1e-19	0.59±0.06	8.9e-24	76,808	0.60±0.04	1e-41	0.22	15
rs1021071	C	G	15	76,755,234	0.62±0.07	6.9e-20	0.25±0.06	2.5e-05	76,808	0.40±0.04	1.4e-19	8.7e-15	76
rs11072785	T	C	15	76,755,284	0.60±0.07	3.6e-19	0.59±0.06	1.1e-23	76,808	0.59±0.04	4e-41	0.26	12
rs11857532	G	T	15	76,755,323	0.54±0.07	4.3e-16	0.49±0.06	5.1e-17	76,931	0.51±0.04	2.5e-31	0.40	4
rs4886580	G	T	15	76,756,440	0.61±0.07	1.1e-19	0.59±0.06	1.3e-23	76,808	0.60±0.04	1.4e-41	0.26	12
rs16970006	T	C	15	76,757,314	0.64±0.15	1.1e-05	0.56±0.12	1.7e-06	74,571	0.59±0.09	9e-11	0.017	37
rs8032552	T	C	15	76,758,191	0.31±0.08	7.8e-05	0.41±0.07	2.2e-09	77,005	0.37±0.05	9.7e-13	0.24	13
rs11072787	T	C	15	76,760,032	0.32±0.08	3.2e-05	0.41±0.07	1e-09	77,002	0.38±0.05	1.9e-13	0.20	16
rs8043123	C	T	15	76,760,448	0.30±0.08	0.00011	0.40±0.07	3.6e-09	76,995	0.36±0.05	2.3e-12	0.25	13

rs8038920	G	A	15	76,761,600	0.38±0.07	7.2e-08	0.30±0.06	7.3e-07	76,699	0.33±0.05	4.3e-13	0.90	0
rs4887077	T	C	15	76,765,419	0.61±0.07	2.2e-19	0.57±0.06	1.5e-22	76,829	0.58±0.04	3.8e-40	0.27	12
rs11638372	T	C	15	76,770,614	0.60±0.07	5.3e-19	0.57±0.06	1.9e-22	76,827	0.58±0.04	1.1e-39	0.31	10
rs922692	A	C	15	76,771,269	0.60±0.07	2.7e-19	0.57±0.06	8.9e-23	76,813	0.58±0.04	2.6e-40	0.29	11
rs12910627	C	G	15	76,781,988	0.60±0.07	2.3e-19	0.24±0.06	4.9e-05	76,808	0.39±0.04	7.7e-19	5.4e-14	75
rs11072791	A	C	15	76,784,131	0.61±0.07	1.4e-19	0.58±0.06	8.6e-23	76,805	0.59±0.04	1.3e-40	0.31	10
rs11633519	G	A	15	76,786,607	0.35±0.08	5.3e-06	0.36±0.07	9.7e-08	76,992	0.36±0.05	2.4e-12	0.57	0
rs12899940	T	C	15	76,788,754	0.38±0.08	1.1e-06	0.36±0.07	4.9e-08	77,015	0.37±0.05	2.6e-13	0.54	0
rs11634628	A	G	15	76,792,634	0.38±0.08	6.6e-07	0.36±0.07	4.5e-08	77,018	0.37±0.05	1.6e-13	0.56	0
rs11072793	A	G	15	76,793,497	0.39±0.08	3.1e-07	0.35±0.07	7.5e-08	76,825	0.37±0.05	1.3e-13	0.44	2
rs11072794	C	T	15	76,793,637	0.39±0.08	5e-07	0.36±0.07	4.6e-08	77,015	0.37±0.05	1.2e-13	0.61	0
rs11638490	T	C	15	76,795,005	0.61±0.07	1.1e-19	0.58±0.06	9.4e-23	76,805	0.59±0.04	1.1e-40	0.37	6
rs4887078	T	C	15	76,798,128	0.41±0.08	2.2e-07	0.36±0.07	7e-08	76,824	0.38±0.05	9.5e-14	0.58	0
rs11629637	T	C	15	76,806,079	0.61±0.07	9.6e-20	0.58±0.06	1.4e-22	76,994	0.59±0.04	1.4e-40	0.37	6
rs899997	T	G	15	76,806,633	0.39±0.08	2.2e-06	0.35±0.07	3.1e-07	76,742	0.36±0.05	3.5e-12	0.57	0
rs3813565	T	G	15	76,806,665	0.64±0.07	7.1e-20	0.61±0.06	3e-23	76,800	0.63±0.05	2.2e-41	0.20	16
rs4887082	C	T	15	76,812,122	0.59±0.07	8e-18	0.58±0.06	1.6e-21	76,869	0.58±0.05	1.1e-37	0.46	1
rs1383634	C	T	15	76,816,451	0.39±0.08	8.1e-07	0.35±0.07	3.4e-07	76,734	0.37±0.05	1.5e-12	0.56	0
rs2219939	A	G	15	76,816,778	0.42±0.08	3.4e-07	0.36±0.07	2.1e-07	75,903	0.38±0.05	4.6e-13	0.61	0
rs4887091	C	T	15	76,830,635	0.39±0.08	2.6e-06	0.34±0.07	6.7e-07	76,910	0.36±0.05	9.4e-12	0.73	0
rs7182567	G	A	15	76,832,109	0.39±0.08	1.2e-06	0.35±0.07	5.6e-07	76,911	0.36±0.05	3.5e-12	0.71	0
rs12286	A	G	15	76,838,814	0.58±0.07	5.3e-17	0.58±0.06	6.3e-21	76,863	0.58±0.05	2.9e-36	0.48	0
rs1809420	C	T	15	76,843,824	0.56±0.07	5.2e-14	0.55±0.06	4.3e-19	72,292	0.55±0.05	1.8e-31	0.31	10
rs7174367	G	A	15	76,851,722	0.57±0.07	1.2e-16	0.55±0.06	1.5e-19	76,866	0.56±0.05	1.7e-34	0.44	1
rs7171916	G	C	15	76,855,006	0.54±0.07	3e-14	0.38±0.06	2e-09	76,717	0.44±0.05	2.4e-21	1.4e-05	57
rs1994016	T	C	15	76,867,289	0.53±0.07	3.4e-14	0.40±0.06	6.2e-11	76,924	0.45±0.05	5.5e-23	0.21	15
rs1994017	C	T	15	76,867,361	0.33±0.08	8.8e-06	0.26±0.07	0.00012	77,004	0.29±0.05	6.7e-09	0.90	0
rs12905740	C	T	15	76,869,419	0.32±0.07	1.7e-05	0.26±0.07	0.00013	76,703	0.28±0.05	1.2e-08	0.90	0
rs2277545	C	T	15	76,870,646	0.50±0.07	7.7e-14	0.41±0.06	2.8e-12	76,965	0.45±0.04	3.1e-24	0.16	19
rs1564499	C	T	15	76,871,863	0.33±0.08	9.5e-06	0.25±0.07	0.0002	76,709	0.28±0.05	1.3e-08	0.92	0
rs12903203	C	T	15	76,871,988	0.51±0.07	2.9e-14	0.41±0.06	3.5e-12	76,965	0.45±0.04	1.7e-24	0.15	20

rs2904228	G	A	15	76,873,154	0.34±0.08	7.9e-06	0.26±0.07	0.00019	76,667	0.29±0.05	1e-08	0.88	0
rs3743057	C	T	15	76,876,062	0.32±0.07	1.6e-05	0.23±0.07	0.00037	76,717	0.27±0.05	3.9e-08	0.88	0
rs3825807	G	A	15	76,876,166	0.50±0.07	6.2e-14	0.41±0.06	4.2e-12	76,959	0.45±0.04	3.7e-24	0.16	19
rs7177699	C	T	15	76,876,789	0.50±0.07	7.6e-14	0.42±0.06	7.9e-12	75,326	0.45±0.04	7.8e-24	0.14	21
rs8038189	C	G	15	76,886,081	0.38±0.08	5.8e-07	0.18±0.07	0.0083	76,667	0.26±0.05	1.8e-07	0.34	7
rs922693	A	G	15	76,886,593	0.40±0.08	1.8e-07	0.26±0.07	0.00011	76,662	0.32±0.05	2.9e-10	0.77	0
rs11634042	T	C	15	76,892,405	0.54±0.07	3.2e-14	0.37±0.08	3e-06	57,483	0.46±0.05	3.3e-18	0.048	33
rs1383636	A	G	15	76,893,275	0.41±0.08	8.6e-08	0.26±0.07	0.00013	76,902	0.33±0.05	1.9e-10	0.79	0
rs4380028	T	C	15	76,898,148	0.31±0.07	4.6e-06	0.29±0.06	6e-07	76,651	0.30±0.04	1.4e-11	0.020	36
rs6495335	G	T	15	76,904,188	0.33±0.07	1.9e-06	0.29±0.06	5.6e-07	76,645	0.31±0.04	5.8e-12	0.027	34
rs7178051	T	C	15	76,905,351	0.35±0.07	5.2e-07	0.30±0.06	6.1e-07	76,895	0.32±0.05	2.1e-12	0.043	31
rs7176187	T	C	15	76,908,428	0.32±0.07	2.3e-06	0.31±0.06	1.6e-07	76,701	0.31±0.04	1.9e-12	0.029	34
rs11852830	A	T	15	76,912,484	0.36±0.06	1.7e-08	0.36±0.06	6.1e-10	76,977	0.36±0.04	5.9e-17	0.28	11
rs6495337	C	G	15	76,912,744	0.30±0.06	1.4e-06	0.16±0.06	0.005	76,999	-0.06±0.04	0.11	1.0e-08	66
rs8032771	A	G	15	76,913,114	0.37±0.06	1.6e-08	0.36±0.06	6.2e-10	76,976	0.36±0.04	5.8e-17	0.30	10
rs4539564	G	A	15	76,915,554	0.35±0.06	5.5e-08	0.36±0.06	6.5e-10	76,973	0.35±0.04	1.9e-16	0.34	8
rs8035039	A	G	15	76,916,878	0.34±0.06	1.1e-07	0.36±0.06	6.3e-10	76,974	0.35±0.04	3.7e-16	0.34	8
rs11072810	T	C	15	76,919,261	0.37±0.07	1.1e-08	0.35±0.06	3.8e-09	77,003	0.36±0.04	2.7e-16	0.65	0
rs11072811	A	C	15	76,919,385	0.38±0.07	5.1e-09	0.34±0.06	7.1e-09	76,998	0.36±0.04	2.5e-16	0.58	0
rs7403393	C	G	15	76,922,857	0.38±0.07	1.2e-08	0.27±0.06	7.6e-06	76,977	0.32±0.04	1.4e-12	0.035	32
rs7173743	C	T	15	76,928,839	0.39±0.07	3e-09	0.34±0.06	1.1e-08	76,437	0.36±0.04	2.3e-16	0.53	0
rs7164529	G	A	15	76,932,853	0.38±0.07	8.4e-09	0.37±0.06	1.1e-09	76,973	0.37±0.04	5.1e-17	0.56	0
rs5029904	G	C	15	76,939,477	0.40±0.07	1.2e-09	0.25±0.06	2.2e-05	76,930	0.31±0.04	1e-12	0.045	30
rs12595538	A	T	15	76,941,508	0.40±0.07	2.5e-09	0.38±0.06	1.1e-09	76,885	0.39±0.05	1.6e-17	0.50	0
rs8029659	A	G	15	76,954,658	0.37±0.07	3.2e-07	0.29±0.07	1.7e-05	76,722	0.32±0.05	3.9e-11	0.46	1
rs17243470	T	G	15	76,959,821	0.36±0.07	1.2e-06	0.30±0.07	1e-05	76,724	0.32±0.05	7.2e-11	0.52	0
rs17832351	A	G	15	76,960,060	0.37±0.07	2.9e-07	0.30±0.07	1e-05	76,724	0.33±0.05	2e-11	0.53	0
rs8047986	C	T	16	6,461,007	0.25±0.06	8.3e-05	0.13±0.06	0.026	76,946	0.18±0.04	2.1e-05	0.25	13
rs809704	A	T	16	6,461,769	0.26±0.06	6.6e-05	0.14±0.06	0.021	76,946	0.19±0.04	1.3e-05	0.25	13
rs802698	C	T	16	6,463,483	0.25±0.06	0.00011	0.14±0.06	0.018	76,695	0.19±0.04	1.5e-05	0.15	20
rs1640968	A	C	16	6,463,672	0.26±0.06	6.2e-05	0.14±0.06	0.019	76,694	0.19±0.04	1.2e-05	0.22	15

rs42347	T	A	16	6,465,592	0.25±0.06	0.00013	0.13±0.06	0.027	76,692	0.18±0.04	3e-05	0.34	7
rs7187508	A	C	16	6,473,550	0.29±0.07	2e-05	0.08±0.08	0.33	57,294	0.19±0.05	0.00015	0.18	20
rs813914	T	C	16	6,474,370	0.20±0.06	0.0015	0.08±0.06	0.18	76,710	0.13±0.04	0.0021	0.61	0
rs3095508	C	A	16	6,490,401	0.23±0.07	0.00052	0.10±0.06	0.11	76,717	0.15±0.04	0.0005	0.42	3
rs811919	G	T	16	6,492,268	0.23±0.07	0.00043	0.09±0.06	0.14	76,717	0.15±0.04	0.00063	0.38	5
rs11645855	G	A	16	6,798,924	0.51±0.13	0.00012	-0.12±0.11	0.27	76,620	0.12±0.08	0.12	0.17	19
rs11648889	A	G	16	6,804,585	0.63±0.16	6.2e-05	-0.13±0.13	0.32	76,408	0.15±0.09	0.11	0.063	29
rs4786123	G	C	16	6,813,922	0.24±0.08	0.0027	-0.08±0.07	0.22	76,517	0.05±0.05	0.37	0.0018	47
rs741591	A	G	16	81,544,689	0.35±0.08	8.1e-06	-0.09±0.06	0.13	74,571	0.06±0.04	0.15	0.083	26
rs9928039	G	C	16	81,555,241	0.26±0.06	5.4e-05	0.01±0.06	0.91	77,001	0.12±0.04	0.0051	0.0037	43
rs12929479	A	G	16	81,555,354	0.22±0.07	0.00082	0.07±0.06	0.23	76,949	0.14±0.04	0.002	0.12	22
rs8064211	G	A	16	81,558,599	0.27±0.06	2.9e-05	0.05±0.06	0.43	77,025	0.14±0.04	0.00092	0.010	39
rs8062451	A	G	16	81,558,637	0.27±0.06	2.4e-05	0.04±0.06	0.45	77,019	0.14±0.04	0.00088	0.012	38
rs8046196	T	G	16	81,558,849	0.24±0.06	0.00024	0.10±0.06	0.1	76,951	0.16±0.04	0.00026	0.029	33
rs10492868	G	C	16	81,559,356	0.30±0.06	4.5e-06	0.02±0.06	0.74	76,939	0.14±0.04	0.0014	0.0026	44
rs8059783	T	G	16	81,570,343	0.30±0.06	3.4e-06	0.03±0.06	0.59	76,997	0.14±0.04	0.0006	0.0017	46
rs4782742	C	A	16	81,573,151	0.31±0.06	1.8e-06	0.04±0.06	0.53	77,005	0.15±0.04	0.00033	0.0035	43
rs8063602	C	A	16	81,573,922	0.32±0.06	8.2e-07	0.04±0.06	0.53	77,001	0.16±0.04	0.00023	0.0040	43
rs7404645	A	G	16	81,578,029	0.28±0.07	0.00022	0.02±0.07	0.81	76,620	0.12±0.05	0.01	0.0054	42
rs8061888	A	G	16	81,578,930	0.26±0.08	0.00067	-0.07±0.06	0.28	77,007	0.06±0.05	0.19	0.020	36
rs11150530	T	A	16	81,583,815	0.29±0.08	0.00015	-0.01±0.07	0.91	76,547	0.12±0.05	0.018	0.0018	46
rs6565099	T	C	16	81,596,483	0.30±0.06	3.1e-06	0.00±0.05	1	76,684	0.13±0.04	0.0024	0.0077	41
rs7206011	A	T	16	81,596,720	0.28±0.06	9.2e-06	-0.04±0.06	0.5	76,929	0.10±0.04	0.017	0.047	30
rs7203988	C	A	16	81,600,439	0.28±0.06	7.8e-06	0.00±0.06	0.94	76,992	0.12±0.04	0.0029	0.0061	41
rs6565100	T	C	16	81,600,819	0.22±0.06	0.00037	0.01±0.06	0.91	76,976	0.10±0.04	0.016	0.026	34
rs12925746	G	A	16	81,602,166	0.48±0.14	0.00046	0.00±0.11	0.96	74,537	0.17±0.08	0.033	0.32	9
rs5000155	T	C	16	81,615,158	0.36±0.10	0.00063	-0.02±0.08	0.77	76,511	0.12±0.06	0.064	0.22	15
rs8057717	A	C	16	81,617,414	0.44±0.10	6.1e-06	-0.07±0.08	0.36	76,406	0.12±0.06	0.045	0.049	31
rs12918209	C	T	16	81,617,613	0.34±0.08	1.9e-05	-0.04±0.07	0.53	76,449	0.11±0.05	0.025	0.0021	46
rs9888896	C	T	16	81,622,904	0.32±0.08	5.6e-05	-0.02±0.07	0.79	76,482	0.12±0.05	0.019	0.0037	44
rs6565105	A	G	16	81,623,165	0.22±0.07	0.0012	-0.00±0.06	0.97	76,977	0.09±0.04	0.043	0.13	21

rs12934188	G	A	16	81,624,733	0.39±0.10	6.4e-05	-0.07±0.08	0.41	76,685	0.10±0.06	0.072	0.37	6
rs12934355	G	A	16	81,624,826	0.41±0.10	2.3e-05	-0.06±0.08	0.43	76,984	0.12±0.06	0.049	0.37	6
rs4366697	C	G	16	81,625,484	0.37±0.08	1.6e-06	-0.06±0.07	0.37	76,370	0.12±0.05	0.014	0.0011	48
rs4329910	A	G	16	81,627,132	0.33±0.09	0.00024	-0.07±0.08	0.37	77,010	0.09±0.05	0.12	0.32	9
rs4473177	T	C	16	81,627,210	0.34±0.08	3.4e-05	-0.03±0.07	0.64	76,474	0.12±0.05	0.022	0.0026	45
rs10220997	T	C	16	81,627,755	0.36±0.09	9.9e-05	-0.07±0.08	0.35	76,990	0.09±0.06	0.092	0.38	5
rs11150533	T	G	16	81,628,647	0.37±0.09	8.4e-05	-0.08±0.08	0.33	76,988	0.09±0.06	0.099	0.37	6
rs4387591	G	C	16	81,629,923	0.27±0.07	0.00014	-0.02±0.07	0.75	76,640	0.12±0.05	0.011	0.034	32
rs4290460	C	A	16	81,629,963	0.36±0.08	2.6e-05	-0.03±0.07	0.65	76,368	0.12±0.05	0.021	0.0033	44
rs4783307	G	T	16	81,634,135	0.43±0.08	1.3e-08	-0.06±0.06	0.38	76,823	0.14±0.05	0.0035	0.0084	40
rs4523912	G	A	16	81,634,243	0.37±0.09	8.7e-05	-0.08±0.08	0.33	74,783	0.10±0.06	0.082	0.058	29
rs4294808	G	A	16	81,636,082	0.44±0.08	2.5e-08	-0.06±0.07	0.35	76,710	0.14±0.05	0.0049	0.0096	39
rs17685517	A	G	16	82,064,531	0.33±0.09	0.00014	-0.06±0.07	0.38	77,018	0.09±0.05	0.088	0.33	8
rs17685702	T	C	16	82,067,235	0.28±0.08	0.00029	-0.05±0.07	0.46	77,011	0.08±0.05	0.088	0.25	13
rs2200793	G	A	16	82,069,004	0.34±0.08	5.4e-05	-0.06±0.07	0.42	77,007	0.10±0.05	0.055	0.42	3
rs16960622	G	A	16	82,072,047	0.32±0.09	0.00017	-0.05±0.07	0.46	77,000	0.09±0.05	0.075	0.42	3
rs17758985	T	C	16	82,075,197	0.33±0.08	0.00012	-0.05±0.07	0.46	77,018	0.10±0.05	0.066	0.27	12
rs17686362	C	T	16	82,075,242	0.35±0.09	3.1e-05	-0.05±0.07	0.48	77,020	0.11±0.05	0.039	0.29	11
rs923419	A	G	16	82,075,911	0.33±0.09	9.9e-05	-0.05±0.07	0.48	77,017	0.10±0.05	0.06	0.28	11
rs12930939	T	C	16	82,095,449	0.32±0.09	0.00014	-0.06±0.07	0.44	77,012	0.09±0.05	0.078	0.16	19
rs1387379	T	C	16	82,097,095	0.30±0.09	0.00039	-0.04±0.07	0.59	76,971	0.09±0.05	0.077	0.20	17
rs4238689	A	G	16	82,097,206	0.32±0.08	0.00016	-0.04±0.07	0.54	76,941	0.10±0.05	0.063	0.41	3
rs4782539	C	G	16	82,097,934	0.29±0.08	0.00053	-0.01±0.07	0.91	76,964	0.11±0.05	0.039	0.40	4
rs7189644	T	C	16	82,098,347	0.31±0.08	0.00028	-0.03±0.07	0.65	76,954	0.10±0.05	0.058	0.45	1
rs2607420	A	G	19	45,936,727	0.32±0.09	0.00043	0.09±0.07	0.23	30,986	0.17±0.06	0.002	0.14	30
rs2305797	C	T	19	45,960,916	0.26±0.07	0.00025	0.08±0.06	0.24	76,855	0.15±0.05	0.0011	0.037	32
rs2279011	T	G	19	45,961,128	0.29±0.07	1.1e-05	0.14±0.06	0.019	76,954	0.20±0.04	3.9e-06	0.51	0
rs12973666	C	G	19	45,981,237	0.22±0.06	0.0004	0.16±0.06	0.0061	76,997	0.15±0.04	0.00045	0.020	36
rs12151282	C	T	19	45,990,259	0.29±0.07	2.2e-05	0.09±0.06	0.13	76,771	0.18±0.05	9.8e-05	0.11	24
rs7252227	T	G	19	45,992,955	0.28±0.07	2.2e-05	0.16±0.06	0.006	77,011	0.21±0.04	1.3e-06	0.65	0
rs7937	T	C	19	45,994,546	0.34±0.07	2.2e-07	0.19±0.06	0.0011	77,007	0.25±0.04	5.3e-09	0.42	3

rs2644916	C	T	19	46,001,051	0.29±0.08	0.00028	0.19±0.07	0.004	76,997	0.23±0.05	6.4e-06	0.63	0
rs7251418	G	A	19	46,033,429	0.52±0.11	7.7e-07	0.19±0.08	0.02	28,522	0.31±0.06	1.4e-06	0.87	0
rs7251570	G	A	19	46,033,590	0.55±0.10	1.1e-08	0.25±0.08	0.0017	28,434	0.36±0.06	2.3e-09	0.59	0
rs4343391	C	G	19	46,036,208	0.52±0.11	7.1e-07	0.22±0.09	0.01	28,546	0.33±0.07	4.7e-07	0.93	0
rs1801272	A	T	19	46,046,373	1.08±0.27	7e-05	0.41±0.24	0.084	28,296	0.68±0.18	0.00011	0.50	0
rs4105144	C	T	19	46,050,464	0.59±0.10	1.2e-09	0.31±0.08	5.8e-05	28,508	0.41±0.06	5.9e-12	0.87	0
rs8102683	C	T	19	46,055,605	0.62±0.10	1.6e-09	0.26±0.08	0.0021	28,535	0.40±0.06	8.4e-10	0.97	0
rs1496402	A	T	19	46,057,974	0.58±0.10	1.9e-09	0.31±0.08	5.9e-05	28,524	0.41±0.06	9.1e-12	0.86	0
rs12461383	G	C	19	46,062,178	0.55±0.09	3.6e-09	0.25±0.07	0.00066	28,206	0.36±0.06	3.1e-10	0.74	0
rs3852872	T	C	19	46,107,983	0.34±0.08	1.4e-05	0.15±0.07	0.027	77,022	0.22±0.05	8.4e-06	0.43	3
rs3852873	G	T	19	46,108,100	0.46±0.09	2.7e-07	0.14±0.07	0.053	74,678	0.26±0.06	3.7e-06	0.30	10
rs4090553	C	T	19	46,118,597	0.00±0.01	0.61	0.15±0.07	0.027	77,019	0.01±0.01	0.42	0.0088	40
rs12459565	C	G	19	46,119,379	0.29±0.07	5.4e-05	0.14±0.07	0.032	77,019	0.21±0.05	1.9e-05	0.39	5
rs3844443	C	T	19	46,123,775	0.34±0.08	1.1e-05	0.12±0.07	0.057	77,020	0.21±0.05	2.2e-05	0.40	4
rs3843043	T	C	19	46,125,771	0.33±0.08	2.3e-05	0.15±0.07	0.024	77,024	0.22±0.05	9.4e-06	0.48	0
rs3844444	G	A	19	46,125,887	0.34±0.08	2e-05	0.15±0.07	0.029	74,856	0.22±0.05	1.3e-05	0.41	3
rs1820025	C	G	19	46,128,386	0.35±0.08	1.1e-05	0.14±0.07	0.043	77,024	0.22±0.05	1.6e-05	0.38	5
rs8110485	G	A	19	46,140,045	0.33±0.09	0.00012	0.12±0.07	0.094	74,157	0.20±0.05	0.00021	0.0020	46
rs12611133	T	C	19	46,140,444	0.32±0.08	2.8e-05	0.10±0.07	0.14	74,496	0.19±0.05	0.00013	0.0058	42
rs4124633	T	C	19	46,141,443	0.33±0.08	6.9e-05	0.05±0.07	0.5	74,331	0.16±0.05	0.0023	0.47	0
rs3745220	T	C	19	46,142,449	0.35±0.08	2.4e-05	0.06±0.07	0.41	74,312	0.18±0.05	0.00088	0.43	2
rs4239510	T	C	19	46,145,339	0.31±0.07	2.3e-05	0.09±0.06	0.15	74,711	0.18±0.05	0.00014	0.015	37
rs4803408	C	T	19	46,148,705	0.92±0.25	0.00018	0.18±0.23	0.43	28,243	0.50±0.16	0.0023	0.99	0
rs3889806	T	C	19	46,151,081	0.33±0.07	6.5e-06	0.10±0.06	0.13	74,739	0.19±0.05	5.6e-05	0.0098	39
rs10417579	T	C	19	46,156,970	0.31±0.07	2.7e-05	0.09±0.06	0.16	74,699	0.17±0.05	0.00021	0.018	36
rs12459237	T	C	19	46,158,771	1.71±0.49	0.00054	-0.66±0.68	0.33	26,857	0.82±0.38	0.032	0.11	43
rs11671108	A	C	19	46,173,813	0.29±0.08	0.00015	0.07±0.07	0.32	76,613	0.16±0.05	0.0013	0.86	0
rs7251950	C	T	19	46,174,582	0.33±0.07	1.5e-06	0.07±0.06	0.24	77,024	0.18±0.04	5.7e-05	0.16	19
rs1808002	C	T	19	46,177,034	0.38±0.07	7.5e-08	0.07±0.06	0.28	77,016	0.19±0.05	2.3e-05	0.12	23
rs1808682	G	A	19	46,181,288	0.29±0.08	0.0002	0.07±0.07	0.33	76,606	0.16±0.05	0.0019	0.83	0
rs10418990	G	C	19	46,182,244	0.32±0.07	2.5e-06	0.07±0.06	0.23	74,810	0.17±0.04	9.5e-05	0.051	30

rs8109525	A	G	19	46,183,758	0.34±0.07	4.8e-07	0.05±0.06	0.44	76,996	0.17±0.04	0.00011	0.21	16
rs2099361	C	A	19	46,190,188	0.30±0.07	1.4e-05	0.07±0.06	0.25	76,951	0.16±0.04	0.00025	0.035	32
rs6508963	T	C	19	46,190,573	0.37±0.07	1.2e-07	0.04±0.06	0.52	77,006	0.17±0.04	0.00011	0.18	18
rs2014141	A	G	19	46,191,829	0.33±0.07	2.1e-06	0.03±0.06	0.56	74,838	0.15±0.04	0.00063	0.033	33
rs8100458	T	C	19	46,192,053	0.37±0.07	8.4e-08	0.04±0.06	0.56	77,002	0.17±0.04	0.0001	0.18	18
rs6508964	G	A	19	46,194,442	0.32±0.07	4.4e-06	0.03±0.06	0.61	74,830	0.14±0.04	0.0011	0.050	30
rs4803417	C	A	19	46,199,860	0.30±0.07	4.4e-06	0.02±0.06	0.78	76,976	0.14±0.04	0.0015	0.033	32
rs8113196	A	C	19	46,206,192	0.30±0.07	2e-05	0.06±0.06	0.31	74,667	0.16±0.05	0.00053	0.012	38
rs8113200	A	G	19	46,206,203	0.30±0.07	2e-05	0.06±0.06	0.32	74,667	0.16±0.05	0.00055	0.013	38
rs2279345	T	C	19	46,207,542	0.30±0.07	2.1e-05	0.06±0.06	0.33	74,667	0.16±0.05	0.00062	0.012	39
rs11671243	A	C	19	46,211,555	0.29±0.07	5.1e-05	0.07±0.06	0.29	74,665	0.15±0.05	0.00074	0.0052	42
rs7260329	G	A	19	46,213,478	0.43±0.07	1.1e-09	0.06±0.06	0.36	76,898	0.21±0.05	3.4e-06	0.12	22
rs3786551	C	G	19	46,213,586	0.41±0.08	6.4e-08	0.10±0.06	0.13	74,731	0.22±0.05	4.6e-06	0.31	10
rs3786552	C	G	19	46,213,597	0.40±0.07	5.8e-08	0.10±0.06	0.13	76,898	0.22±0.05	3.8e-06	0.36	6
rs707265	A	G	19	46,215,927	0.30±0.07	1e-05	0.05±0.06	0.4	76,812	0.16±0.04	0.00045	0.0079	40
rs1552222	T	A	19	46,217,744	0.36±0.10	0.00043	0.11±0.09	0.22	74,167	0.21±0.07	0.0015	0.89	0
rs2113103	G	A	19	46,220,507	0.34±0.10	0.00045	0.12±0.08	0.15	74,528	0.21±0.06	0.00091	0.79	0
rs7257703	A	G	19	46,228,462	0.32±0.08	3.9e-05	0.10±0.07	0.15	74,303	0.19±0.05	0.0002	0.013	38
rs9608562	C	T	22	25,725,385	0.42±0.11	7.9e-05	-0.08±0.10	0.39	76,572	0.13±0.07	0.055	0.49	0
rs12628550	C	A	22	25,727,683	0.49±0.12	1.8e-05	0.03±0.10	0.77	76,733	0.23±0.08	0.0027	0.93	0
rs2516082	T	C	22	25,728,512	0.41±0.08	6e-07	0.02±0.07	0.83	77,017	0.18±0.05	0.0007	0.73	0
rs9608564	C	T	22	25,728,910	0.40±0.08	7.4e-07	0.01±0.07	0.84	77,017	0.18±0.05	0.00079	0.72	0
rs11090466	G	A	22	25,729,321	0.42±0.08	2.1e-07	0.01±0.07	0.87	77,017	0.18±0.05	0.00053	0.72	0
rs12628017	T	C	22	25,729,405	0.39±0.08	1.1e-06	0.01±0.07	0.89	77,017	0.17±0.05	0.0011	0.63	0
rs9613336	C	T	22	25,730,316	0.39±0.08	9e-07	0.01±0.07	0.93	77,017	0.17±0.05	0.0011	0.69	0
rs9613337	C	T	22	25,730,447	0.38±0.08	1.9e-06	0.00±0.07	0.97	77,017	0.16±0.05	0.0019	0.67	0
rs9608565	C	T	22	25,733,729	0.40±0.08	9.7e-07	0.01±0.07	0.87	77,017	0.17±0.05	0.0011	0.68	0
rs5761920	A	G	22	25,767,550	0.32±0.09	0.0003	-0.07±0.07	0.33	76,627	0.08±0.05	0.14	0.42	3
rs5761921	C	T	22	25,768,386	0.30±0.09	0.00073	-0.06±0.07	0.37	76,700	0.07±0.05	0.17	0.50	0
rs12160816	T	C	22	25,770,602	0.29±0.09	0.00083	-0.02±0.07	0.74	76,699	0.09±0.05	0.074	0.75	0
rs572784	C	T	22	25,936,778	0.23±0.06	0.00033	-0.01±0.06	0.86	76,954	0.09±0.04	0.026	0.33	8

Smoking Initiation

rs839756	G	C	1	43,629,135	0.52±0.14	0.00024	-0.02±0.16	0.88	0.26±0.10	0.011	0.75	0
rs1762343	T	A	1	43,631,524	0.49±0.14	0.00035	-0.03±0.11	0.76	0.10±0.08	0.24	0.55	0
rs839758	A	G	1	43,634,745	0.54±0.13	5.2e-05	0.22±0.11	0.04	0.34±0.08	4.6e-05	0.81	0
rs710249	G	C	1	43,641,822	0.57±0.14	7.4e-05	0.22±0.11	0.043	0.20±0.09	0.024	0.25	13
rs839768	A	G	1	43,644,210	0.59±0.15	5.5e-05	0.25±0.11	0.019	0.35±0.08	3.6e-05	0.73	0
rs839771	T	G	1	43,646,056	0.54±0.14	0.00011	0.28±0.11	0.0095	0.37±0.08	1.2e-05	0.76	0
rs839772	G	A	1	43,646,070	0.56±0.14	8.4e-05	0.27±0.11	0.012	0.37±0.08	1.6e-05	0.75	0
rs2842177	G	C	1	43,657,244	0.56±0.14	8.1e-05	0.25±0.11	0.019	0.23±0.09	0.011	0.26	12
rs2782642	A	G	1	43,658,908	0.59±0.15	4.9e-05	0.27±0.11	0.011	0.37±0.08	1.3e-05	0.75	0
rs2782643	C	T	1	43,659,081	0.60±0.15	4.1e-05	0.28±0.11	0.01	0.37±0.09	1.1e-05	0.75	0
rs2782644	G	A	1	43,659,733	0.55±0.14	0.00011	0.27±0.11	0.011	0.37±0.08	1.6e-05	0.77	0
rs2782645	G	A	1	43,661,189	0.56±0.14	8.5e-05	0.27±0.11	0.011	0.37±0.08	1.3e-05	0.76	0
rs2782646	G	A	1	43,664,776	0.56±0.14	8.4e-05	0.28±0.11	0.01	0.37±0.08	1.3e-05	0.76	0
rs2842179	C	T	1	43,672,214	0.59±0.15	4.9e-05	0.27±0.11	0.013	0.37±0.08	1.7e-05	0.73	0
rs2039531	A	C	1	43,673,598	0.59±0.15	5.9e-05	0.27±0.11	0.013	0.36±0.08	1.9e-05	0.74	0
rs2782647	T	G	1	43,674,045	0.56±0.14	7.4e-05	0.28±0.11	0.01	0.37±0.08	1.2e-05	0.74	0
rs2842180	C	T	1	43,674,503	0.58±0.15	6.2e-05	0.26±0.11	0.016	0.36±0.09	2.5e-05	0.80	0
rs2782648	G	T	1	43,676,176	0.64±0.15	3.4e-05	0.23±0.14	0.11	0.40±0.10	9.4e-05	0.57	0
rs2842182	A	G	1	43,676,282	0.25±0.10	0.012	-0.01±0.11	0.92	0.13±0.07	0.081	0.66	0
rs2842184	A	G	1	43,676,903	0.64±0.15	3e-05	0.23±0.14	0.11	0.40±0.10	8.8e-05	0.56	0
rs2782649	T	C	1	43,678,406	0.56±0.14	7.3e-05	0.27±0.11	0.011	0.37±0.08	1.2e-05	0.74	0
rs2027130	A	G	1	43,679,483	0.59±0.15	5.6e-05	0.27±0.11	0.013	0.36±0.08	1.9e-05	0.74	0
rs2782650	A	G	1	43,685,177	0.59±0.15	4.8e-05	0.27±0.11	0.014	0.36±0.08	1.8e-05	0.73	0
rs2251804	T	C	1	43,689,996	0.55±0.14	0.00013	0.25±0.11	0.022	0.34±0.08	4.8e-05	0.69	0
rs2251802	G	A	1	43,690,224	0.55±0.14	9.7e-05	0.23±0.14	0.11	0.38±0.10	0.00012	0.50	0
rs2782651	C	G	1	43,693,273	0.61±0.15	7.7e-05	0.03±0.11	0.78	0.08±0.10	0.42	0.54	0
rs2842195	G	T	1	43,693,532	0.62±0.15	2.4e-05	0.27±0.11	0.012	0.36±0.08	1.4e-05	0.72	0
rs1334973	T	G	1	43,693,971	0.07±0.05	0.16	0.26±0.11	0.014	0.11±0.05	0.017	0.20	16
rs2782657	G	C	1	43,702,575	0.57±0.15	0.0002	0.11±0.11	0.35	0.12±0.10	0.24	0.18	17
rs7413861	C	A	1	43,711,388	0.55±0.15	0.0002	0.32±0.11	0.0038	0.40±0.09	6.3e-06	0.73	0

rs11210860	G	A	1	43,755,114	0.60±0.15	7.5e-05	0.36±0.11	0.00093	0.44±0.09	7.3e-07	0.60	0
rs2152113	C	T	1	43,756,156	0.65±0.15	2.6e-05	0.36±0.11	0.0011	0.45±0.09	4.3e-07	0.50	0
rs11577403	G	A	1	43,762,360	0.66±0.16	4.4e-05	0.39±0.12	0.00084	0.47±0.09	4.2e-07	0.56	0
rs2782640	T	C	1	43,781,620	0.64±0.15	2.5e-05	0.34±0.11	0.0016	0.40±0.08	1.8e-06	0.50	0
rs2782641	A	G	1	43,785,942	0.62±0.15	3.2e-05	0.32±0.11	0.003	0.36±0.08	8.7e-06	0.63	0
rs2842188	C	T	1	43,786,867	0.62±0.15	2.6e-05	0.36±0.11	0.00087	0.43±0.09	4.2e-07	0.43	2
rs2819333	T	A	1	43,787,160	0.60±0.15	4.5e-05	0.32±0.11	0.0034	0.29±0.09	0.00077	0.069	27
rs2819334	T	C	1	43,787,322	0.58±0.15	6.8e-05	0.36±0.11	0.00086	0.44±0.09	5.2e-07	0.41	3
rs2842187	C	T	1	43,787,536	0.60±0.15	7.1e-05	0.36±0.11	0.00083	0.42±0.09	9e-07	0.47	0
rs2842185	T	C	1	43,792,318	0.57±0.15	7.8e-05	0.33±0.10	0.0013	0.41±0.08	1.1e-06	0.34	7
rs11210869	A	G	1	43,798,627	0.65±0.15	1.3e-05	0.36±0.11	0.00092	0.44±0.09	2.8e-07	0.39	4
rs1887402	G	A	1	43,808,672	0.55±0.15	0.00015	0.35±0.11	0.00097	0.42±0.09	1.1e-06	0.33	8
rs3791136	C	T	1	43,822,534	0.59±0.15	7.9e-05	0.35±0.11	0.0012	0.41±0.09	1.3e-06	0.34	7
rs605709	C	T	1	43,831,054	0.64±0.15	2.4e-05	0.33±0.11	0.0021	0.42±0.09	1.2e-06	0.32	9
rs17371903	A	G	1	43,843,278	0.62±0.15	4.5e-05	0.33±0.11	0.002	0.40±0.09	2.2e-06	0.27	11
rs660899	G	T	1	43,889,593	0.57±0.15	0.00022	0.37±0.11	0.001	0.43±0.09	1.6e-06	0.60	0
rs489319	C	T	1	43,904,381	0.60±0.15	0.0001	0.33±0.11	0.0034	0.41±0.09	4e-06	0.31	9
rs618678	C	T	1	43,905,886	0.61±0.15	9.4e-05	0.33±0.11	0.0032	0.42±0.09	3.4e-06	0.32	9
rs10789442	A	C	1	43,912,662	0.61±0.15	7.5e-05	0.31±0.11	0.0062	0.41±0.09	6.6e-06	0.29	10
rs9787076	A	C	1	43,913,736	0.61±0.15	6.8e-05	0.33±0.11	0.0032	0.42±0.09	2.7e-06	0.36	6
rs3791034	A	G	1	43,917,717	0.60±0.15	9.2e-05	0.34±0.11	0.0021	0.43±0.09	2e-06	0.43	2
rs4660257	T	C	1	43,920,755	0.65±0.16	4.4e-05	0.35±0.11	0.0019	0.45±0.09	1.1e-06	0.33	8
rs17401357	G	C	1	43,926,206	0.65±0.16	4e-05	0.12±0.11	0.27	0.15±0.10	0.12	0.010	38
rs3791035	G	C	1	43,927,066	0.66±0.16	2.7e-05	0.12±0.11	0.27	0.16±0.10	0.11	0.0072	39
rs2270972	C	G	1	43,930,716	0.66±0.15	2.1e-05	0.02±0.12	0.84	0.24±0.09	0.0088	0.025	33
rs12410155	A	C	1	43,961,052	0.67±0.16	1.9e-05	0.34±0.11	0.0027	0.45±0.09	9.9e-07	0.30	10
rs3791040	A	G	1	43,975,320	0.67±0.16	2.3e-05	0.45±0.15	0.003	0.55±0.11	4.5e-07	0.58	0
rs12354267	T	C	1	44,020,859	0.70±0.17	2.8e-05	0.32±0.13	0.013	0.41±0.10	1.8e-05	0.32	8
rs2884216	G	C	1	231,463,228	0.75±0.15	5.4e-07	0.25±0.11	0.026	0.19±0.10	0.047	0.059	27
rs12122968	G	T	1	231,463,989	0.83±0.15	3.9e-08	0.26±0.11	0.023	0.45±0.09	5e-07	0.56	0
rs1033325	C	T	1	231,465,336	0.80±0.15	7.8e-08	0.28±0.11	0.012	0.45±0.09	3.1e-07	0.57	0

rs1033322	A	G	1	231,467,047	0.77±0.15	1.7e-07	0.28±0.11	0.011	0.44±0.09	3.6e-07	0.54	0
rs10910122	C	T	1	231,469,297	0.73±0.15	1.8e-06	0.27±0.11	0.018	0.41±0.09	3.3e-06	0.52	0
rs11587411	C	T	1	231,476,321	0.77±0.15	1.6e-07	0.28±0.11	0.011	0.45±0.09	3.3e-07	0.61	0
rs6683734	G	A	1	231,481,990	0.67±0.16	1.9e-05	0.21±0.12	0.064	0.37±0.09	4.3e-05	0.58	0
rs4649294	T	C	1	231,483,051	0.60±0.15	7.8e-05	0.31±0.11	0.0054	0.41±0.09	3.7e-06	0.79	0
rs12044078	T	C	1	231,483,565	0.62±0.15	3.9e-05	0.31±0.11	0.0055	0.42±0.09	2.3e-06	0.78	0
rs10737196	G	T	1	231,486,940	0.68±0.15	4e-06	0.29±0.11	0.01	0.43±0.09	1.8e-06	0.69	0
rs1294327	G	T	1	231,493,299	0.60±0.15	6.6e-05	0.20±0.12	0.089	0.34±0.09	0.00019	0.57	0
rs1561227	T	C	2	45,018,893	0.13±0.07	0.051	-0.16±0.11	0.14	0.04±0.05	0.42	0.010	38
rs83995	T	G	2	45,021,074	0.38±0.11	0.0003	-0.16±0.11	0.13	0.10±0.07	0.16	0.0097	38
rs338070	G	C	2	45,028,793	0.41±0.11	0.00025	0.06±0.10	0.57	0.05±0.09	0.54	0.0087	39
rs173076	A	G	2	45,029,089	0.59±0.13	3.5e-06	-0.15±0.11	0.17	0.12±0.07	0.11	0.011	37
rs163516	G	T	2	45,037,503	0.42±0.11	0.00027	-0.13±0.11	0.25	0.10±0.07	0.17	0.032	32
rs4952728	T	C	2	45,037,927	0.52±0.13	3.3e-05	-0.09±0.11	0.4	0.15±0.08	0.053	0.067	27
rs163513	G	A	2	45,038,728	0.28±0.09	0.0023	-0.14±0.11	0.2	0.10±0.07	0.15	0.026	33
rs1983312	A	G	2	45,040,631	0.49±0.12	6.6e-05	-0.09±0.11	0.4	0.12±0.07	0.11	0.075	26
rs340514	T	C	2	45,042,515	0.49±0.12	7.9e-05	-0.13±0.11	0.23	0.12±0.08	0.11	0.029	32
rs163507	A	G	2	45,047,793	0.41±0.11	0.00037	-0.23±0.11	0.042	0.07±0.07	0.33	0.020	34
rs163503	G	A	2	45,050,643	0.55±0.15	0.00033	-0.10±0.11	0.38	0.12±0.09	0.17	0.12	22
rs16824949	T	G	2	145,884,678	0.60±0.13	6.1e-06	0.21±0.11	0.054	0.35±0.08	1.9e-05	0.11	22
rs1533427	G	A	2	145,887,503	0.65±0.15	2e-05	0.18±0.11	0.1	0.32±0.09	0.0002	0.19	16
rs10192394	T	C	2	146,014,477	0.65±0.15	2.3e-05	0.17±0.12	0.14	0.32±0.09	0.00032	0.16	19
rs1473550	T	C	3	65,775,272	0.75±0.16	2e-06	0.08±0.12	0.52	0.05±0.04	0.27	0.0093	38
rs1473551	G	A	3	65,775,400	0.47±0.13	0.00032	0.08±0.12	0.52	0.23±0.08	0.0056	0.092	24
rs883570	T	A	3	65,776,543	0.75±0.16	1.8e-06	0.08±0.12	0.49	0.02±0.04	0.55	0.0067	40
rs868633	C	T	3	65,776,574	0.04±0.04	0.38	0.09±0.12	0.48	0.04±0.04	0.28	0.0062	40
rs1473531	C	T	3	65,776,979	0.61±0.14	9.8e-06	0.09±0.12	0.44	0.28±0.09	0.001	0.040	30
rs1473530	T	G	3	65,777,027	0.74±0.16	2.6e-06	0.09±0.12	0.46	0.04±0.04	0.27	0.0095	38
rs6796986	C	T	3	65,777,595	0.05±0.04	0.21	0.10±0.12	0.43	0.06±0.04	0.15	0.011	37
rs13059631	G	C	3	65,777,697	0.56±0.12	7.1e-06	0.20±0.12	0.09	0.08±0.04	0.069	0.013	36
rs12634960	C	T	3	65,777,960	0.59±0.14	2.3e-05	0.10±0.12	0.38	0.27±0.08	0.0013	0.059	28

rs12635056	G	A	3	65,778,128	0.54±0.12	9.6e-06	0.10±0.12	0.42	0.06±0.04	0.14	0.011	37
rs1108716	C	A	3	65,779,300	0.43±0.11	7.8e-05	0.10±0.12	0.4	0.07±0.04	0.12	0.012	37
rs1108718	G	A	3	65,779,623	0.67±0.14	1.8e-06	0.12±0.11	0.28	0.30±0.08	0.00022	0.069	26
rs2888253	C	A	3	65,780,675	0.64±0.13	2.1e-06	0.13±0.11	0.25	0.32±0.08	0.00011	0.037	31
rs12485806	T	C	3	65,781,126	0.57±0.13	1.8e-05	0.11±0.11	0.31	0.28±0.08	0.00042	0.042	30
rs716244	A	T	3	65,781,513	0.10±0.06	0.089	0.09±0.12	0.47	0.06±0.05	0.26	0.011	37
rs1495456	C	T	3	65,781,939	0.11±0.06	0.086	0.07±0.12	0.55	0.10±0.06	0.075	0.019	35
rs1495457	T	C	3	65,782,138	0.35±0.10	0.00073	0.09±0.12	0.44	0.22±0.07	0.0033	0.061	27
rs7624282	T	C	3	65,782,553	0.35±0.12	0.0021	0.09±0.12	0.43	0.21±0.08	0.0086	0.064	27
rs2036069	A	G	3	65,782,762	0.58±0.13	1.6e-05	0.13±0.12	0.27	0.24±0.08	0.002	0.085	25
rs4688248	C	A	3	65,784,256	0.40±0.11	0.00026	0.12±0.11	0.3	0.25±0.07	0.00077	0.044	29
rs1874320	C	A	3	65,784,882	0.55±0.13	2.1e-05	0.09±0.12	0.45	0.09±0.05	0.092	0.020	34
rs2372151	T	A	3	65,785,178	0.20±0.08	0.0067	0.11±0.11	0.32	0.14±0.06	0.023	0.016	35
rs1495448	T	G	3	65,785,954	0.53±0.13	2.5e-05	0.14±0.11	0.22	0.29±0.08	0.0002	0.043	30
rs17372566	T	A	3	65,787,443	0.36±0.10	0.00032	0.11±0.11	0.34	0.19±0.07	0.0088	0.017	35
rs12490463	A	C	3	65,788,413	0.58±0.13	8e-06	0.08±0.11	0.49	0.24±0.08	0.0025	0.13	21
rs10935353	G	A	3	141,016,599	0.56±0.14	4.4e-05	-0.13±0.10	0.22	0.10±0.07	0.17	0.093	24
rs10935354	G	A	3	141,026,326	0.53±0.14	0.00011	-0.10±0.10	0.33	0.11±0.08	0.15	0.14	20
rs10935356	C	T	3	141,026,782	0.59±0.14	2.4e-05	-0.10±0.11	0.35	0.13±0.08	0.094	0.079	25
rs6777464	C	T	3	141,029,906	0.56±0.14	4.8e-05	-0.12±0.10	0.24	0.10±0.07	0.17	0.10	23
rs6421891	G	C	5	124,100,202	0.58±0.15	0.00018	0.05±0.11	0.63	0.05±0.11	0.66	0.043	30
rs7718029	G	A	5	124,101,912	0.56±0.15	0.0002	0.07±0.11	0.53	0.25±0.09	0.0036	0.17	18
rs4836114	C	G	5	124,110,481	0.76±0.16	3.7e-06	-0.05±0.15	0.74	-0.05±0.09	0.55	0.026	33
rs7705693	C	T	5	124,112,264	0.72±0.15	1.8e-06	0.04±0.20	0.86	0.45±0.12	0.00012	0.045	32
rs883322	G	T	5	166,920,252	0.48±0.14	0.00046	0.18±0.11	0.12	0.28±0.09	0.00094	0.086	24
rs888976	A	G	5	166,920,483	0.51±0.13	0.00012	0.16±0.11	0.15	0.29±0.08	0.00053	0.056	28
rs888975	T	C	5	166,921,084	0.54±0.17	0.0016	0.02±0.12	0.86	0.22±0.10	0.038	0.0068	40
rs1862347	T	C	5	166,921,163	0.62±0.15	3.4e-05	0.16±0.11	0.14	0.31±0.09	0.00036	0.056	28
rs888974	G	T	5	166,921,545	0.64±0.14	8.4e-06	0.17±0.11	0.13	0.31±0.08	0.00022	0.082	25
rs10071347	A	G	5	166,921,820	0.66±0.15	1.3e-05	0.16±0.11	0.14	0.31±0.09	0.00038	0.057	28
rs2336894	T	G	5	166,923,173	0.61±0.14	9.6e-06	0.17±0.11	0.13	0.33±0.08	0.00012	0.052	28

rs2080976	T	C	5	166,923,617	0.62±0.15	3.7e-05	0.17±0.11	0.13	0.31±0.09	0.00037	0.060	27
rs2098651	C	G	5	166,923,848	0.04±0.03	0.26	0.16±0.11	0.14	0.02±0.04	0.65	0.0076	39
rs13186288	T	C	5	166,924,274	0.65±0.16	3.4e-05	0.17±0.11	0.14	0.31±0.09	0.00042	0.057	28
rs4869056	G	A	5	166,924,656	0.04±0.05	0.35	0.18±0.11	0.1	0.07±0.04	0.12	0.017	35
rs4869058	T	A	5	166,924,825	0.58±0.15	7.1e-05	0.17±0.11	0.13	0.24±0.09	0.0055	0.021	34
rs11747772	C	T	5	166,925,286	0.56±0.14	0.0001	0.16±0.11	0.15	0.28±0.09	0.00096	0.067	26
rs11738110	T	G	5	166,925,338	0.56±0.14	0.00011	0.17±0.11	0.13	0.30±0.09	0.00051	0.036	31
rs986391	G	A	5	166,926,550	0.66±0.16	2.3e-05	0.13±0.11	0.25	0.29±0.09	0.00099	0.022	34
rs12188010	A	T	5	166,929,044	0.50±0.13	0.00015	0.18±0.11	0.099	0.24±0.08	0.0029	0.032	31
rs4267883	C	T	5	166,929,300	0.58±0.14	6.9e-05	0.18±0.11	0.099	0.30±0.09	0.00043	0.061	27
rs4324704	G	C	5	166,929,514	0.64±0.16	3.3e-05	0.04±0.12	0.76	0.22±0.09	0.01	0.012	37
rs12188278	A	G	5	166,930,800	0.49±0.14	0.00053	0.14±0.11	0.21	0.26±0.09	0.0027	0.0076	39
rs10039321	T	C	5	166,930,963	0.50±0.16	0.0014	0.14±0.11	0.21	0.26±0.09	0.0046	0.0056	40
rs10042499	A	G	5	166,931,157	0.36±0.13	0.0065	0.14±0.11	0.21	0.22±0.08	0.0093	0.0059	40
rs13153563	T	C	5	166,932,406	0.27±0.11	0.012	0.12±0.11	0.28	0.19±0.08	0.012	0.0024	43
rs13160227	G	A	5	166,935,946	0.41±0.15	0.0066	0.12±0.11	0.29	0.21±0.09	0.015	0.0021	44
rs10475853	G	T	5	166,936,147	0.14±0.08	0.092	0.14±0.11	0.22	0.13±0.07	0.042	0.0031	42
rs1024993	C	T	5	166,938,587	0.49±0.15	0.0011	0.11±0.11	0.31	0.23±0.09	0.0092	0.0038	42
rs1024994	T	C	5	166,939,254	0.48±0.15	0.00092	0.13±0.12	0.26	0.26±0.09	0.0039	0.0067	39
rs9313385	A	G	5	166,939,971	0.57±0.15	0.00015	0.14±0.11	0.23	0.27±0.09	0.002	0.0063	40
rs278016	A	G	5	166,951,589	0.56±0.16	0.00035	0.14±0.11	0.22	0.26±0.09	0.0034	0.0073	39
rs11750548	G	A	5	166,958,525	0.50±0.15	0.00077	0.15±0.11	0.16	0.27±0.09	0.0022	0.0057	40
rs4869061	C	T	5	166,962,903	0.55±0.16	0.00043	0.12±0.11	0.28	0.24±0.09	0.0053	0.0034	42
rs11738133	C	T	5	166,964,671	0.53±0.16	0.00093	0.12±0.11	0.26	0.24±0.09	0.0074	0.0028	43
rs4869062	T	C	5	166,965,607	0.47±0.15	0.0016	0.12±0.11	0.27	0.24±0.09	0.0066	0.0029	42
rs4868804	A	G	5	166,965,813	0.57±0.15	0.0001	0.15±0.12	0.2	0.29±0.09	0.0012	0.0049	41
rs898171	G	A	5	166,966,356	0.46±0.14	0.0013	0.15±0.12	0.2	0.26±0.09	0.003	0.0048	41
rs732711	A	C	5	166,966,645	0.59±0.16	0.00016	0.10±0.11	0.37	0.25±0.09	0.005	0.0026	43
rs10475856	A	G	5	166,968,159	0.58±0.15	0.00014	0.15±0.12	0.2	0.29±0.09	0.0015	0.0049	41
rs981898	A	T	5	166,968,792	0.57±0.16	0.0004	0.15±0.12	0.2	0.29±0.09	0.002	0.0060	40
rs6893866	A	C	5	166,970,303	0.58±0.16	0.00038	0.15±0.12	0.21	0.28±0.09	0.0031	0.0042	42

rs11134465	G	A	5	166,970,512	0.51±0.16	0.0016	0.11±0.12	0.35	0.24±0.09	0.0098	0.0042	43
rs11134466	T	C	5	166,972,188	0.61±0.17	0.00025	0.12±0.12	0.33	0.27±0.10	0.0041	0.0046	41
rs11738927	A	G	5	166,972,378	0.59±0.16	0.00025	0.11±0.12	0.37	0.26±0.09	0.0057	0.0033	42
rs11743417	G	A	5	166,975,676	0.48±0.16	0.0021	0.14±0.12	0.25	0.25±0.09	0.0064	0.0019	44
rs1459066	C	T	5	166,977,244	0.61±0.17	0.00023	0.15±0.13	0.22	0.29±0.10	0.0025	0.0057	40
rs2336897	C	T	5	166,982,854	0.61±0.17	0.00023	0.16±0.13	0.2	0.30±0.10	0.0021	0.0083	39
rs962065	T	C	5	166,983,151	0.56±0.16	0.00058	0.16±0.13	0.2	0.31±0.10	0.002	0.0087	39
rs1966924	C	A	5	166,985,787	0.57±0.16	0.0005	0.16±0.13	0.21	0.31±0.10	0.0021	0.0099	38
rs2336898	A	G	5	166,988,514	0.62±0.17	0.0002	0.12±0.13	0.34	0.29±0.10	0.004	0.0074	39
rs12701627	G	A	7	38,397,140	0.02±0.02	0.13	0.01±0.08	0.93	0.02±0.02	0.13	0.0030	42
rs2072507	T	C	7	38,400,511	0.21±0.07	0.0032	0.02±0.10	0.85	0.15±0.06	0.011	0.16	19
rs720667	T	C	7	38,400,790	0.24±0.08	0.0017	0.03±0.11	0.81	0.16±0.06	0.0073	0.18	17
rs720668	C	T	7	38,400,798	0.64±0.14	4e-06	0.06±0.11	0.61	0.27±0.08	0.0015	0.074	26
rs715413	T	C	7	38,401,048	0.08±0.04	0.057	0.02±0.10	0.81	0.08±0.04	0.062	0.10	23
rs6976111	A	C	7	117,282,903	0.20±0.08	0.0089	0.42±0.12	0.00053	0.27±0.07	3.8e-05	0.0040	41
rs7776980	T	C	7	117,283,555	0.53±0.14	0.00015	0.37±0.12	0.0012	0.43±0.09	1e-06	0.13	21
rs10252771	G	T	7	117,284,126	0.58±0.14	5.8e-05	0.38±0.12	0.001	0.44±0.09	6.8e-07	0.12	21
rs10259910	G	T	7	117,291,218	0.57±0.14	6.5e-05	0.37±0.11	0.0011	0.43±0.09	8.3e-07	0.12	22
rs10244364	C	T	7	117,316,877	0.57±0.14	7.1e-05	0.38±0.11	0.00067	0.44±0.09	4.4e-07	0.12	22
rs727164	A	G	7	117,319,388	0.51±0.14	0.00036	0.38±0.11	0.00087	0.42±0.09	2e-06	0.076	27
rs6952555	C	T	7	117,322,514	0.58±0.14	6e-05	0.37±0.12	0.0012	0.45±0.09	6.3e-07	0.10	23
rs7807019	G	A	7	117,330,299	0.14±0.08	0.069	0.29±0.11	0.0075	0.19±0.06	0.0021	0.046	29
rs17488728	T	C	7	117,331,416	0.26±0.10	0.0088	0.26±0.11	0.014	0.26±0.07	0.00032	0.12	21
rs10266994	C	T	7	117,333,073	0.64±0.14	7e-06	0.26±0.10	0.014	0.26±0.07	0.00033	0.090	24
rs1477114	T	C	7	117,334,918	0.26±0.10	0.0085	0.26±0.10	0.014	0.26±0.07	0.00033	0.091	24
rs7789130	G	T	7	117,335,533	0.64±0.14	6.7e-06	0.26±0.10	0.014	0.26±0.07	0.00032	0.092	24
rs12706159	C	A	7	117,335,743	0.26±0.10	0.0083	0.25±0.10	0.015	0.26±0.07	0.00033	0.096	23
rs2193257	G	A	7	117,337,480	0.25±0.10	0.011	0.25±0.10	0.016	0.25±0.07	0.00049	0.11	22
rs6466630	G	A	7	117,339,057	0.26±0.10	0.0089	0.25±0.10	0.015	0.25±0.07	0.00037	0.088	24
rs6964051	C	T	7	117,341,868	0.64±0.14	6.8e-06	0.28±0.11	0.01	0.27±0.07	0.00024	0.10	23
rs12706160	T	C	7	117,342,153	0.26±0.10	0.009	0.28±0.11	0.0097	0.27±0.07	0.00024	0.10	23
rs1548460	T	C	7	117,354,727	0.13±0.07	0.087	0.27±0.11	0.011	0.18±0.06	0.0038	0.042	30

rs6466636	T	A	7	117,356,633	0.26±0.10	0.0089	0.27±0.11	0.011	0.25±0.07	0.00053	0.087	24
rs10272923	C	T	7	117,359,540	0.64±0.14	8.1e-06	0.28±0.11	0.011	0.27±0.07	0.00028	0.10	23
rs6950622	T	C	7	117,360,641	0.26±0.10	0.0087	0.28±0.11	0.01	0.27±0.07	0.00025	0.12	22
rs11978052	A	C	7	117,363,804	0.65±0.14	7e-06	0.28±0.11	0.0099	0.27±0.07	0.00025	0.11	22
rs6971964	T	C	7	117,364,617	0.26±0.10	0.0096	0.29±0.11	0.0086	0.27±0.07	0.00022	0.11	22
rs2158050	G	C	7	117,366,098	0.26±0.10	0.009	0.20±0.11	0.08	0.24±0.07	0.0011	0.068	26
rs1024432	T	G	7	117,366,565	0.26±0.10	0.0089	0.38±0.14	0.0072	0.30±0.08	0.00021	0.16	22
rs1024433	C	T	7	117,366,759	0.65±0.14	5.6e-06	0.33±0.12	0.0061	0.29±0.08	0.00015	0.40	4
rs1024434	A	C	7	117,367,289	0.65±0.14	5.2e-06	0.39±0.14	0.0063	0.31±0.08	0.00016	0.15	23
rs6950716	T	A	7	117,367,969	0.26±0.10	0.0084	0.30±0.11	0.0073	0.26±0.07	0.00041	0.095	24
rs10276758	A	G	7	117,369,189	0.58±0.14	4.8e-05	0.38±0.12	0.0012	0.45±0.09	5.8e-07	0.15	19
rs7782815	G	A	7	117,373,015	0.60±0.14	1.8e-05	0.41±0.12	0.00049	0.48±0.09	7.2e-08	0.23	14
rs10487380	G	A	7	117,373,527	0.64±0.15	1.2e-05	0.38±0.12	0.0012	0.48±0.09	1.8e-07	0.16	18
rs6959314	G	A	7	117,374,593	0.26±0.10	0.0096	0.30±0.11	0.0079	0.28±0.07	0.00021	0.12	21
rs13221302	G	A	7	117,375,933	0.26±0.10	0.0097	0.30±0.11	0.0082	0.27±0.07	0.00022	0.13	21
rs6966339	A	G	7	117,376,444	0.62±0.14	1.3e-05	0.29±0.11	0.0088	0.27±0.07	0.00028	0.12	21
rs6943120	C	G	7	117,378,624	0.61±0.14	1.6e-05	0.22±0.11	0.045	0.12±0.08	0.13	0.018	35
rs1989880	G	C	7	117,379,136	0.25±0.10	0.011	0.18±0.11	0.11	0.23±0.07	0.0019	0.071	26
rs6969783	A	T	7	117,380,544	0.64±0.14	5.9e-06	0.28±0.11	0.012	0.20±0.07	0.0078	0.035	31
rs1156954	A	G	7	117,382,074	0.54±0.14	0.00015	0.39±0.12	0.0012	0.44±0.09	1.6e-06	0.30	10
rs916784	G	A	7	117,386,750	0.44±0.14	0.0015	0.14±0.11	0.19	0.26±0.08	0.0014	0.19	16
rs7801876	G	A	7	117,389,362	0.39±0.14	0.0045	0.14±0.11	0.19	0.25±0.08	0.0026	0.22	14
rs1013278	C	G	7	117,391,056	0.44±0.13	0.0011	0.13±0.10	0.22	0.08±0.09	0.42	0.086	24
rs1468183	A	G	7	117,392,950	0.45±0.14	0.0011	0.13±0.11	0.22	0.24±0.08	0.0036	0.24	13
rs7784849	G	A	7	117,398,486	0.41±0.14	0.0034	0.14±0.11	0.19	0.25±0.08	0.0022	0.24	13
rs10280709	T	C	7	117,400,345	0.40±0.14	0.0049	0.14±0.11	0.21	0.25±0.08	0.0032	0.22	14
rs10237233	C	A	7	117,402,159	0.41±0.14	0.0034	0.14±0.11	0.21	0.25±0.08	0.0025	0.21	15
rs10226992	C	T	7	117,402,553	0.47±0.14	0.00059	0.13±0.11	0.21	0.25±0.08	0.0023	0.21	15
rs7793280	T	C	7	117,405,155	0.39±0.14	0.006	0.14±0.11	0.2	0.24±0.08	0.0036	0.21	15
rs12111806	C	G	7	117,407,087	0.46±0.14	0.00077	0.13±0.11	0.23	0.08±0.09	0.41	0.059	27
rs970185	A	T	7	117,415,419	0.45±0.14	0.00085	0.13±0.11	0.22	0.18±0.08	0.026	0.12	21

rs989996	T	C	7	117,429,488	0.58±0.14	3.6e-05	0.24±0.11	0.022	0.37±0.08	8.9e-06	0.56	0
rs13438629	A	T	7	117,435,455	0.59±0.14	3e-05	0.26±0.11	0.013	0.25±0.08	0.0033	0.17	18
rs10249457	C	A	7	117,439,807	0.58±0.15	0.0001	0.27±0.11	0.011	0.38±0.08	9.1e-06	0.55	0
rs739619	C	G	7	117,443,502	0.60±0.14	1.4e-05	0.17±0.11	0.1	0.12±0.09	0.21	0.063	27
rs10240110	G	C	7	117,450,234	0.59±0.15	7.6e-05	0.22±0.11	0.033	0.34±0.08	5.3e-05	0.41	3
rs10255829	C	T	7	117,450,335	0.60±0.14	2.2e-05	0.26±0.11	0.013	0.37±0.08	8.1e-06	0.61	0
rs17168159	C	T	7	134,321,159	0.82±0.21	0.0001	0.16±0.14	0.25	0.36±0.12	0.0021	0.044	30
rs11983164	T	C	7	134,328,121	0.78±0.20	0.00014	0.17±0.14	0.25	0.36±0.11	0.0018	0.12	22
rs11973318	T	C	7	134,331,846	0.87±0.22	6.4e-05	0.15±0.14	0.3	0.35±0.12	0.0023	0.059	28
rs4565407	A	G	7	134,346,538	0.86±0.19	7.8e-06	0.14±0.14	0.31	0.39±0.11	0.00059	0.074	26
rs4329203	A	C	7	134,347,280	0.84±0.18	2.5e-06	0.14±0.14	0.3	0.41±0.11	0.00022	0.052	28
rs4415249	C	A	7	134,347,420	0.87±0.22	6e-05	0.14±0.14	0.34	0.35±0.12	0.0027	0.043	30
rs1122979	A	G	7	150,546,004	0.11±0.05	0.022	-0.04±0.24	0.87	0.10±0.05	0.032	0.076	25
rs7812088	A	G	7	150,550,762	0.43±0.14	0.0016	-0.04±0.21	0.83	0.22±0.10	0.027	0.083	25
rs7781265	A	G	7	150,581,873	0.04±0.02	0.077	-0.06±0.20	0.76	0.03±0.02	0.086	0.087	24
rs10891481	G	A	11	112,335,772	0.30±0.10	0.003	0.29±0.11	0.007	0.30±0.07	6.3e-05	0.18	17
rs7937151	G	T	11	112,340,234	0.59±0.14	2.5e-05	0.31±0.11	0.0043	0.33±0.08	2.7e-05	0.19	16
rs2155281	A	G	11	112,343,548	0.54±0.13	4e-05	0.29±0.11	0.0069	0.28±0.07	9.3e-05	0.17	17
rs720023	T	A	11	112,344,077	0.27±0.10	0.0046	0.29±0.11	0.0068	0.21±0.07	0.0029	0.057	28
rs7948789	G	A	11	112,344,742	0.28±0.10	0.0045	0.30±0.11	0.0063	0.29±0.07	8.1e-05	0.15	19
rs7126748	C	T	11	112,348,186	0.61±0.14	1.7e-05	0.30±0.11	0.0059	0.28±0.07	0.00013	0.13	21
rs7110863	G	A	11	112,348,348	0.25±0.09	0.0076	0.32±0.11	0.0031	0.28±0.07	7.1e-05	0.12	21
rs11214441	A	T	11	112,351,923	0.60±0.13	7.7e-06	0.29±0.11	0.0068	0.32±0.08	9.2e-05	0.090	24
rs2186707	A	T	11	112,355,853	0.56±0.13	2.3e-05	0.31±0.11	0.0052	0.31±0.08	0.00012	0.11	22
rs2155290	G	C	11	112,356,278	0.49±0.13	0.00011	0.15±0.11	0.17	0.21±0.08	0.0082	0.023	33
rs2298527	G	C	11	112,357,171	0.58±0.13	1.7e-05	0.16±0.11	0.14	0.19±0.07	0.0076	0.049	29
rs1940727	T	G	11	112,357,798	0.49±0.13	9.3e-05	0.31±0.11	0.005	0.38±0.08	3.7e-06	0.27	11
rs1940724	G	A	11	112,358,156	0.48±0.12	0.0001	0.30±0.11	0.0054	0.38±0.08	4.1e-06	0.29	10
rs7121047	T	A	11	112,366,103	0.33±0.11	0.002	0.31±0.11	0.005	0.32±0.08	3.2e-05	0.17	17
rs10891487	A	G	11	112,374,264	0.56±0.13	3e-05	0.30±0.11	0.006	0.37±0.08	7.4e-06	0.24	13
rs4589334	C	G	11	112,384,666	0.62±0.14	8.4e-06	0.20±0.11	0.059	0.14±0.09	0.13	0.010	37

rs7113596	A	C	11	112,388,971	0.44±0.12	0.00022	0.31±0.11	0.0051	0.34±0.08	1.5e-05	0.22	14
rs10732853	G	C	11	112,392,620	0.42±0.12	0.00067	0.14±0.11	0.17	0.27±0.08	0.00063	0.084	25
rs999851	G	A	11	112,395,056	0.49±0.13	0.00025	0.31±0.11	0.0048	0.37±0.08	8.3e-06	0.27	11
rs1940733	A	G	11	112,397,484	0.61±0.14	1.7e-05	0.31±0.11	0.0049	0.38±0.08	5.2e-06	0.26	12
rs7926312	G	A	11	112,399,066	0.55±0.14	4.8e-05	0.31±0.11	0.0047	0.39±0.08	2.8e-06	0.26	12
rs1940734	C	G	11	112,400,238	0.61±0.14	1.3e-05	0.20±0.11	0.054	0.13±0.09	0.16	0.010	38
rs10750022	T	G	11	112,401,523	0.52±0.14	0.00011	0.31±0.11	0.005	0.38±0.08	5.1e-06	0.29	10
rs1892983	C	T	11	112,404,424	0.62±0.14	1.3e-05	0.30±0.11	0.0065	0.38±0.08	5e-06	0.28	11
rs11214469	A	T	11	112,405,553	0.42±0.12	0.00037	0.30±0.11	0.0053	0.24±0.08	0.0023	0.047	29
rs7113099	A	T	11	112,409,545	0.61±0.14	2e-05	0.30±0.11	0.006	0.28±0.08	0.0008	0.066	27
rs1940712	C	G	11	112,411,428	0.50±0.13	0.0001	0.19±0.10	0.063	0.11±0.09	0.22	0.013	36
rs7948327	A	C	11	112,415,287	0.61±0.14	2e-05	0.29±0.11	0.007	0.37±0.08	8.5e-06	0.26	12
rs7938812	G	T	11	112,416,214	0.61±0.14	1.4e-05	0.31±0.11	0.0036	0.39±0.08	2.7e-06	0.31	9
rs7942723	G	T	11	112,417,049	0.61±0.14	1.8e-05	0.29±0.11	0.0068	0.37±0.08	7.7e-06	0.26	12
rs3802847	C	T	11	112,417,513	0.14±0.06	0.035	0.29±0.11	0.0075	0.17±0.06	0.0018	0.054	28
rs3802848	C	A	11	112,417,597	0.51±0.14	0.00017	0.29±0.11	0.0068	0.37±0.08	1.1e-05	0.26	12
rs3802850	C	A	11	112,417,728	0.52±0.14	0.00011	0.29±0.11	0.007	0.37±0.08	8.1e-06	0.27	11
rs2186874	C	T	11	112,417,934	0.48±0.12	8.8e-05	0.29±0.11	0.0071	0.35±0.08	1.2e-05	0.21	15
rs2663907	A	C	15	79,160,087	0.67±0.17	6e-05	-0.10±0.15	0.51	0.22±0.11	0.039	0.0013	46
rs868954	G	A	15	79,169,043	0.71±0.16	1.4e-05	-0.00±0.01	0.97	0.29±0.10	0.0049	0.0015	46
rs10852660	T	C	16	5,549,163	0.57±0.14	6.1e-05	0.04±0.12	0.75	0.23±0.09	0.0078	0.011	37
rs9888783	G	C	16	5,549,316	0.63±0.15	2.4e-05	0.06±0.13	0.66	0.04±0.14	0.76	0.0078	39
rs9888773	C	G	16	5,549,451	0.63±0.15	2.5e-05	0.14±0.12	0.24	0.30±0.09	0.00064	0.030	32
rs9888774	A	G	16	5,549,464	0.62±0.15	3.1e-05	0.02±0.13	0.89	0.22±0.09	0.011	0.013	37
rs2880356	T	C	16	5,549,672	0.61±0.15	4.4e-05	0.02±0.13	0.9	0.22±0.09	0.013	0.014	36
rs17790267	C	T	16	5,550,469	0.60±0.15	5.3e-05	0.02±0.13	0.91	0.21±0.09	0.015	0.019	35
rs1969139	T	C	16	5,551,122	0.59±0.15	6.5e-05	0.02±0.13	0.88	0.21±0.09	0.015	0.023	34
rs1948951	A	G	16	5,553,998	0.60±0.15	3.8e-05	0.05±0.12	0.68	0.24±0.09	0.0062	0.014	36
rs7186722	A	G	16	5,556,055	0.45±0.13	0.00041	-0.02±0.10	0.84	0.17±0.08	0.035	0.12	21

Supplementary Table 3. Association results of CPD SNPs listed in Table 1 for individual studies within the meta-analysis (ENGAGE), *in silico* replication (TAG and OX-GSK) and single-SNP assay replication. Shown are for each marker, the chromosome location, position in build 36, name of consortium, name of study within consortium, number of smokers (N), effect allele frequency (Freq), effect size and standard error, the P-value for the test of association (P), and the the SNP genotyping imputation information (Info). *The FTC study although part of ENGAGE was included in the *in-silico* replication and not in the meta analysis.

SNP	Chr	Position	Consortium	Sample	N	Freq	Effect	P	Info
rs215605 chr7 32303490 (G/T)									
rs215605	7	32303490	ENGAGE	Corogene	265	0.278	0.39±1.13	0.73	0.99
rs215605	7	32303490	ENGAGE	EGPUT	531	0.341	0.03±0.41	0.95	1
rs215605	7	32303490	ENGAGE	ERF	511	0.362	1.43±0.51	0.0046	1
rs215605	7	32303490	ENGAGE	Rotterdam	3,513	0.357	0.39±0.22	0.078	1
rs215605	7	32303490	ENGAGE	Rotterdam-ext	1,246	0.353	0.67±0.39	0.082	1
rs215605	7	32303490	ENGAGE	KORA3	197	0.332	0.44±0.88	0.62	0.89
rs215605	7	32303490	ENGAGE	KORA4	295	0.381	0.24±0.67	0.72	0.42
rs215605	7	32303490	ENGAGE	NFBC	2,167	0.259	0.25±0.29	0.39	0.99
rs215605	7	32303490	ENGAGE	NTRNESDA	2,071	0.352	0.50±0.27	0.065	1
rs215605	7	32303490	ENGAGE	Sorbs	321	0.406	0.08±0.51	0.88	0.99
rs215605	7	32303490	ENGAGE	TwinUK	673	0.367	0.01±0.25	0.97	1
rs215605	7	32303490	ENGAGE	deCODE	15,310	0.357	0.42±0.10	2.8·10 ⁻⁵	1
rs215605	7	32303490	ENGAGE	WTCCC-CAD	1,235	0.392	-0.49±0.39	0.21	0.98
rs215605	7	32303490	ENGAGE	NL-BLC	2,971	0.376	0.90±0.25	0.00041	1
rs215605	7	32303490	ENGAGE	FTC*	502	0.255	0.10±0.65	0.88	0.94
rs215605	7	32303490	OX	GEMS	862	0.379	0.11±0.44	0.81	0.98
rs215605	7	32303490	OX	WTCCC HT	830	0.357	0.08±0.46	0.86	0.98
rs215605	7	32303490	OX	CoLaus	3,132	0.373	0.02±0.25	0.93	0.98
rs215605	7	32303490	OX	LOLIPOP	650	0.367	0.96±0.53	0.072	0.98
rs215605	7	32303490	OX	GSK- BIPOLAR	944	0.382	-0.27±0.50	0.59	1
rs215605	7	32303490	OX	GSK-COPD	1,632	0.321	-0.08±0.26	0.75	1
rs215605	7	32303490	OX	SHIP	2,011	0.344	0.58±0.26	0.025	0.99
rs215605	7	32303490	OX	MEDSTAR	820	0.394	0.67±0.55	0.22	0.99
rs215605	7	32303490	OX	POPGEN	573	0.356	0.38±0.53	0.47	1

Supplementary Table 3. Association results of CPD SNPs listed in Table 1 for individual studies within the meta-analysis (ENGAGE), *in silico* replication (TAG and OX-GSK) and single-SNP assay replication. Shown are for each marker, the chromosome location, position in build 36, name of consortium, name of study within consortium, number of smokers (N), effect allele frequency (Freq), effect size and standard error, the P-value for the test of association (P), and the the SNP genotyping imputation information (Info). *The FTC study although part of ENGAGE was included in the *in-silico* replication and not in the meta analysis.

SNP	Chr	Position	Consortium	Sample	N	Freq	Effect	P	Info
rs215605 chr7 32303490 (G/T)									
rs215605	7	32303490	ENGAGE	Corogene	265	0.278	0.39±1.13	0.73	0.99
rs215605	7	32303490	ENGAGE	EGPUT	531	0.341	0.03±0.41	0.95	1
rs215605	7	32303490	ENGAGE	ERF	511	0.362	1.43±0.51	0.0046	1
rs215605	7	32303490	ENGAGE	Rotterdam	3,513	0.357	0.39±0.22	0.078	1
rs215605	7	32303490	ENGAGE	Rotterdam-ext	1,246	0.353	0.67±0.39	0.082	1
rs215605	7	32303490	ENGAGE	KORA3	197	0.332	0.44±0.88	0.62	0.89
rs215605	7	32303490	ENGAGE	KORA4	295	0.381	0.24±0.67	0.72	0.42
rs215605	7	32303490	ENGAGE	NFBC	2,167	0.259	0.25±0.29	0.39	0.99
rs215605	7	32303490	ENGAGE	NTRNESDA	2,071	0.352	0.50±0.27	0.065	1
rs215605	7	32303490	ENGAGE	Sorbs	321	0.406	0.08±0.51	0.88	0.99
rs215605	7	32303490	ENGAGE	TwinUK	673	0.367	0.01±0.25	0.97	1
rs215605	7	32303490	ENGAGE	deCODE	15,310	0.357	0.42±0.10	2.8·10 ⁻⁵	1
rs215605	7	32303490	ENGAGE	WTCCC-CAD	1,235	0.392	-0.49±0.39	0.21	0.98
rs215605	7	32303490	ENGAGE	NL-BLC	2,971	0.376	0.90±0.25	0.00041	1
rs215605	7	32303490	ENGAGE	FTC*	502	0.255	0.10±0.65	0.88	0.94
rs215605	7	32303490	OX	GEMS	862	0.379	0.11±0.44	0.81	0.98
rs215605	7	32303490	OX	WTCCC HT	830	0.357	0.08±0.46	0.86	0.98
rs215605	7	32303490	OX	CoLaus	3,132	0.373	0.02±0.25	0.93	0.98
rs215605	7	32303490	OX	LOLIPOP	650	0.367	0.96±0.53	0.072	0.98
rs215605	7	32303490	OX	GSK- BIPOLAR	944	0.382	-0.27±0.50	0.59	1
rs215605	7	32303490	OX	GSK-COPD	1,632	0.321	-0.08±0.26	0.75	1
rs215605	7	32303490	OX	SHIP	2,011	0.344	0.58±0.26	0.025	0.99
rs215605	7	32303490	OX	MEDSTAR	820	0.394	0.67±0.55	0.22	0.99
rs215605	7	32303490	OX	POPGEN	573	0.356	0.38±0.53	0.47	1

rs215614	7	32313860	ENGAGE	WTCCC-CAD	1,235	0.389	-0.50±0.39	0.20	1
rs215614	7	32313860	ENGAGE	NL-BLC	2,971	0.365	0.90±0.25	0.00043	1
rs215614	7	32313860	ENGAGE	FTC*	502	0.256	0.10±0.65	0.87	0.95
rs215614	7	32313860	OX	GEMS	862	0.376	0.12±0.44	0.79	1
rs215614	7	32313860	OX	WTCCC HT	830	0.355	0.13±0.46	0.77	1
rs215614	7	32313860	OX	CoLaus	3,132	0.369	0.02±0.25	0.95	1
rs215614	7	32313860	OX	LOLIPOP	650	0.363	0.91±0.53	0.085	1
rs215614	7	32313860	OX	GSK- BIPOLAR	944	0.381	-0.31±0.50	0.53	1
rs215614	7	32313860	OX	GSK-COPD	1,632	0.319	-0.12±0.26	0.66	0.99
rs215614	7	32313860	OX	SHIP	2,011	0.344	0.60±0.26	0.021	0.99
rs215614	7	32313860	OX	MEDSTAR	820	0.392	0.66±0.55	0.23	1
rs215614	7	32313860	OX	POPGEN	573	0.356	0.36±0.53	0.48	1
rs215614	7	32313860	OX	GSK- UNIPOLAR	899	0.379	0.23±0.44	0.59	1
rs215614	7	32313860	TAG	ADVANCE	68	0.378	-0.12±1.66	0.94	0.9
rs215614	7	32313860	TAG	ARIC	4,970	0.37	0.32±0.18	0.079	1
rs215614	7	32313860	TAG	ATVB	2,190	0.382	0.47±0.30	0.11	1
rs215614	7	32313860	TAG	CHS	1,634	0.383	-0.10±0.31	0.75	1.01
rs215614	7	32313860	TAG	FHS	3,918	0.384	-0.22±0.22	0.32	0.99
rs215614	7	32313860	TAG	FUSION	443	0.273	0.52±0.68	0.44	1
rs215614	7	32313860	TAG	GAIN	984	0.378	1.49±0.51	0.0033	1
rs215614	7	32313860	TAG	IARC	6,420	0.358	0.10±0.15	0.53	1
rs215614	7	32313860	TAG	InCHIANTI	527	0.387	0.72±0.50	0.15	1
rs215614	7	32313860	TAG	NHS	1,211	0.373	0.68±0.41	0.095	1
rs215614	7	32313860	TAG	WGHS	10,486	0.366	0.08±0.12	0.48	0.98
rs6474412 chr8 42669655 (T/C)									
rs6474412	8	42669655		Australia	2,501	0.789	0.14±0.45	0.71	1
rs6474412	8	42669655		DANCOPD	1,142	0.779	-0.13±0.27	0.63	1
rs6474412	8	42669655		deCODE	4,759	0.761	0.31±0.26	0.20	1
rs6474412	8	42669655		Spain	400	0.78	1.64±0.93	0.077	1

Supplementary Table 3. Association results of CPD SNPs listed in Table 1 for individual studies within the meta-analysis (ENGAGE), *in silico* replication (TAG and OX-GSK) and single-SNP assay replication. Shown are for each marker, the chromosome location, position in build 36, name of consortium, name of study within consortium, number of smokers (N), effect allele frequency (Freq), effect size and standard error, the P-value for the test of association (P), and the the SNP genotyping imputation information (Info). *The FTC study although part of ENGAGE was included in the *in-silico* replication and not in the meta analysis.

SNP	Chr	Position	Consortium	Sample	N	Freq	Effect	P	Info
rs215605 chr7 32303490 (G/T)									
rs215605	7	32303490	ENGAGE	Corogene	265	0.278	0.39±1.13	0.73	0.99
rs215605	7	32303490	ENGAGE	EGPUT	531	0.341	0.03±0.41	0.95	1
rs215605	7	32303490	ENGAGE	ERF	511	0.362	1.43±0.51	0.0046	1
rs215605	7	32303490	ENGAGE	Rotterdam	3,513	0.357	0.39±0.22	0.078	1
rs215605	7	32303490	ENGAGE	Rotterdam-ext	1,246	0.353	0.67±0.39	0.082	1
rs215605	7	32303490	ENGAGE	KORA3	197	0.332	0.44±0.88	0.62	0.89
rs215605	7	32303490	ENGAGE	KORA4	295	0.381	0.24±0.67	0.72	0.42
rs215605	7	32303490	ENGAGE	NFBC	2,167	0.259	0.25±0.29	0.39	0.99
rs215605	7	32303490	ENGAGE	NTRNESDA	2,071	0.352	0.50±0.27	0.065	1
rs215605	7	32303490	ENGAGE	Sorb	321	0.406	0.08±0.51	0.88	0.99
rs215605	7	32303490	ENGAGE	TwinUK	673	0.367	0.01±0.25	0.97	1
rs215605	7	32303490	ENGAGE	deCODE	15,310	0.357	0.42±0.10	2.8·10 ⁻⁵	1
rs215605	7	32303490	ENGAGE	WTCCC-CAD	1,235	0.392	-0.49±0.39	0.21	0.98
rs215605	7	32303490	ENGAGE	NL-BLC	2,971	0.376	0.90±0.25	0.00041	1
rs215605	7	32303490	ENGAGE	FTC*	502	0.255	0.10±0.65	0.88	0.94
rs215605	7	32303490	OX	GEMS	862	0.379	0.11±0.44	0.81	0.98
rs215605	7	32303490	OX	WTCCC HT	830	0.357	0.08±0.46	0.86	0.98
rs215605	7	32303490	OX	CoLaus	3,132	0.373	0.02±0.25	0.93	0.98
rs215605	7	32303490	OX	LOLIPOP	650	0.367	0.96±0.53	0.072	0.98
rs215605	7	32303490	OX	GSK- BIPOLAR	944	0.382	-0.27±0.50	0.59	1
rs215605	7	32303490	OX	GSK-COPD	1,632	0.321	-0.08±0.26	0.75	1
rs215605	7	32303490	OX	SHIP	2,011	0.344	0.58±0.26	0.025	0.99
rs215605	7	32303490	OX	MEDSTAR	820	0.394	0.67±0.55	0.22	0.99
rs215605	7	32303490	OX	POPGEN	573	0.356	0.38±0.53	0.47	1

rs6474412	8	42669655	TAG	FUSION	443	0.759	1.08±0.73	0.14	1
rs6474412	8	42669655	TAG	GAIN	984	0.775	0.55±0.60	0.36	0.99
rs6474412	8	42669655	TAG	IARC	6,420	0.773	0.17±0.17	0.33	1
rs6474412	8	42669655	TAG	InCHIANTI	527	0.78	1.44±0.60	0.016	1
rs6474412	8	42669655	TAG	NHS	1,211	0.755	0.68±0.46	0.13	1
rs6474412	8	42669655	TAG	WGHS	10,486	0.773	0.40±0.14	0.0038	0.99
rs13280604 chr8 42678743 (A/G)									
rs13280604	8	42678743	ENGAGE	Corogene	265	0.786	1.54±1.52	0.31	0.82
rs13280604	8	42678743	ENGAGE	EGPUT	531	0.758	0.69±0.45	0.13	1
rs13280604	8	42678743	ENGAGE	ERF	511	0.757	-0.72±0.56	0.2	0.98
rs13280604	8	42678743	ENGAGE	Rotterdam	3,513	0.776	0.12±0.26	0.63	1
rs13280604	8	42678743	ENGAGE	Rotterdam-ext	1,246	0.781	0.75±0.46	0.1	1
rs13280604	8	42678743	ENGAGE	KORA3	150	0.877	0.04±1.19	0.97	0.46
rs13280604	8	42678743	ENGAGE	NFBC	2,167	0.772	0.33±0.32	0.29	0.8
rs13280604	8	42678743	ENGAGE	NTRNESDA	2,071	0.83	-0.20±0.36	0.57	1
rs13280604	8	42678743	ENGAGE	Sorbs	321	0.781	0.11±0.68	0.88	0.81
rs13280604	8	42678743	ENGAGE	TwinUK	673	0.768	0.24±0.35	0.49	1
rs13280604	8	42678743	ENGAGE	deCODE	15,310	0.772	0.41±0.11	0.00029	1
rs13280604	8	42678743	ENGAGE	WTCCC-CAD	1,235	0.791	-0.04±0.51	0.94	0.86
rs13280604	8	42678743	ENGAGE	NL-BLC	2,971	0.789	0.40±0.30	0.18	1
rs13280604	8	42678743	ENGAGE	FTC*	502	0.724	-0.82±0.70	0.23	0.94
rs13280604	8	42678743	OX	GEMS	862	0.811	-0.02±0.61	0.98	0.86
rs13280604	8	42678743	OX	WTCCC HT	830	0.82	-0.16±0.61	0.79	0.81
rs13280604	8	42678743	OX	CoLaus	3,132	0.809	-0.03±0.32	0.92	0.84
rs13280604	8	42678743	OX	LOLIPOP	650	0.785	1.15±0.70	0.098	0.83
rs13280604	8	42678743	OX	GSK-	944	0.772	0.16±0.60	0.79	1
rs13280604	8	42678743	OX	BIPOLAR					
rs13280604	8	42678743	OX	GSK-COPD	1,632	0.792	0.18±0.30	0.54	1
rs13280604	8	42678743	OX	SHIP	2,011	0.774	0.05±0.29	0.86	0.99
rs13280604	8	42678743	OX	MEDSTAR	820	0.792	1.08±0.67	0.10	1
rs13280604	8	42678743	OX	POPGEN	573	0.778	1.23±0.63	0.048	1

rs13280604	8	42678743	OX	GSK- UNIPOLAR	899	0.794	-0.85±0.54	0.11	1	
rs13280604	8	42678743	TAG	ADVANCE	68	0.818	1.43±1.78	0.41	0.93	
rs13280604	8	42678743	TAG	ARIC	4,970	0.789	0.76±0.23	0.00089	0.88	
rs13280604	8	42678743	TAG	ATVB	2,190	0.777	-0.14±0.36	0.70	0.98	
rs13280604	8	42678743	TAG	CHS	1,634	0.752	-0.28±0.38	0.46	0.97	
rs13280604	8	42678743	TAG	FHS	3,918	0.799	0.37±0.31	0.23	0.73	
rs13280604	8	42678743	TAG	FUSION	443	0.759	1.05±0.73	0.15	1	
rs13280604	8	42678743	TAG	GAIN	984	0.775	0.55±0.61	0.36	0.98	
rs13280604	8	42678743	TAG	IARC	6,420	0.773	0.17±0.17	0.34	1	
rs13280604	8	42678743	TAG	InCHIANTI	527	0.781	1.50±0.60	0.013	1	
rs13280604	8	42678743	TAG	NHS	1,211	0.755	0.70±0.46	0.12	1	
rs13280604	8	42678743	TAG	WGHS	10,486	0.773	0.39±0.14	0.0039	1	
rs1051730 chr15 76681394 (A/G)										
rs1051730	15	76681394	ENGAGE	Corogene	265	0.335	1.37±1.08	0.21	1	
rs1051730	15	76681394	ENGAGE	EGPUT	531	0.342	0.33±0.41	0.43	1	
rs1051730	15	76681394	ENGAGE	ERF	511	0.39	1.11±0.49	0.025	0.99	
rs1051730	15	76681394	ENGAGE	Rotterdam	3,513	0.321	0.43±0.23	0.067	1	
rs1051730	15	76681394	ENGAGE	Rotterdam-ext	1,246	0.306	0.58±0.41	0.16	1	
rs1051730	15	76681394	ENGAGE	KORA3	183	0.344	0.10±0.85	0.91	0.37	
rs1051730	15	76681394	ENGAGE	KORA4	274	0.363	0.48±0.65	0.46	0.62	
rs1051730	15	76681394	ENGAGE	NFBC	2,167	0.319	0.90±0.22	6.0·10 ⁻⁵	0.99	
rs1051730	15	76681394	ENGAGE	NTRNESDA	2,071	0.311	1.37±0.28	1.5·10 ⁻⁶	1	
rs1051730	15	76681394	ENGAGE	Sorbs	+321		0.307	0.29±0.54	0.59	0.96
rs1051730	15	76681394	ENGAGE	TwinUK	668	0.327	0.46±0.28	0.094	1	
rs1051730	15	76681394	ENGAGE	deCODE	15,310	0.348	0.96±0.10	2.6·10 ⁻²¹	1	
rs1051730	15	76681394	ENGAGE	WTCCC-CAD	1,235	0.317	1.14±0.43	0.0073	0.95	
rs1051730	15	76681394	ENGAGE	NL-BLC	2,971	0.331	0.81±0.26	0.0021	1	
rs1051730	15	76681394	ENGAGE	FTC*	502	0.37	0.79±0.61	0.19	0.94	
rs1051730	15	76681394	OX	GEMS	862	0.32	1.79±0.49	0.00024	0.96	
rs1051730	15	76681394	OX	WTCCC HT	830	0.302	0.84±0.49	0.088	0.96	

rs13280604	8	42678743	OX	GSK- UNIPOLAR	899	0.794	-0.85±0.54	0.11	1
rs13280604	8	42678743	TAG	ADVANCE	68	0.818	1.43±1.78	0.41	0.93
rs13280604	8	42678743	TAG	ARIC	4,970	0.789	0.76±0.23	0.00089	0.88
rs13280604	8	42678743	TAG	ATVB	2,190	0.777	-0.14±0.36	0.70	0.98
rs13280604	8	42678743	TAG	CHS	1,634	0.752	-0.28±0.38	0.46	0.97
rs13280604	8	42678743	TAG	FHS	3,918	0.799	0.37±0.31	0.23	0.73
rs13280604	8	42678743	TAG	FUSION	443	0.759	1.05±0.73	0.15	1
rs13280604	8	42678743	TAG	GAIN	984	0.775	0.55±0.61	0.36	0.98
rs13280604	8	42678743	TAG	IARC	6,420	0.773	0.17±0.17	0.34	1
rs13280604	8	42678743	TAG	InCHIANTI	527	0.781	1.50±0.60	0.013	1
rs13280604	8	42678743	TAG	NHS	1,211	0.755	0.70±0.46	0.12	1
rs13280604	8	42678743	TAG	WGHS	10,486	0.773	0.39±0.14	0.0039	1
rs1051730 chr15 76681394 (A/G)									
rs1051730	15	76681394	ENGAGE	Corogene	265	0.335	1.37±1.08	0.21	1
rs1051730	15	76681394	ENGAGE	EGPUT	531	0.342	0.33±0.41	0.43	1
rs1051730	15	76681394	ENGAGE	ERF	511	0.39	1.11±0.49	0.025	0.99
rs1051730	15	76681394	ENGAGE	Rotterdam	3,513	0.321	0.43±0.23	0.067	1
rs1051730	15	76681394	ENGAGE	Rotterdam-ext	1,246	0.306	0.58±0.41	0.16	1
rs1051730	15	76681394	ENGAGE	KORA3	183	0.344	0.10±0.85	0.91	0.37
rs1051730	15	76681394	ENGAGE	KORA4	274	0.363	0.48±0.65	0.46	0.62
rs1051730	15	76681394	ENGAGE	NFBC	2,167	0.319	0.90±0.22	6.0·10 ⁻⁵	0.99
rs1051730	15	76681394	ENGAGE	NTRNESDA	2,071	0.311	1.37±0.28	1.5·10 ⁻⁶	1
rs1051730	15	76681394	ENGAGE	Sorbs	321	0.307	0.29±0.54	0.59	0.96
rs1051730	15	76681394	ENGAGE	TwinUK	668	0.327	0.46±0.28	0.094	1
rs1051730	15	76681394	ENGAGE	deCODE	15,310	0.348	0.96±0.10	2.6·10 ⁻²¹	1
rs1051730	15	76681394	ENGAGE	WTCCC-CAD	1,235	0.317	1.14±0.43	0.0073	0.95
rs1051730	15	76681394	ENGAGE	NL-BLC	2,971	0.331	0.81±0.26	0.0021	1
rs1051730	15	76681394	ENGAGE	FTC*	502	0.37	0.79±0.61	0.19	0.94
rs1051730	15	76681394	OX	GEMS	862	0.32	1.79±0.49	0.00024	0.96
rs1051730	15	76681394	OX	WTCCC HT	830	0.302	0.84±0.49	0.088	0.96

rs7937	19	45994546	ENGAGE	Rotterdam-ext	1,246	0.542	0.94±0.37	0.011	1
rs7937	19	45994546	ENGAGE	KORA3	195	0.603	-1.22±0.87	0.16	0.48
rs7937	19	45994546	ENGAGE	KORA4	293	0.56	0.19±0.65	0.77	0.57
rs7937	19	45994546	ENGAGE	NFBC	2,167	0.646	0.27±0.22	0.22	0.95
rs7937	19	45994546	ENGAGE	NTRNESDA	2,071	0.525	0.69±0.30	0.020	1
rs7937	19	45994546	ENGAGE	Sorbs	321	0.503	0.38±0.50	0.45	0.96
rs7937	19	45994546	ENGAGE	TwinUK	673	0.562	-0.15±0.21	0.48	1
rs7937	19	45994546	ENGAGE	deCODE	15,310	0.545	0.40±0.10	3.8·10 ⁻⁵	1
rs7937	19	45994546	ENGAGE	WTCCC-CAD	1,235	0.549	0.34±0.39	0.39	0.93
rs7937	19	45994546	ENGAGE	NL-BLC	2,971	0.535	0.45±0.25	0.066	1
rs7937	19	45994546	ENGAGE	FTC*	502	0.606	-0.62±0.58	0.28	0.94
rs7937	19	45994546	OX	GEMS	862	0.556	0.35±0.45	0.44	0.97
rs7937	19	45994546	OX	WTCCC HT	830	0.518	0.41±0.44	0.35	0.97
rs7937	19	45994546	OX	CoLaus	3,132	0.544	0.33±0.24	0.17	0.96
rs7937	19	45994546	OX	LOLIPOP	650	0.523	-0.10±0.53	0.85	0.96
rs7937	19	45994546	OX	GSK-	944	0.562	0.21±0.48	0.67	1
				BIPOLAR					
rs7937	19	45994546	OX	GSK-COPD	1,632	0.583	0.05±0.24	0.83	1
rs7937	19	45994546	OX	SHIP	2,011	0.553	0.35±0.24	0.14	0.98
rs7937	19	45994546	OX	MEDSTAR	820	0.553	0.61±0.56	0.27	0.98
rs7937	19	45994546	OX	POPGEN	573	0.551	0.40±0.52	0.43	0.98
rs7937	19	45994546	OX	GSK-	899	0.546	0.47±0.43	0.27	1
				UNIPOLAR					
rs7937	19	45994546	TAG	ADVANCE	68	0.603	-0.77±1.41	0.58	1
rs7937	19	45994546	TAG	ARIC	4,970	0.558	0.35±0.18	0.057	0.98
rs7937	19	45994546	TAG	ATVB	2,190	0.544	0.17±0.31	0.59	0.94
rs7937	19	45994546	TAG	CHS	1,634	0.55	-0.11±0.31	0.72	1.02
rs7937	19	45994546	TAG	FHS	3,918	0.545	-0.19±0.22	0.39	0.96
rs7937	19	45994546	TAG	FUSION	443	0.641	0.13±0.62	0.83	1
rs7937	19	45994546	TAG	GAIN	984	0.565	-0.70±0.51	0.16	0.94
rs7937	19	45994546	TAG	IARC	6,420	0.56	0.28±0.15	0.058	1
rs7937	19	45994546	TAG	InCHIANTI	527	0.526	0.38±0.47	0.42	1

rs7937	19	45994546	TAG	NHS	1,211	0.547	-0.35±0.39	0.37	1
rs7937	19	45994546	TAG	WGHS	10,486	0.556	0.25±0.12	0.032	1
rs1801272 chr19 46046373 (A/T)									
rs1801272	19	46046373	ENGAGE	EGPUT	530	0.965	0.84±1.71	0.62	0.4
rs1801272	19	46046373	ENGAGE	ERF	511	0.959	2.64±2.03	0.19	0.93
rs1801272	19	46046373	ENGAGE	Rotterdam	3,513	0.946	1.42±0.74	0.054	0.93
rs1801272	19	46046373	ENGAGE	Rotterdam-ext	1,246	0.946	1.75±1.26	0.16	0.93
rs1801272	19	46046373	ENGAGE	NTRNESDA	2,071	0.96	0.04±0.78	0.96	1
rs1801272	19	46046373	ENGAGE	Sorbs	321	0.98	-0.82±1.95	0.67	0.36
rs1801272	19	46046373	ENGAGE	TwinUK	2,071	0.991	3.78±2.07	0.068	0.95
rs1801272	19	46046373	ENGAGE	deCODE	15,310	0.982	1.31±0.40	0.00097	0.42
rs1801272	19	46046373	ENGAGE	WTCCC-CAD	1,235	0.978	-1.30±1.46	0.37	0.53
rs1801272	19	46046373	ENGAGE	NL-BLC	2,971	0.972	1.23±0.87	0.16	0.45
rs1801272	19	46046373	ENGAGE	FTC*	502	0.913	3.46±2.13	0.099	0.43
rs1801272	19	46046373	OX	GEMS	862	0.963	0.44±1.97	0.82	0.34
rs1801272	19	46046373	OX	WTCCC HT	830	0.958	-0.30±1.55	0.85	0.48
rs1801272	19	46046373	OX	CoLaus	3,132	0.953	0.77±0.86	0.37	0.43
rs1801272	19	46046373	OX	LOLIPOP	650	0.96	0.99±2.15	0.64	0.38
rs1801272	19	46046373	OX	GSK-	944	0.953	0.82±1.87	0.66	0.37
rs1801272	19	46046373	OX	BIPOLAR					
rs1801272	19	46046373	OX	GSK-COPD	1,632	0.953	0.70±0.97	0.47	0.35
rs1801272	19	46046373	OX	MEDSTAR	820	0.969	1.35±2.42	0.58	0.42
rs1801272	19	46046373	OX	POPGEN	573	0.971	1.30±2.46	0.59	0.4
rs1801272	19	46046373	OX	SHIP	2,011	0.968	-0.21±1.05	0.84	0.41
rs1801272	19	46046373	OX	GSK-	899	0.955	3.37±1.56	0.030	0.45
rs1801272	19	46046373	OX	UNIPOLAR					
rs1801272	19	46046373	TAG	ARIC	4,970	0.958	1.61±0.86	0.060	0.32
rs1801272	19	46046373	TAG	ATVB	2,190	0.961	2.17±1.68	0.20	0.23
rs1801272	19	46046373	TAG	FHS	3,918	0.945	1.07±0.74	0.15	0.39
rs1801272	19	46046373	TAG	FUSION	443	0.964	-0.33±2.65	0.90	0.35
rs1801272	19	46046373	TAG	InCHIANTI	527	0.957	2.66±1.44	0.065	0.48

rs1801272	19	46046373	TAG	NHS	1,211	0.945	-0.01±1.26	0.99	0.46
rs1801272	19	46046373	TAG	WGHS	10,486	0.974	-0.47±0.37	0.20	0.96
rs4105144 chr19 46050464 (C/T)									
rs4105144	19	46050464		Australia	2,511	0.691	-0.13±0.40	0.7	1
rs4105144	19	46050464		DANCOPD	1,134	0.653	-0.11±0.24	0.66	1
rs4105144	19	46050464		deCODE	4,762	0.661	0.38±0.24	0.079	1
rs4105144	19	46050464		Spain	469	0.684	0.13±0.74	0.86	1
rs4105144	19	46050464		Germany	411	0.667	0.68±0.76	0.37	1
rs4105144	19	46050464	ENGAGE	Corogene	265	0.822	1.10±1.96	0.58	0.33
rs4105144	19	46050464	ENGAGE	EGPUT	530	0.743	-0.09±0.67	0.89	0.5
rs4105144	19	46050464	ENGAGE	ERF	511	0.710	2.35±0.81	0.0038	0.7
rs4105144	19	46050464	ENGAGE	Rotterdam	3,513	0.690	0.40±0.25	0.11	0.92
rs4105144	19	46050464	ENGAGE	Rotterdam-ext	1,246	0.678	0.31±0.41	0.45	0.95
rs4105144	19	46050464	ENGAGE	KORA3	184	0.717	0.44±0.93	0.64	0.59
rs4105144	19	46050464	ENGAGE	KORA4	137	0.832	0.56±0.84	0.50	0.82
rs4105144	19	46050464	ENGAGE	NTRNESDA	2,071	0.657	0.68±0.30	0.022	1
rs4105144	19	46050464	ENGAGE	Sorbs	321	0.696	0.60±0.69	0.38	0.57
rs4105144	19	46050464	ENGAGE	TwinUK	2,071	0.836	1.02±0.73	0.16	0.77
rs4105144	19	46050464	ENGAGE	deCODE	15,310	0.729	0.61±0.14	2.1·10 ⁻⁵	0.55
rs4105144	19	46050464	ENGAGE	WTCCC-CAD	1,235	0.656	0.46±0.39	0.24	0.98
rs4105144	19	46050464	ENGAGE	NL-BLC	2,971	0.739	0.88±0.37	0.018	0.55
rs4105144	19	46050464	ENGAGE	FTC*	502	0.779	0.75±0.69	0.27	0.83
rs4105144	19	46050464	OX	GEMS	862	0.673	0.10±0.45	0.83	0.98
rs4105144	19	46050464	OX	WTCCC HT	830	0.644	0.13±0.44	0.77	0.98
rs4105144	19	46050464	OX	CoLaus	3,132	0.653	0.47±0.25	0.052	0.98
rs4105144	19	46050464	OX	LOLIPOP	650	0.644	0.13±0.54	0.81	0.98
rs4105144	19	46050464	OX	GSK-	944	0.661	0.44±0.51	0.38	0.94
BIPOLAR									
rs4105144	19	46050464	OX	GSK-COPD	1,632	0.707	-0.29±0.28	0.30	0.9
rs4105144	19	46050464	OX	MEDSTAR	820	0.673	1.42±0.70	0.042	0.68
rs4105144	19	46050464	OX	POPGEN	573	0.702	0.85±0.68	0.20	0.71

rs4105144	19	46050464	OX	SHIP	2,011	0.684	0.90±0.31	0.0032	0.68
rs4105144	19	46050464	OX	GSK- UNIPOLAR	899	0.708	0.29±0.49	0.56	0.92
rs4105144	19	46050464	TAG	ADVANCE	68	0.676	0.29±1.57	0.85	0.82
rs4105144	19	46050464	TAG	ARIC	4,970	0.690	0.66±0.25	0.0085	0.59
rs4105144	19	46050464	TAG	ATVB	2,190	0.689	-0.09±0.43	0.84	0.54
rs4105144	19	46050464	TAG	FHS	3,918	0.662	0.06±0.23	0.78	1
rs4105144	19	46050464	TAG	FUSION	443	0.734	0.74±1.01	0.46	0.47
rs4105144	19	46050464	TAG	GAIN	984	0.667	-1.82±0.94	0.053	0.34
rs4105144	19	46050464	TAG	IARC	6,420	0.728	0.43±0.26	0.091	0.4
rs4105144	19	46050464	TAG	InCHIANTI	527	0.676	0.75±0.54	0.16	0.91
rs4105144	19	46050464	TAG	NHS	1,211	0.684	0.23±0.42	0.59	0.9
rs4105144	19	46050464	TAG	WGHS	10,486	0.713	0.22±0.18	0.22	0.48
rs7260329 chr19 46213478 (G/A)									
rs7260329	19	46213478		Australia	2,511	0.691	-0.13±0.40	0.7	1
rs7260329	19	46213478		DANCOPD	1,134	0.653	-0.11±0.24	0.66	1
rs7260329	19	46213478		deCODE	4,762	0.661	0.38±0.24	0.079	1
rs7260329	19	46213478		Spain	469	0.684	0.13±0.74	0.86	1
rs7260329	19	46213478		Germany	318	0.657	-1.14±0.84	0.17	1
rs7260329	19	46213478	ENGAGE	Corogene	265	0.655	0.58±0.97	0.55	0.96
rs7260329	19	46213478	ENGAGE	EGPUT	528	0.705	0.46±0.43	0.29	1
rs7260329	19	46213478	ENGAGE	ERF	511	0.734	-0.05±0.60	0.93	0.96
rs7260329	19	46213478	ENGAGE	Rotterdam	3,513	0.677	0.56±0.23	0.016	1
rs7260329	19	46213478	ENGAGE	Rotterdam-ext	1,246	0.678	0.26±0.39	0.51	1
rs7260329	19	46213478	ENGAGE	KORA3	130	0.796	-0.07±1.08	0.95	0.48
rs7260329	19	46213478	ENGAGE	KORA4	252	0.756	0.96±0.70	0.17	0.41
rs7260329	19	46213478	ENGAGE	NFBC	2,167	0.653	0.51±0.22	0.023	0.69
rs7260329	19	46213478	ENGAGE	NTRNESDA	2,071	0.665	0.54±0.28	0.051	1
rs7260329	19	46213478	ENGAGE	Sorbs	321	0.665	0.43±0.63	0.5	0.73
rs7260329	19	46213478	ENGAGE	TwinUK	672	0.680	0.06±0.27	0.82	1
rs7260329	19	46213478	ENGAGE	deCODE	15,310	0.668	0.43±0.10	2.9·10 ⁻⁵	1

rs7260329	19	46213478	ENGAGE	WTCCC-CAD	1,235	0.691	0.64±0.42	0.13	0.96
rs7260329	19	46213478	ENGAGE	NL-BLC	2,971	0.666	0.42±0.26	0.11	1
rs7260329	19	46213478	ENGAGE	FTC*	502	0.676	1.11±0.61	0.063	0.94
rs7260329	19	46213478	OX	GEMS	862	0.647	-0.58±0.51	0.25	0.92
rs7260329	19	46213478	OX	WTCCC HT	830	0.691	-0.12±0.47	0.8	0.96
rs7260329	19	46213478	OX	CoLaus	3,132	0.712	0.23±0.29	0.42	0.82
rs7260329	19	46213478	OX	LOLIPOP	650	0.697	0.15±0.62	0.81	0.83
rs7260329	19	46213478	OX	GSK- BIPOLAR	944	0.711	-0.30±0.53	0.57	1
rs7260329	19	46213478	OX	GSK-COPD	1,632	0.664	0.14±0.25	0.59	0.99
rs7260329	19	46213478	OX	SHIP	2,011	0.689	0.05±0.27	0.84	0.88
rs7260329	19	46213478	OX	MEDSTAR	820	0.707	1.10±0.65	0.086	0.89
rs7260329	19	46213478	OX	POPGEN	573	0.690	-0.05±0.61	0.93	0.89
rs7260329	19	46213478	OX	GSK- UNIPOLAR	899	0.656	-0.77±0.45	0.086	1
rs7260329	19	46213478	TAG	ADVANCE	68	0.699	0.11±1.38	0.93	1
rs7260329	19	46213478	TAG	ARIC	4,970	0.700	0.40±0.21	0.055	0.86
rs7260329	19	46213478	TAG	ATVB	2,190	0.703	-0.54±0.35	0.12	0.82
rs7260329	19	46213478	TAG	CHS	1,634	0.672	0.41±0.34	0.23	0.95
rs7260329	19	46213478	TAG	FHS	3,918	0.683	-0.27±0.23	0.24	0.95
rs7260329	19	46213478	TAG	FUSION	443	0.668	-0.18±0.63	0.78	1
rs7260329	19	46213478	TAG	GAIN	984	0.712	-0.18±0.62	0.77	0.78
rs7260329	19	46213478	TAG	IARC	6,420	0.667	0.02±0.15	0.87	0.99
rs7260329	19	46213478	TAG	InCHIANTI	527	0.620	0.93±0.50	0.064	1
rs7260329	19	46213478	TAG	NHS	1,211	0.703	0.62±0.43	0.15	1
rs7260329	19	46213478	TAG	WGHS	10,486	0.685	-0.00±0.12	1	1

Supplementary Table 4. Association with Nicotine Dependence (A) and Peripheral Arterial Disease (B). Shown are the number of cases and controls (N), the frequencies of the effect allele (see **Table 1**) in cases and controls, the odds ratio and 95% confidence intervals (OR and 95%CI), the P value for the test of association (P). The results for LC are shown in **Table 2**.

A – Nicotine Dependence

SNP-Allele	Population	N		Freq		OR (95% CI)	P
		cases	controls	cases	controls		
<i>rs1051730-A</i> Chrs 15	Iceland	1976	36147	0.384	0.343	1.20 (1.12, 1.28)	1.0·10 ⁻⁷
	NTR-NESDA	835	611	0.286	0.34	1.28 (1.09, 1.50)	0.0026
	Combined	-	-	-	-	1.21 (1.14, 1.29)	1.3·10 ⁻⁹
<i>rs6474412-T</i> Chrs 8	Iceland	1979	36202	0.785	0.771	1.09 (1.01, 1.18)	0.032
	NTR-NESDA	835	611	0.833	0.846	1.10 (0.89, 1.36)	0.38
	Combined	-	-	-	-	1.09 (1.01, 1.17)	0.020
<i>rs13280604-A</i> Chrs 8	Iceland	1979	36202	0.785	0.771	1.09 (1.01, 1.18)	0.032
	NTR-NESDA	835	611	0.833	0.846	1.10 (0.89, 1.36)	0.39
	Combined	-	-	-	-	1.09 (1.01, 1.17)	0.021
<i>rs215614-G</i> Chrs 7	Iceland	1979	36202	0.37	0.355	1.07 (1.00, 1.14)	0.050
	NTR-NESDA	835	611	0.342	0.341	0.99 (0.86, 1.15)	0.95
	Combined	-	-	-	-	1.06 (0.99, 1.12)	0.080
<i>rs215605-G</i> Chrs 7	Iceland	1979	36163	0.372	0.357	1.07 (1.00, 1.14)	0.055
	NTR-NESDA	835	611	0.346	0.345	1.00 (0.84, 1.17)	0.96
	Combined	-	-	-	-	1.06 (0.99, 1.12)	0.078
<i>rs7937-T</i> Chrs 19	Iceland	1975	36121	0.548	0.549	1.00 (0.93, 1.06)	0.92
	NTR-NESDA	835	611	0.529	0.531	1.01 (0.83, 1.23)	0.93
	Combined	-	-	-	-	1.00 (0.94, 1.06)	0.95
<i>rs1801272-A</i> Chrs 19	Iceland	1979	36202	0.96	0.964	0.90 (0.69, 1.18)	0.45
	NTR-NESDA	835	611	0.987	0.981	0.67 (0.30, 1.46)	0.31
	Combined	-	-	-	-	0.88 (0.68, 1.13)	0.30
<i>rs4105144-C</i> Chrs 19	Iceland	1979	36202	0.697	0.706	0.96 (0.87, 1.06)	0.40
	NTR-NESDA	835	611	0.681	0.665	0.93 (0.74, 1.16)	0.51
	Combined	-	-	-	-	0.96 (0.88, 1.04)	0.30
<i>rs7260329-G</i> Chrs 19	Iceland	1969	35982	0.678	0.669	1.04 (0.97, 1.11)	0.25
	NTR-NESDA	835	611	0.67	0.697	1.14 (0.92, 1.40)	0.23
	Combined	-	-	-	-	1.05 (0.98, 1.12)	0.14

B – Peripheral Arterial Disease.

Population	N		Freq		OR (95% CI)	P
	case	control	case	control		
<i>rs6474412-T, chromosome 8</i>						
Iceland	1,484	36,697	0.757	0.771	0.93 (0.85, 1.01)	0.077
New Zealand	457	434	0.795	0.773	1.14 (0.91, 1.43)	0.25
Denmark	451	2,776	0.800	0.795	1.03 (0.87, 1.23)	0.71
Austria	271	227	0.795	0.819	0.86 (0.62, 1.17)	0.34
Combined	-	-	-	-	0.96 (0.89, 1.03)	0.24
<i>rs215614-G, chromosome 7</i>						
Iceland	1,484	36,697	0.359	0.355	1.02 (0.94, 1.10)	0.62
New Zealand	452	457	0.358	0.360	0.99 (0.82, 1.20)	0.95
Denmark	457	2,894	0.365	0.355	1.05 (0.90, 1.21)	0.54
Austria	462	376	0.384	0.370	1.06 (0.87, 1.30)	0.54
Combined	-	-	-	-	1.03 (0.97, 1.09)	0.41
<i>rs7937-T, chromosome 19</i>						
Iceland	1,482	36,614	0.545	0.549	0.98 (0.92, 1.06)	0.69
New Zealand	453	459	0.591	0.577	1.06 (0.88, 1.27)	0.57
Denmark	460	2,903	0.573	0.568	1.02 (0.89, 1.18)	0.76
Austria	472	425	0.536	0.538	0.99 (0.83, 1.20)	0.94
Combined	-	-	-	-	1.00 (0.94, 1.06)	0.97
<i>rs7258728-C, chromosome 19</i>						
Iceland	1,484	36,697	0.444	0.459	0.94 (0.88, 1.02)	0.13
New Zealand	171	357	0.518	0.465	1.23 (0.95, 1.60)	0.11
Denmark	456	2,868	0.456	0.497	0.85 (0.74, 0.97)	0.021
Austria	459	396	0.480	0.471	1.04 (0.86, 1.26)	0.70
Combined	-	-	-	-	0.95 (0.89, 1.01)	0.085
<i>rs7260329-G, chromosome 19</i>						
Iceland	1,472	36,479	0.672	0.669	1.01 (0.94, 1.09)	0.77
New Zealand	436	415	0.724	0.700	1.12 (0.91, 1.38)	0.28
Denmark	462	2,892	0.690	0.682	1.04 (0.89, 1.21)	0.62
Austria	472	424	0.678	0.696	0.92 (0.75, 1.12)	0.42
Combined	-	-	-	-	1.02 (0.95, 1.08)	0.62

Supplementary Note

A brief description of the participating samples is provided below. The NLBLC sample that participated in the CPD meta analysis is described with the lung cancer and peripheral arterial disease samples.

Description of individual samples in the ENGAGE GWA analysis of CPD and smoking initiation

COROGENE: Corogene controls are selected as population controls for CAD cases from the National Finrisk 1997, 2002, and 2007 surveys (More information at http://www.ktl.fi/portal/english/research_people_programs/health_promotion_and_chronic_disease_prevention/units/chronic_disease_epidemiology_unit/the_national_finrisk_study). The number of individuals that smoked regularly was 554 and 610 had never smoked. The number of cigarettes smoked per day was available for 353 individuals with mean of 16.3 (9.6). The mean age in the Corogene controls was 57.5 (11.0) and 56 % of the individuals were males.

Decode: The Icelandic cigarette smoking data were described in detail previously¹, and additional subjects were characterized in the same way. All Icelandic subjects in the study of smoking-related phenotypes, including Icelandic population controls, were originally recruited for different genetic studies conducted over 13 years (1996–2009) at deCODE Genetics, and information on the number of cigarettes smoked per day was available from questionnaires. These studies were approved by the Data Protection Commission of Iceland and the National Bioethics Committee of Iceland. Personal identifiers associated with phenotypic information and blood samples were encrypted using a third-party encryption system as previously described². Altogether we included data for 15,310 smokers and 6,077 never smokers who have been genotyped on a chip containing the Illumina 317K set of SNPs in one of several GWA studies conducted by deCODE Genetics. Of these 10,995 smokers were included in our previous study of CPD¹. In addition 4,859 Icelandic subjects, were genotyped for replication using a single-track assay (Nanogen – Centaurus).

EGPUT : The Estonian cohort is from the population-based biobank of the Estonian Genome Project of University of Tartu (EGPUT). The project is conducted according to Estonian Gene Research Act and all participants have signed the broad informed consent (www.geenivaramu.ee ref³). Cohort size is 37,000, from 18 years of age and up which reflects closely the age distribution in the Estonian population, 33% male, 67% female, 83% Estonians, 14% Russians, 3% other. Subjects are recruited by the general practitioners (GP) and physicians in the hospitals were randomly selected from individuals visiting GP offices or hospitals⁴. Computer Assisted Personal interview (CAPI) is filled during 1-2 hours at doctors office including personal data (place of birth, place(s) of living, nationality etc.), genealogical data (family history, four generations), educational and occupational history, lifestyle data (physical activity, dietary habits, smoking, alcohol consumption, women´s health, quality of life), also anthropometric and physiological measurements are taken. For the current study GWAS was performed on 1,019 selected randomly from all over the country. The smoking quantity was determined from the following questions: “If you have ever smoked how old were you when you started to smoke regularly?”; “How often and how much have you smoked in last 12 months?”; “How many years have you smoked?”; “If you have changed your smoking habits then how?”; “How long have you smoked so?” and “How many hours per day do you spend in a smoking area?”. Smoking quantity was available for 506 individuals (325 current smokers and 181 former smokers). The cohort mean age was 42.7 (SD 14.9) years and included 327 (64.6%) males and 179 (35.4%) females.

ERF: This is a family-based cohort study that is embedded in the Genetic Research in Isolated Populations (GRIP) program in the South West of the Netherlands⁵. The aim of this program was to identify genetic risk factors in the development of complex disorders. For the ERF study, 22 families that had at least five children baptized in the community church between 1850-1900 were identified with the help of genealogical records. All living descendants of these couples and their spouses were invited to take part in the study (N~4,700). Data collection started in June 2002 and

was finished in February 2005. 2,923 successfully completed the questionnaire. Females constituted 55% of this sample and average age was 50 years.

Genmets/FTC: The Finnish Twin Cohort includes nationwide samples of twins follow-up longitudinally, and forms a part of the GenomEUtwin project, in which female monozygotic pairs were genotyped. DNA samples from one member of each monozygotic twin pair were used for genotyping⁶. The Finnish twins were unselected with respect to disease status, and had participated in several waves of data collection in which smoking behaviors have been asked as a part of larger surveys of health, health habits and other health-related factors. Details of the data collection are available elsewhere⁷⁻⁸. The female twins came from the older Finnish Twin Cohort (questionnaire assessments in 1975, 1981 and 1990) and from the Finntwin16 sample (surveys as young adults was used for smoking assessments). Because of the low number of subjects in the FTC cohort we pooled the data with Health 2000 dataset. Health 2000 is a large Finnish cross-sectional health examination survey. It includes a total of 8,028 subjects aged 30 or over and is a nationally representative sample of adult Finnish population. Here, we studied a subcohort of 2,124 individuals, GenMetS, selected for GWA study on metabolic syndrome. Cases were selected according to the IDF Worldwide Definition of the Metabolic Syndrome (<http://www.idf.org/home/index.cfm?node=1429>). Controls were selected for not carrying the trait. For the cigarettes per day measure for the twins, mean of the two measures was used if both had the information. We had smoking information for 1996 individuals of which 488 had smoked regularly and 1,508 had never smoked. The continuous smoking information as cigarettes per day (CPD) was available for 502 individuals with mean of 15.4 (sd = 9.5). The mean age in the pooled dataset was 51.4 (11.7) and 51.3 % of the dataset were females. For a subset of the GenMetS subjects (N=485) serum cotinine levels were available. The cotinine concentration (ng/ml) was determined from the serum using liquid-phase radioimmunoassay methodology (Nicotine Metabolite DOUBLE ANTIBODY kit, Diagnostic Products Corporation, Los Angeles, USA).

KORA: All participants from KORA study are of white European ancestry. Briefly, KORA S4 and KORA F3 epidemiological cohorts represent independent samples of unrelated subjects from the general population from the Augsburg Area (Southern Germany). KORA F3 was a follow-up examination in 2004/05 of KORA S3 individuals recruited in 1994–1995, where as individuals in KORA S4 were recruited in 1999–2001. From KORA F3 survey (full cohort $n = 3,006$), 1,644 individuals between 35 to 79 years were selected for Genotyping on Affymetrix 500K⁹. From KORA S4 survey (full cohort $n = 4261$), 1,814 individuals between 25 to 74 years were selected for Genotyping on Affymetrix 1000K.

NFBC (Northern Finnish Birth Cohort of 1966): Mothers expected to give birth in the two northern provinces of Oulu and Lapland in 1966 were enrolled in NFBC1966 ($n = 12,058$ live births)³⁴. At the 31-year clinical examination ($n = 5,654$) and DNA was also extracted from the blood samples provided at this time. Of the genotyped individuals 3,299 had smoked regularly and 1,896 had never smoked. The continuous smoking measured as cigarettes per day (CPD) was available for 2,233 individuals having mean CPD of 12.4 (7.9). The sex distribution in the NFBC1966 was 47.8 % males and 52.2 % females.

NLBC (Nijmegen Lung and Bladder Cancer sample): The Dutch series consists of 3 groups: population controls, patients with urinary bladder cancer, and patients with lung cancer. Population controls: the 1,832 population controls (46% males) were recruited within a project entitled “Nijmegen Biomedical Study” (NBS). The details of this study were reported previously¹⁰. Briefly, this is a population-based survey conducted by the Department of Epidemiology and Biostatistics and the Department of Clinical Chemistry of the Radboud University Nijmegen Medical Centre (RUNMC), in which 9,371 individuals participated from a total of 22,500 age- and sex stratified, randomly selected inhabitants of Nijmegen. Control individuals from the NBS were invited to participate in a study on gene-environment interactions in multifactorial diseases, such as cancer. The 1,832 controls is a subsample of all the participants to the NBS, frequency-age-matched to a series of breast cancer and a series of prostate cancer patients. All the 1,832 participants are of self-

reported European descent and were fully informed about the goals and the procedures of the study. The study protocols of the NBS were approved by the Institutional Review Board of the RUNMC and all study subjects signed a written informed consent form. The Dutch bladder cancer population has been described in a previous publication¹¹. Briefly, patients were recruited for the Nijmegen Bladder Cancer Study (NBCS) (see <http://dceg.cancer.gov/icbc/membership.html>). The NBCS identified patients through the population-based regional cancer registry held by the Comprehensive Cancer Centre East, Nijmegen. Patients diagnosed between 1995 and 2006 under the age of 75 years were selected and their vital status and current addresses updated through the hospital information systems of the 7 community hospitals and one university hospital (RUNMC) that are covered by the cancer registry. All patients still alive on August 1, 2007 were invited to the study by the Comprehensive Cancer Center on behalf of the patients' treating physicians. In case of consent, patients were sent a lifestyle questionnaire to fill out and blood samples were collected by Thrombosis Service centers which hold offices in all the communities in the region. 1,651 patients were invited to participate. Of all the invitees, 1,082 gave informed consent (66%): 992 filled out the questionnaire (60%) and 1016 (62%) provided a blood sample. The number of participating patients was increased with a non-overlapping series of 376 bladder cancer patients who were recruited previously for a study on gene-environment interactions in three hospitals (RUNMC, Canisius Wilhelmina Hospital, Nijmegen, and Streektziekenhuis Midden-Twente, Hengelo, the Netherlands). Ultimately, completed questionnaires that included questions on smoking and blood samples were available for 1,276 and 1,392 patients, respectively. All the patients that were selected for the analyses (N=1,277) were of self-reported European descent. The median age at diagnosis was 62 (range 25-93) years and 82% of the participants were males. The study protocols of the NBCS were approved by the Institutional Review Board of the RUNMC and all study subjects gave written informed consent. The series of patients with lung cancer has been described before¹², Briefly, Patients with lung cancer were identified through the population-based cancer registry of the Comprehensive Cancer Center IKO, Nijmegen, the Netherlands. Patients who were diagnosed

in one of three hospitals (Radboud University Nijmegen Medical Center and Canisius Wilhelmina Hospital in Nijmegen and Rijnstate Hospital in Arnhem) and who were alive at April 15th, 2008 were recruited for a study on gene-environment interactions in lung cancer. 458 patients gave informed consent and donated a blood sample. This case series was increased with 94 patients to a total of 552 by linking three other studies to the population-based cancer registry in order to identify new occurrences of lung cancer among the participants of these other studies. Information on histology, stage of disease, and age at diagnoses was obtained through the cancer registry.

NTR-NESDA: The sample comes from two large-scale longitudinal studies: the Netherlands Study of Depression and Anxiety (NESDA)²⁶ and the Netherlands Twin Registry (NTR)²⁷. NESDA and NTR studies were approved by the Central Ethics Committee of the VU University Medical Center Amsterdam. The GWA sample consisted of 1,777 participants from the NTR and 1,763 participants from NESDA¹³. The mean age of the participants was 43.8 years (SD 13.4) and 65.7% of the sample was female. For participants of the NTR data longitudinal survey data from 7 waves of data collection (1991-2004) were used to determine smoking behavior. For participants from NESDA, data on smoking behavior were collected during a clinical interview between 2004 and 2007²⁶. The total sample consisted of 1,207 never smokers and 2,236 ever smokers.

Rotterdam: The Rotterdam Study was planned and designed in the early 1990s as a longitudinal study investigating the incidence and progression of diseases in the elderly. From 1991 to 1995 all inhabitants of Ommoord, a district of Rotterdam in the Netherlands, who were 55 years or older, were invited to participate in this study. Of 10,275 eligible individuals, 7,983 agreed to participate (78%). In 1999, 3,011 participants (out of 4,472 invitees) who had become 55 years of age or moved into the study district since the start of the study were added to the cohort¹⁴. The Rotterdam Study has been approved by the institutional review board (Medical Ethics Committee) of the Erasmus Medical Center and by the review board of the Netherlands Ministry of Health, Welfare and Sports. All participants provided written informed consent. The current analysis included 6,234 participants for whom genotyping was successful and information on smoking behavior was

available. 3,610 participants reported to smoke or have smoked in the past while 2,624 participants were never smokers. The mean age was 67.9 years (SD – 8.81) and 60% were female.

SORBS: All subjects are part of a sample from an extensively phenotyped isolated population from Eastern Germany, the Sorbs. The Sorbs are of Slavonic origin, and have lived in ethnic isolation among the Germanic majority during the past 1,100 years. Today, the Sorbian speaking, Catholic minority comprises approximately 15,000 full-blooded Sorbs resident in about 10 villages in rural Upper Lusatia (Oberlausitz), Eastern Saxony. Smoking habits were assessed in a standardized interview. Subjects were asked “Do you smoke or have you ever smoked?, If yes, how many cigarettes per day do/did you smoke on average (on most days) and for how many years ?” At present, more than 1,000 Sorbian individuals are enrolled in the study. 913 subjects (321 smokers and 592 never-smokers) were available for the present study. The smokers (208 males, 113 women) had a mean age of 42.77 (± 18.2) years, and the never-smokers (162 males, 430 females) had a mean age of 47.97 (± 18.75) years.

TWINS UK: The cohort (www.twinsuk.ac.uk) is an adult twin British registry shown to be representative of singleton populations and the United Kingdom population¹⁵. A total of 924 females with smoking phenotype were included in the analysis. The mean age of the TwinsUK cohort was 53.73 (22-80). Ethics approval was obtained from the Guy’s and St. Thomas’ Hospital Ethics Committee. Written informed consent was obtained from every participant to the study. The study design and genotyping methodology is described in detail elsewhere¹⁶.

WTCCC-CAD: Detailed descriptions of the *Wellcome Trust Case Controls Consortium Study* data have already been provided elsewhere, and the CAD cases are European Caucasians who had a validated history of either myocardial infarction (MI) or coronary revascularisation (coronary artery bypass surgery or percutaneous coronary angioplasty) before their 66th birthday¹⁷. They were recruited from April 1998 to November 2003 on a national basis¹⁷.

Additional Samples

AUS: The Australian sample took part in the single SNP assay replication. Data obtained from 3264 Australian subjects (49% women), 18-88 years of age (mean: 45; SD: 11 years) were used as one of the replication samples. Subjects were participants in either the Australian Nicotine Addiction Genetics (NAG) or a community-based (BigSib) family study. Families chosen for both studies were identified from two cohorts of the Australian Twin Panel, which included spouses of the older of these two cohorts. The NAG families were identified through heavy cigarette smoking index cases, and the BigSib families were comprised of families ascertained through the Australian Twin Panel selected for five or more offspring sharing both biological parents. The ancestry of the Australian samples is predominantly Anglo-Celtic or northern European (>90%). The same assessment protocol was used for both the NAG and BigSib studies¹⁸. Clinical data were collected using a computer-assisted telephone diagnostic interview (CATI), and adaptation of the Semi-Structured Assessment for the Genetics of Alcoholism (SSAGA)¹⁹⁻²⁰ for telephone administration. The tobacco section of the CATI was derived from the Composite International Diagnostic Interview (CIDI)²¹ and incorporated standard FTND, DSM-IIR, and DSM-IV assessments of nicotine dependence. It also included a detailed history of cigarette and other tobacco use, including quantity and frequency of use for current, most recent, and heaviest period of use. The measure examined for the purposes of this study was the number of cigarettes smoked per day, during heaviest period of use.

All data-collection procedures were approved by institutional review boards at Washington University in the United States, and the Queensland Institute of Medical Research in Australia.

DCLST: The Danish Lung Cancer Screening Trial (DCLST)⁴⁰ participated in the single-SNP assay replications for CPD. DCLST is a randomised 5-year trial comparing the effect of annual screening with low dose CT on the mortality of lung cancer, with no genetic screening in the control arm. Lung function tests are performed annually and information on smoking exposure recorded in all participants. Individuals volunteered for the study in response to advertisements in local and regional free newspapers and weeklies. Participants were current or former smokers of both sexes

at an age between 50-70 years at inclusion and with a smoking history of more than 20 pack years. Participants had to be able to climb 2 flights of stairs (around 36 steps) without pausing. FEV1 was at least 30% of predicted normal. Ineligible were those applicants with body weight above 130 kg or previous treatment for lung cancer, breast cancer, malignant melanoma or hypernephroma. Individuals with a history of any other cancer within 5 years or tuberculosis within 2 years or any serious illness that would shorten life expectancy to less than 10 years were also excluded.

GER: Unrelated community-based volunteers of German descent (i.e., both parents German) were randomly selected from the general population of Munich, Germany, and contacted by mail. To exclude subjects with central neurological diseases and psychotic disorders or subjects who had first-degree relatives with psychotic disorders, several screenings were conducted before the volunteers were enrolled in the study. First, subjects who responded were initially screened by phone for the absence of neuropsychiatric disorders. Second, detailed medical and psychiatric histories were assessed for both themselves and their first-degree relatives by using a semi-structured interview. Third, if no exclusion criteria were fulfilled, they were invited to a comprehensive interview including the Structured Clinical Interview for DSM-IV (SCID I and SCID II) to validate the absence of any lifetime psychotic disorder. Additionally, the Family History Assessment Module was conducted to exclude psychotic disorders among their first-degree relatives. Furthermore, a neurological examination was conducted to exclude subjects with subjects with current CNS impairment. In the case that the volunteers were older than 60 years, the Mini Mental Status Test was performed to exclude subjects with possible cognitive impairment.

Lung Cancer and Peripheral Arterial Disease

The case-control samples utilized for testing for association with the smoking-related diseases LC and PAD were included in our prior study¹, with the addition of LC samples from Denver and a the Danish PAD sample. The NLBLC sample was also included in the GWA study of CPD. All samples included in the present study are described below.

Lung cancer (Iceland). Recruitment began in the year 1998 with a nationwide list from the Icelandic Cancer Registry (ICR). About 1,265 LC patients were alive during the period of recruitment, and 665 participated in the project. Information in the ICR includes year and age at diagnosis, year of death, SNOMED (Systematized Nomenclature of Medicine) code and ICD-10 (International Statistical Classification of Diseases and Related Health Problems, 10th revision) classification. Histological and cytological verification was available for 647 cases; the remaining 18 cases were diagnosed clinically.

Lung cancer (Nijmegen): The series of patients with lung cancer has been described before¹². Patients with lung cancer were identified through the population-based cancer registry of the Comprehensive Cancer Center IKO, Nijmegen, the Netherlands. Patients who were diagnosed in one of three hospitals (Radboud University Nijmegen Medical Center and Canisius Wilhelmina Hospital in Nijmegen and Rijnstate Hospital in Arnhem) and who were alive at April 15th, 2008 were recruited for a study on gene-environment interactions in lung cancer. 458 patients gave informed consent and donated a blood sample. This case series was increased with 94 patients to a total of 552 by linking three other studies to the population-based cancer registry in order to identify new occurrences of lung cancer among the participants of these other studies. Information on histology, stage of disease, and age at diagnoses was obtained through the cancer registry. The controls were from the “Nijmegen Biomedical Study” (NBS)¹⁰.

Lung cancer (Spain): Patients were recruited at the Oncology Department of Zaragoza Hospital. Clinical information including age at onset and histology were collected from medical records. All lung cancer cases and 865 of the 1507 control individuals answered a lifestyle questionnaire, including questions on smoking status (never, former, current), and the amount of smoking. Study protocols were approved by the Institutional Review Board of Zaragoza University Hospital.

Lung cancer (Denver): DNA samples from blood samples and clinical data were provided from the University of Colorado Cancer Center under COMIRB protocol 08-0380. Blood samples were collected from 1217 patients enrolled in any of 20 clinical research trials carried out at Colorado

SPORE protocols between 1993 and 2008. Of these 1217 patients, 246 were lung cancer cases and 971 had never had lung cancer at the time of sample shipment. Lung cancer cases were identified either from data matches with the Colorado Central Cancer Registry or by having malignant lung tissue collected via enrollment in a surgical protocol.

PAD sample (Austria): patients and controls were recruited through the Linz Peripheral Arterial Disease (LIPAD) study during 2000 to 2002, at the Department of Surgery, St John of God Hospital. All patients with chronic atherosclerotic occlusive disease of the lower extremities with typical symptoms, *eg* claudication or leg pain on exertion, rest pain, or minor or major tissue loss, were included on the basis of the final clinical diagnosis established by attending vascular surgeons. The diagnosis was verified by interview, physical examination, noninvasive techniques, and angiography²². All control subjects were patients at the St John of God Hospital and fulfilled the following criteria: no clinical indication of PAD by history and physical examination, and systolic brachial blood pressure equal to or less than the blood pressure in each of the right and left anterior tibial and posterior tibial arteries (that is, ankle brachial index ≥ 1.0)²². Smoking status was assessed as described in ref. ²³.

PAD sample (Denmark). The sample consist of five hundred and seven patients were consecutively included during November 1999 to January 2004. All patients had PAD. The diagnosis was established from typical findings in clinical investigation (intermittent claudication, rest pain, ulcer or gangrene, and ankle-brachial-index<0.9). The samples were taken at baseline in a randomized, double-blind trial of roxithromycin versus placebo²⁴. All patients were enrolled at Vascular Surgery Department, Viborg Hospital, Denmark. Exclusion criteria were allergy to macrolides and liver insufficiency.

PAD sample (Iceland). Patients have been recruited over the past eleven years, as part of a genetic study at deCODE, from a registry of individuals diagnosed with PAD at the major hospital in Reykjavik, the Landspítali University Hospital, during the years 1983–2006. Diagnosis was confirmed by vascular imaging or segmental pressure measurements.

PAD sample (New Zealand): Patients were recruited from the Otago–Southland region, and PAD was confirmed by an ankle brachial index of less than 0.7, pulse volume recordings and angiography/ultrasound imaging. The control group consisted of elderly individuals with no history of vascular disease from the same geographical region. Controls were asymptomatic for PAD and had ankle brachial indexes of more than 1. An abdominal ultrasound scan excluded concurrent abdominal aortic aneurysm from both the PAD and control groups, and Anglo-European ancestry was required for inclusion.

FUNDING AND ACKNOWLEDGEMENTS

AUSTRALIA: The project has been supported by the National Institute of Drug Abuse (DA12854 and AA13320).

deCODE: The project was supported in part by NIH (R01-DA017932) and the European Commission's Sixth Framework Program, EU Integrated Project GENADDICT (LSHM-CT-2004-005166).

DANISH PAD SAMPLE: We thank the VIVA staff, The Mid Region of Denmark and the 7th European framework programme: Health-2007-2.4.2-2.:Project full title: Fighting Aneurysmal disease. Grant agreement no: 200647.

EGPUT: T.E., M.N. and A.M. received support from FP7 grants (201413 ENGAGE, 212111 BBMRI, ECOGENE (#205419, EBC)) and targeted financing from the Estonian Government SF0180142s08 and from the EU via the European Regional Development Fund (Centre of Excellence in Genomics). The genotyping of the Estonian Genome Project samples was performed in the Estonian Biocenter Genotyping Core Facility. We thank Mr. Viljo Soo for his contributions.

ERF: The genotyping for the ERF study was supported by EUROSPAN (European Special Populations Research Network) through the European Commission FP6 STRP grant (018947; LSHG-CT-2006-01947). The ERF study was further supported by grants from the Netherlands

Organisation for Scientific Research (NWO), Erasmus MC, the Centre for Medical Systems Biology (CMSB1 and CMSB2) and the Netherlands Genomics Initiative (NGI). We are grateful to all patients and their relatives, general practitioners and neurologists for their contributions and to P. Veraart for her help in genealogy, Jeannette Vergeer for the supervision of the laboratory work and P. Snijders for his help in data collection.

FTC: The Finnish Twin Cohort is supported by the Academy of Finland Center of Excellence in Complex Disease Genetics.

KORA: The KORA Augsburg studies were financed by the Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany and supported by grants from the German Federal Ministry of Education and Research (BMBF). Part of this work was financed by the German National Genome Research Network (NGFN-2 and NGFNPlus:01GS0823). Our research was supported within the Munich Center of Health Sciences (MC Health) as part of LMUinnovativ. We gratefully acknowledge the contribution of P. Lichtner, G. Eckstein, N. Klopp, Thomas Meitinger and all other members of the Helmholtz Zentrum München genotyping staff in generating the SNP data. We thank all members of field staff who were involved in the planning and conduct of the KORA Augsburg studies. Finally, we express our appreciation to all study participants.

NEW ZEALAND: The Vascular Research Consortium of New Zealand was supported by a programme grant from the Health Research Council of New Zealand. We are grateful to all study participants and local collaborators for their contribution to this study. In particular, we thank Mrs Vicky Phillips for her contribution.

NTR/NESDA: The projects were supported by NWO/ZonMW: 904-61-090; 904-61-193; 480-04-004; SPI 56-464-14192; NBIC-Bioassist; Center for Medical Systems Biology; Neuroscience Campus Amsterdam and NWO-VENI 451-06-004 and by the Geestkracht program of ZonMW (10-000-1002); matching funds from universities and mental health care institutes involved in NESDA (GGZ Buitendamstel-Geestgronden, Rivierduinen, University Medical Center Groningen, GGZ Lentis, GGZ Friesland, GGZ Drenthe). Genotyping was funded by the Genetic Association

Rotterdam: The generation and management of GWAS genotype data for the Rotterdam Study is

175.010.2005.011, 911-03-012). The Rotterdam Study is funded by Erasmus Medical Center and Erasmus University, Rotterdam, Netherlands Organization for the Health Research and Development (ZonMw), the Research Institute for Diseases in the Elderly (RIDE and RIDE2), the Ministry of Education, Culture and Science, the Ministry for Health, Welfare and Sports, the European Commission (DG XII), the Municipality of Rotterdam and the Netherlands Genomics Initiative (NGI)/Netherlands Organisation for Scientific Research (NWO) project nr. 050-060-810. We thank Pascal Arp, Mila Jhamai, Dr Michael Moorhouse, Marijn Verkerk, and Sander Bervoets for their help in creating the GWAS database. The authors are grateful to the study participants, the staff from the Rotterdam Study and the participating general practitioners and pharmacists.

SORBS: The project received support from the German Research Council (KFO-152), IZKF (B27) and the German Diabetes Association.

Twins UK : The study was funded by the Wellcome Trust; European Community's Seventh Framework Programme (FP7/2007-2013)/grant agreement HEALTH-F2-2008-201865-GEFOS and (FP7/2007-2013), ENGAGE project grant agreement HEALTH-F4-2007-201413 and the FP-5 GenomEUtwin Project (QLG2-CT-2002-01254). The study also receives support from the Dept of Health via the National Institute for Health Research (NIHR) comprehensive Biomedical Research Centre award to Guy's & St Thomas' NHS Foundation Trust in partnership with King's College London. TDS is an NIHR senior Investigator. The project also received support from a *Biotechnology and Biological Sciences Research Council (BBSRC)* project grant. (G20234). The authors acknowledge the funding and support of the National Eye Institute via an NIH/CIDR genotyping project (PI: Terri Young). We thank the staff from the Genotyping Facilities at the Wellcome Trust Sanger Institute for sample preparation, Quality Control and Genotyping led by Leena Peltonen and Panos Deloukas; Le Centre National de Génotypage, France, led by Mark Lathrop, for genotyping; Duke University, North Carolina, USA, led by David Goldstein, for genotyping; and the Finnish Institute of Molecular Medicine, Finnish Genome Center, University of

Helsinki, led by Aarno Palotie. Genotyping was also performed by CIDR as part of an NEI/NIH project grant.

WTCCC-CAD: Recruitment of the WTCCC-CAD Study was supported by the British Heart Foundation (BHF) and genotyping by the Wellcome Trust through the Wellcome Trust Case Control Consortium. NJS is supported by the BHF and the Leicester NIHR Biomedical Research Unit in Cardiovascular Disease.

ENGAGE membership list (Principal Investigators):

Institute For Molecular Genetics Finland, FIMM, University Of Helsinki: Leena Peltonen, Jaakko Kaprio, Samuli Ripatti, and Markus Perola.

University Of Oxford: Mark McCarthy.

European Molecular Biology Laboratory: Alvis Brasma.

The Queen's University Of Belfast: Alun Evans.

King's College London: Tim Spector.

Illumina: David Bentley and Mark Ross.

Leiden University Medical Center, Centre for Medical Systems Biology: Gert-Jan van Ommen.

VU University Medical Center, Amsterdam: Dorret Boomsma and Brenda Pennix.

Erasmus University Medical Center, Rotterdam: Albert Hofman and Cornelia van Duijn.

Helmholtz Zentrum: Erich Wichman, Thomas Illig, and Christian Geiger.

Karolinska Institutet: Nancy Pedersen.

Lunds Universitetet: Leif Groop.

Kungliga Tekniska Högskolan: Mathias Uhlen.

Norwegian Institute of Public Health: Jennifer Harris.

University of Tartu: Andres Metspalu.

Decode genetics: Kari Stefansson, Unnur Thorsteinsdottir.

Ontario Institute For Cancer Research: Thomas Hudson.

Université de Montréal: Bartha Maria Knoppers.

Fundació Privada Centre De Regulació Genòmica: Xavier Estivill.

University of Leicester: Nilesh Samani.

Imperial College Of Science, Technology And Medicine: Marjo-Riitta Jarvelin.

Queensland Institute Of Medical Research: Nick Martin, John Whitfield.

Wellcome Trust Sanger Institute, Hinxton: Leena Peltonen, Aarno Palotie,

Institute Of Mathematics and Computer Science, University Of Latvia: Juris Viskna.

References

References

1. Thorgeirsson, T.E. et al. A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. *Nature* **452**, 638-42 (2008).
2. Gulcher, J.R., Kristjansson, K., Gudbjartsson, H. & Stefansson, K. Protection of privacy by third-party encryption in genetic research in Iceland. *Eur J Hum Genet* **8**, 739-42 (2000).
3. Metspalu, A. The Estonian Genome Project. *Drug Rev Res* **62**, 97-101 (2004).
4. Nelis, M. et al. Genetic structure of Europeans: a view from the North-East. *PLoS One* **4**, e5472 (2009).
5. Aulchenko, Y.S. et al. Linkage disequilibrium in young genetically isolated Dutch population. *Eur J Hum Genet* **12**, 527-34 (2004).
6. Aulchenko, Y.S. et al. Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts. *Nat Genet* **41**, 47-55 (2009).
7. Kaprio, J. & Koskenvuo, M. Genetic and environmental factors in complex diseases: the older Finnish Twin Cohort. *Twin Res* **5**, 358-65 (2002).
8. Kaprio, J., Pulkkinen, L. & Rose, R.J. Genetic and environmental factors in health-related behaviors: studies on Finnish twins and twin families. *Twin Res* **5**, 366-71 (2002).
9. Wichmann, H.E., Gieger, C. & Illig, T. KORA-gen--resource for population genetics, controls and a broad spectrum of disease phenotypes. *Gesundheitswesen* **67 Suppl 1**, S26-30 (2005).
10. Wetzels, J.F., Kiemeneij, L.A., Swinkels, D.W., Willems, H.L. & den Heijer, M. Age- and gender-specific reference values of estimated GFR in Caucasians: the Nijmegen Biomedical Study. *Kidney Int* **72**, 632-7 (2007).
11. Kiemeneij, L.A. et al. Sequence variant on 8q24 confers susceptibility to urinary bladder cancer. *Nat Genet* **40**, 1307-12 (2008).
12. Rafnar, T. et al. Sequence variants at the TERT-CLPTMIL locus associate with many cancer types. *Nat Genet* **41**, 221-7 (2009).
13. Boomsma, D.I. et al. Genome-wide association of major depression: description of samples for the GAIN Major Depressive Disorder Study: NTR and NESDA biobank projects. *Eur J Hum Genet* **16**, 335-42 (2008).
14. Hofman, A. et al. The Rotterdam Study: 2010 objectives and design update. *Eur J Epidemiol* **24**, 553-72 (2009).
15. Spector, T.D. & MacGregor, A.J. The St. Thomas' UK Adult Twin Registry. *Twin Res* **5**, 440-3 (2002).
16. Richards, J.B. et al. Bone mineral density, osteoporosis, and osteoporotic fractures: a genome-wide association study. *Lancet* **371**, 1505-12 (2008).

17. Samani, N.J. et al. A genomewide linkage study of 1,933 families affected by premature coronary artery disease: The British Heart Foundation (BHF) Family Heart Study. *Am J Hum Genet* **77**, 1011-20 (2005).
18. Saccone, S.F. et al. Genetic linkage to chromosome 22q12 for a heavy-smoking quantitative trait in two independent samples. *Am J Hum Genet* **80**, 856-66 (2007).
19. Bucholz, K.K. et al. A new, semi-structured psychiatric interview for use in genetic linkage studies: a report on the reliability of the SSAGA. *J Stud Alcohol* **55**, 149-58 (1994).
20. Hesselbrock, M., Easton, C., Bucholz, K.K., Schuckit, M. & Hesselbrock, V. A validity study of the SSAGA--a comparison with the SCAN. *Addiction* **94**, 1361-70 (1999).
21. Cottler, L.B. et al. The CIDI-core substance abuse and dependence questions: cross-cultural and nosological issues. The WHO/ADAMHA Field Trial. *Br J Psychiatry* **159**, 653-8 (1991).
22. Mueller, T. et al. Factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations are not associated with chronic limb ischemia: the Linz Peripheral Arterial Disease (LIPAD) study. *J Vasc Surg* **41**, 808-15 (2005).
23. Rutherford, R.B. et al. Recommended standards for reports dealing with lower extremity ischemia: revised version. *J Vasc Surg* **26**, 517-38 (1997).
24. Joensen, J.B. et al. Can long-term antibiotic treatment prevent progression of peripheral arterial occlusive disease? A large, randomized, double-blinded, placebo-controlled trial. *Atherosclerosis* **196**, 937-42 (2008).